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Summary
This research project was concerned with two areas, the synthesis of 
new antimalarial agents and the synthesis of new antifungal agents.
Malaria is spread to humans by parasites of the Plasmodium genus. 
The vector is the female Anopheles  mosquito. It is the most important 
parasitic disease affecting mankind and kills about two million people every 
year. The parasites have developed resistance to the majority of the 
available treatments, including the naturally occurring compound quinine 
(A) and the synthetic drug chloroquine (B). Hence there is an urgent need 
for new antimalarial agents.
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The resistance of fungi which grow on important food crops to 
available fungicides has increased the need to find new antifungal agents.
Polyamines such as putrescine (C) and spermine (D) a re  
widespread in nature. They are important in cell development and are vital 
for normal cell growth. The study of these compounds, particularly their 
synthesis and biosynthetic enzymes, has stimulated the development of 
polyamines to treat a number of diseases including malaria and plant fungal 
diseases.
Previous workers within our group had synthesised a number of 
acyclic putrescine analogues such as (E) which was found to have
promising antimalarial and antifungal activity. We wanted to investigate the 
properties of a number of bicyclic putrescine analogues.
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In this work we have developed a route to prepare novel symmetrical 
and unsymmetrical putrescine analogues of the general structure (F).
NRR1
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We have also synthesised a number of polyamine analogues (G), 
(H) and (I), varying the distance between the nitrogen atoms.
Antimalarial testing was carried out by Prof. Steven Phillips and Ms. 
Fiona McMonagle in the Division of Infection and Immunity, University of 
Glasgow. Antifungal tests were performed by Dr Dale Walters at the Scottish 
Agricultural College, Auchincruive.
Measurements of the in vitro antimalarial activity of (G) showed an 
improvement as the distance between the nitrogen atoms increased. The 
most active had activity comparable to chloroquine (B). Unfortunately they 
showed no in vivo activity. Analogues (H) showed good in vitro activity 
which improved as the distance between the nitrogen atoms decreased. 
The most active compounds (I) showed similar activity to the corresponding 
analogues (G). The in vitro antifungal results followed a similar pattern. 
The most active compounds substantially inhibit fungal growth, although not 
all the compounds have yet been evaluated.
A number of compounds containing pyridyl rings were prepared with 
general structures (J), (K) and (L). In each case those compounds bearing 
benzyl or cyclohexylmethyl substituents displayed the greatest antimalarial 
activity.
In vitro antimalarial activity increased from (J) to (K) but the results 
we have so far for (L) are disappointing. The most active analogue (K) in 
vitro was tested for in vivo activity, but was found to be inactive.
The in vitro antifungfal testing results for (J) were disappointing. 
None of the compounds showed appreciable activity at 0.1 mM. We are 
awaiting the results for compounds (K) and (L).
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1.1 A Brief History of Important Dates and Important People
Malaria is still the most important parasitic disease affecting mankind. Its 
symptoms have been known since time immemorial, although it has only been in 
the last 100 or so years that the actual causes have become well understood.
One hundred years ago it was established that malaria is caused by 
Plasmodium  parasites with Anopheline mosquitoes as the vectors. Malaria 
parasites have been found in fossils of mosquitoes up to 30 million years old. 
The mosquito parasites are highly specific with man as the only natural 
vertebrate host. This specificity points to a long and adaptive relationship with 
man.1
Although in earlier times the causes of malaria were not known a number 
of treatments and remedies have been recorded to cure its fever-like symptoms 
and to prevent mosquito bites. It was thought that malaria was due to miasma 
(bad air or "mal aria") which came from swamps. Herodotus (485-425 BC) noted 
that in the swamps of Egypt, some people slept in tower-like structures out of the 
reach of mosquitoes, and others slept under nets.
Ancient remedies have proved remarkably effective and are still of 
immense value today.
An infusion of quighao has been used in China for at least 2000 years. Its 
active ingredient, qinghaosu (artemesinin 1), was only recently identified.
The bark of the cinchona tree (Cinchona ledgeriana) was used by native 
Peruvians well before the 15th century as a treatment for recurring fevers. The 
alkaloid quinine (2) originates from the cinchona tree and has been and 
continues to be used to treat and cure millions of malaria sufferers, was isolated 
in 1820 by the French pharmacists Pelletier and Caventou.2
1
2It was not until 1880 that the French army surgeon Laveran discovered in 
the blood of a patient the malaria parasite and suggested it as the causative 
agent. He observed some hair-like projections (flagella) which developed from a 
pigmented spherical body in a wet smear of fresh blood from a malaria patient. 
He was certain that this was from a living organism. A parasite was in the human 
blood. His work was greeted with scepticism for a number of years until the 
phenomenon was also observed by the Italians Marchiafava and Celli. Laveran 
was awarded the Nobel prize for medicine in 1907 for his pioneering work.3
Almost exactly 100 years ago another army surgeon, this time the Scot 
Ronald Ross carried out a series of experiments that finally proved that the 
mosquito was the vector of malaria. On the 20th August 1897 while observing 
some Anopheles mosquitoes that had fed on a patient's blood he observed 
a pigmented malaria cyst on the stomach wall of the insect. A day later Ross 
dissected the last mosquito in the batch under study and found the same 
pigmented cells "now much larger". Ross had seen the malaria parasites of man 
and they were undergoing development in a mosquito.3
The discoveries of Lavernan and Ross led to the first systematic malaria 
control measures. Initial controls involved improved "sanitation". It was known 
that mosquitoes bred in ponds, marshes, swamps and standing water and that 
better drainage of these areas could provide outstanding results by reducing the 
vector population.4 For instance the efforts of William Crawford Gorgas (1854- 
1920) saved the United States government some 80 million dollars in the building 
of the Panama canal. The malaria rate in the canal area showed a remarkable 
decline under the leadership of Gorgas. The number of canal workers admitted to
2
hospital suffering from malaria fell from a yearly rate of 821 per 1000 in 1906 to 
76 per 1000 in 1913.4
In the second half of the twentieth century the treatments available for 
malaria increased greatly. The remarkable insecticidal properties of 
dichlorodiphenyltrichloroethane (DDT, 3) were discovered by Paul Muller in 
1939.3 DDT was originally synthesised by Othmar Zeidler in 1874 but its effects 
on insects were not noted. After its discovery DDT was used in vast quantities 
and to great effect around the world as a general purpose insecticide. However 
by 1951 some species of Anopheles vectors had become resistant and when the 
major toxicity problems associated with DDT were discovered its widespread use 
was discontinued.3-4 It is still used in Africa but banned in the U.S.A. and Europe.
Among a number of safe synthetic drugs developed around the time of the 
second world war was chloroquine (4).3 It seemed to be free from the problem of 
resistance and it became the standby for prevention and treatment of malaria 
until the early 1960s when chloroquine resistance was reported in Plasmodium 
falciparum  in highly endemic regions of South America and South-east Asia. 
Resistance has since spread throughout South America, and on to the 
remainder of South-east Asia, South Asia and reached East Africa in 1978. By 
1985 chloroquine resistance had spread to West Africa.5-6
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The resistance of malaria parasites to existing antimalarial agents, not 
just chloroquine, is the biggest problem being faced in the fight against malaria. 
This is why the search for new antimalarial agents is so vital. The topic of 
resistance will be discussed more fully in section 1.7.
1.2 Morphology of Plasmodium Parasites and Anopheles Mosquitoes
As indicated earlier malaria is caused by the protozoan parasites of the 
genus Plasmodium. The parasites are transmitted from one person to another by 
the female anopheline mosquito.1 The males do not transmit the disease as they 
feed only on plant juices. The females feed on the blood of their victim in order to
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propogate successfully. There are 380 species of mosquito but only 60 species 
are capable of transmitting the malaria parasites.7 There are four species of 
Plasmodium which can infect and produce the disease in its various forms in 
man. These are Plasmodium falciparum, P.vivax, P.ovale, and P. malariae.
Of these four types P. falciparum is the most widespread and dangerous; 
untreated it can lead to severe and life threatening conditions such as cerebral 
malaria. Like all mosquitoes the Anophelines breed in water, each species 
having its preferred breeding grounds, feeding patterns and resting places. 
Sensitivity to insecticides and antimalarial drugs is also highly variable.1-7
1.2.1 The Life Cycle of the Plasm odium  Parasite in Man and the 
Mosquito1-7
The parasite has a life cycle which is split between a vertebrate host and 
an insect vector. When the mosquito takes its blood meal, sporozoites from its 
salivary gland are injected into the victim.1 The saliva must be injected as 
anticoagulant contained in it ensures a smooth-flowing meal. Once in the human 
bloodstream the sporozoites travel to the liver and penetrate hepatocytes, where 
they remain for 9-16 days. After multiplying within the cell they return to the 
blood and penetrate red blood cells in which they produce either merozoites or 
micro-gametocytes and macro-gametocytes.1-7 The merozoites reinfect the liver 
whereas micro-gametocytes and macro-gametocytes have no further activity 
within the host. When new mosquitoes arrive to feed on the victims blood they 
suck the gametocytes into their guts and exflagellation of the micro-gametocytes 
occurs while the macrogametocytes are fertilised. The result of this fertilisation is 
an ookinete. This penetrates the cell wall in the midgut and this develops into an 
oocyst. Sporogony within the oocyst produces many sporozoites when rupture 
of the oocyst occurs then sporozoites migrate to the salivary gland and can be 
injected into another host.7
Sexual development of the Plasmodium begins as the merozoites invade 
the erythrocytes after their release from the liver. Schizogony occurs within the 
erythrocyte to produce more merozoites or the sexual micro and 
macrogametocytes. In P. falciparum erthyrocytic schizogony takes 48 hours and 
gametocytosis takes between 10-12 days.7 A variable number of cycles of 
asexual erythrocytic schizogony takes place before any gametocytes are 
produced. At this stage the body's immune system may produce antibodies to 
the gametocytes.7 Once drawn into the mosquito the gametocytes increase in
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volume and escape from the erthyrocyte. Microgametes are formed by three 
mitotic divisions within the microgametocytes and are expelled explosively.7
Fertilisation of the female mosquito occurs where the outer membranes 
(plasmalemmas) of male and female gametes fuse and the nucleus of the 
microgamete and enters the female cytoplasm to produce a zygote. After about 
18-24 hours the zygote which contains micronemes and a pellicle becomes 
elongated and motile. It invades the microvillus border, passes through the 
midgut cells, and lies beneath the basement membrane. The ookinete then 
becomes a static oocyst between the basal lamina and the basement cell 
membrane, and bounded by a thick plasmalemma. The main source of nutrients 
is the haemolymph in which the oocyst develops. Sporoblasts form and 
sporozoites bud off.
The oocyst ruptures and sporozoites escape into the haemocoele and 
migrate to and penetrate the salivary gland cells, where they can lie in vacuoles 
for up to 59 days. The sporozoites develop further and become 1000 times more 
infective than when they were in the oocyst.1 These sporozoites are more 
antigenic, their motility is involved in their invasion of cells and escape from 
salivary glands. The sporozoites are about 12 mm long and 1mm across with a 
single nucleus and they posses a complex pellicle responsible for motility. The 
penetrating region contains extensions of the microneme ducts which release an 
agent which interacts with host cell plasma membrane during penetration.7 The 
bite from a mosquito transfers almost 10% of its sporozoite load into the 
capillaries and the sporozoites begin their invasion of the host defences. This 
may be done binding serum proteins for "camouflage". Some are destroyed by 
macrophages or by antigen specific antibodies in immune individuals but not in 
non-immune individuals. They reach the hepatocytes and initiate schizogony or 
become hypnozoites. All sporozoites have left peripheral circulation within 45 
minutes. The life cycle of Plasmodium vivax in man and the mosquito is shown 
diagramatically on page six.1-7
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1.3 The Diagnosis of Malaria
Malaria is diagnosed by its clinical symptoms and by detecting parasites in 
blood by microscopic examination of a blood smear. When the disease takes 
hold and the red blood cells break down the symptoms include fever, anaemia, 
shivering, pain in the joints and headaches. More severe forms of the disease 
include cerebral malaria where infected red blood cells obstruct blood vessels in 
the brain leading to hospitalisation and often death. Other vital organs including 
the kidneys, liver and lungs can be damaged.8
A definite diagnosis of malaria requires the finding of parasites in the blood 
because the symptoms of malaria are common to a number of ailments. The 
parasites are detected by making a blood smear on a slide and staining with 
Giemsa's stain and searching under the microscope for the parasite. Depending 
on the type of smear taken it can be possible to determine which particular 
parasite is responsible for the infection. 7>8
1.4 The Current Situation
Malaria is a serious public health problem in more than 90 countries, 
inhabited by a total of 2.4 billion people, encompassing about 40% of the world's 
population. More than 90% of malaria cases are in sub-Saharan Africa. Other 
greatly affected countries include India and Brazil. It should be noted that 
outbreaks have recently been reported in Europe and in the United States 1000 
to 1200 cases have been reported every year for the past few years.9- 10
Worldwide the incidence of the disease has quadrupled in the past five 
years. The World Health Organisation (WHO) estimates that malaria is 
responsible for between 300-500 million clinical cases and 1.5 to 2.7 million 
deaths each year. It kills more people than any other communicable disease 
except tuberculosis and kills roughly twice as many people as AIDS each 
year.9-10
A number of factors are responsible for the large increase in malaria 
cases. In the Amazon road building, mining, logging and new agricultural and 
irrigation projects have been linked to the increase. In other parts of the world 
the disintegration of health services and armed conflicts with the mass 
movements of refugees worsen the situation.11
The main reason for the resurgence of malaria has been the resistance 
developed to common antimalarial drugs by the Plasm odium  parasites. 
Resistance to chloroquine was noticed as long ago as 1961 but it is still used 
throughout most of that malaria endemic world as the first line of treatment.
7
Recent evidence indicates that it can no longer be considered an effective 
therapy.
The map below shows the world distribution of malaria in 1995 and how P. 
falciparum reacts to chloroquine. As well as resistance to chloroquine many 
strains of malaria are resistant to newer drugs such as mefloquine and 
halofantrine. Of more concern is the knowledge that many species of parasite 
are resistant to a number of antimalarial drugs. This is referred to as cross 
resistance. It is possible to treat some outbreaks of malaria by administering a 
combination of drugs but this is very expensive and already this has been shown 
to have a limited effect.12
o
^  chloroquine-sensitive malaria
O  chloroquine-resistant malaria 
■ fT  multiple-drug-resistant malaria
World distribution of malaria in 1995, with delineation of areas where P. falciparum  is sensitive to 
chloroquine, and resistant to numerous antimalarial drugs.12
The map indicates that malaria affects some of the poorest communities in 
the world, hence the need for cheap and affordable treatments. Table 1 shows 
the cost of treatment for a single bout of malaria per patient.12 Chloroquine was 
almost ideal due to its ease of administration, rapid action and it only cost $US
0.01 whereas the treatment with halofantrine costs $US 5.31.
Table 1 Cost of treatment for malaria.
$0.01 Chloroquine
$0.13 Pyrimethamine/sulfadoxine
$1.92 Mefloquine
8
$5.31 Halofantrine
As well as the terrible human suffering caused by malaria there are a 
number of social and economic costs that have to be paid. A single bout of 
malaria costs a sum equivalent to ten working days in Africa. This affects the 
ability of the sufferer to provide for his family and children lose out on education 
which could help them escape from the poverty trap. It has been estimated that 
in 1995 the global annual direct and indirect costs of malaria was $US 2 billion, 
whereas the estimated world-wide expenditure on malaria research, prevention 
and treatment in 1993 was a mere $US 84 million. In order to try and alleviate 
the situation WHO has formulated a global malaria strategy.13-14
1.4.1 The Malaria Control Strategy
The four basic elements of WHO's Global Malaria Strategy are:
1. Provision of early diagnosis and treatment for the disease;
2. Planning and implementation of selective and sustainable preventative 
measures, including vector control;
3. Early detection for the prevention of epidemics; and
4. Strengthening of local research capacities to promote regular assessment of a 
country's malaria situation; in particular the ecological, social and economic 
determinants of the disease.2-10
WHO based their fight against malaria on a number of fronts. This was a 
direct result of less than satisfactory results from their Global Malaria Eradication 
Plan between 1955 and 1969. They launched a series of campaigns to eradicate 
the mosquito by spraying homes with insecticides. This initiative was successful 
in North America, Southern Europe, the former Soviet Union and parts of Asia 
and South America. The results were disappointing in Latin America and most 
Asian countries where malaria persisted. Due to logistical problems large scale 
eradication was not attempted in African countries. In 1968 a massive epidemic 
broke out in Sri Lanka after malaria had been believed to be eradicated and 20 
years later 25,000 people in Madagascar died from malaria. In 1994 there was a 
serious malaria outbreak in India and one reported in Azerbijan where it was 
thought the disease had been beaten.15-16
The ideal of global eradication of malaria was finally abandoned in 1969. 
It became obvious that an effective control plan had to be adapted to local
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conditions and involve the whole community, the local health services and those 
involved in development of affected areas.2
The main objectives of the Global Malaria Control Strategies are:
1. To have at least 90% of affected countries or territories to be implementing 
appropriate control plans by 1997; and
2. To reduce malaria mortality by at least 20% in at least 75% of affected 
countries by 2000.17
One of the biggest achievements of the plan is in capacity building. This 
entails establishing a group of professionals in each endemic country who are 
responsible for the implementation and evaluation of national control 
programmes. For example in Africa 150 trainers have instructed 16,000 people 
on malaria courses with particular emphasis on the development of national drug 
policies, monitoring of drug efficacy, and the management of severe malaria.17
Significant strides have been made in the development of new tools for 
use in the control of malaria. One of the most promising and most successful 
has been the use of bed nets and curtains treated with insecticides. Controlled 
field trials by WHO suggest that in certain situations childhood mortality can be 
lowered by 15 to 35% by the use of impregnated bednets. Results have been 
very encouraging, but more work has to be done to optimise their effects in 
operational settings.10
The most important achievement of the Global Malarial Control Plan has 
been to complete successfully the first objective they set; at least 90% of 
affected countries have installed appropriate control plans. An accelerated 
control plan for Africa was started in 1998. However the global fight against 
malaria is still an enormous task.17
1.5 The Biological Classification of Antimalarial Drugs18
The biological classification of antimalarial drugs is based upon which part of the 
life cycle of the parasite they inhibit. The five groups are as follows.
1. Tissue Schizontocides - These inhibit the growth of the pre-erythrocytic 
stages of the parasite in the liver. The less toxic members of this group include 
proguanil (5) and pyrimethamine (6). They are used singularly or in combination 
with sulfonamides as "casual prophylactics" to prevent infection.
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2. Hypnozoitocides - These kill at the dormant liver stage known as the 
hypnozoites. They are used as "antirelapse drugs" in P. vivax and P. ovale 
infections. Primaquine (7), an 8-aminoquinoline is one of the few hypnozoitocidal 
drugs found to be of any practical use in man.
3. Blood Schizontocides - These act rapidly and only at the erythrocytic stage. 
This group includes chloroquine and quinine. They can be used as "suppressive 
prophylactics" in the prevention of the disease. Both are ineffective against the 
mature gametocytes of P. falciparum.
4. Gam etocytocides - These will destroy the mature gametocytes of P. 
fa lciparum . They act at the sexual stage of the parasites in the blood. 
Primaquine, an 8-aminoquinoline, has been used to good effect.
5. Sporontocides - These drugs or their metabolites have an inhibitory effect on 
the development of the oocyst and sporozoites in the mosquito. Agents of this 
group include pyrimethamine and proguanil.
1.5.1 The Chemical/Biological Classification of Antimalarial Drugs.18
Another way which is also used to classify antimalarial drugs is based upon a 
mixed chemical/biological system. The three classes are outlined in brief below.
1. 8-Aminoquinolines - They are most active on dormant parasite stages such 
as the gametocyte and the hypnozoite. They also have some effect at toxic 
concentrations on the asexual stages in the blood. Primaquine (7) is an example 
of this class of antimalarial drug.
2. Antimetabolites - These are active on all growing stages of the parasite. 
They include proguanil (5), pyrimethamine (6) and sulfonamides.
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3. Blood Schizontocides - This class includes quinine (2), chloroquine (4), 
(and other aryl aminoalcohols). They are only active against growing stages of 
the parasite.
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1.6 Antimalarial Drugs - Past and Present
This section will contain a discussion on some of the more commonly used 
antimalarial drugs with particular emphasis on their mode of action and the 
possible ways in which resistance has become possible.
1.6.1 Chloroquine (4)
This is a synthetic compound which was first synthesised and developed 
in Germany in the late 1930s. It was the first choice for treatment and prophylaxis 
until the early 1960s. The spread of the chloroquine-resistant parasites has for 
the most part made it redundant for chemoprophylaxis. It is, however, used 
widely for uncomplicated P. falciparum infections (i.e. those infections not 
involving cerebral malaria).19
Chloroquine contains a quinoline heterocyclic ring, which is a feature 
common to many antimalarial agents. It is a diprotic weak base and accumulates 
to high concentrations in the acidic food vacuole of the parasite. This is the 
proposed site for drug action.20
The most widely accepted theory to explain the therapeutic affects of 
chloroquine was proposed by Slater and Cerami in 1992.21 Their work indicates 
that chloroquine interferes with a haem detoxification enzyme that is essential to 
the malaria parasites in the red blood cell.
The rapid spread of the parasite produces a demand for nutrients that in 
part is met through the digestion of host cell haemoglobin in the acid food 
vacuole. This presents a problem for the parasite as one of the breakdown
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products, ferriprotoporphyrin IX (FPIX) is toxic. The parasites, unlike their 
human host, cannot degrade these haem molecules. Instead they store FPIX 
within the food vacuoles as harmless dark brown granules called malaria pigment 
or haemozoin. The pigment is an insoluble, crystalline polymer of haem 
molecules linked between the central ferric ion of one haem and a carboxylate 
side-group oxygen of another. This is achieved by a haem polymerase enzyme 
that is unique to the malaria parasite.
Until Slater and Cerami proposed their theory in 1992, no one theory 
could explain all the experimental observations accumulated in the studies of 
chloroquine action. They showed that a catalytic activity in P. falciparum extracts 
polymerises haem in the form of FPIX hydroxide or haemoglobin into malaria 
pigment. Chloroquine and six other quinoline ring compounds block haem 
polymerisation in a manner directly related to the extent to which they stop the 
growth of malaria parasites. These data indicate that quinoline ring compounds 
like chloroquine act by inhibiting the haem polymerase enzyme that detoxifies 
FPIX, thus poisoning the acidic food vacuole and starving the parasite. This 
would explain the specific vulnerability of growing intraerythrocytic malaria 
parasites to quinoline-containing drugs such as chloroquine.21 >22
Unfortunately the problem of resistance to chloroquine has arisen. The 
method by which resistance operates is not completely understood, although it is 
known to be associated with reduced concentrations of the drug in the acid food 
vacuole of the parasite. This is due to an increased efflux of chloroquine from the 
cell, not because of a reduced uptake of the drug. It has been calculated that 
resistant parasites can remove chloroquine between 40-50 times faster from the 
cell than sensitive parasites.21- 22
This process can be reversed or inhibited by a number of drugs including 
verapamil and desipramine. This has led to the suggestion that a parasite 
homologue of the P-glycoprotein responsible for the multidrug resistance (MDR) 
in mammalian tumour cells is responsible for the rapid efflux of chloroquine in 
resistant P. falciparum. This was suggested as these compounds also reverse 
MDR in mammalian tumour cells. Studies have yet to confirm this hypothesis 23
1.6.2 (-)-Quinine (2)
Since the discovery of chloroquine resistant P. falciparum, quinine has 
once again become an important therapeutic antimalarial drug.24
It is one of four major alkaloids found in cinchona bark. The others are 
(+)-quinidine (8), cinchonidine and cinchonine. They all posses antimalarial 
activity. The same backbone structure is present; they all share a quinoline
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heterocyclic nucleus and a tertiary amino aliphatic ring system, quinuclidine. 
These two moieties are linked via a hydroxymethylene bridge para to the 
aromatic nitrogen atom. In all cases the quinuclidine ring carries a vinyl group at 
position 3. In the case of quinine and quinidine the 6'-position bears a methoxy 
group which is missing in both cinchonidine and cinchonine. Each molecule 
possess four chiral centres, but in the naturally occurring alkaloids the 
configurations at C-3 and C-4 are the same. The configurations can vary at C-8 
and C-9 giving rise to the four naturally occurring members of the family.24
Although it has been used to replace chloroquine in many endemic areas, 
quinine has also suffered problems with resistance. In Thailand it replaced 
chloroquine in 1978 but soon afterwards quinine resistance was reported in large 
areas of the country. It has now been replaced by its dextrarotatory 
diasteroisomer, quinidine, which is intrinsically more active than quinine but is 
also more cardiotoxic. Both agents reduce parasitaemia quickly, but they are 
generally used in combination with other drugs to prevent relapse 25
HQ
Quinine and quinidine are both blood schizonticides. Their mechanism of 
action is to inhibit the haem polymerase enzyme in a manner similar to 
chloroquine.18
Resistance to both drugs is in part reversed by verapamil which leads 
people to believe that the rapid efflux mechanism shown in chloroquine 
resistance plays a part here.25
1.6.3 Proguanil (5) and Pyrimethamine (6)
Both will be considered here as they were synthesised around the same 
time and have a related mode of action. Proguanil, a biguanide and 
pyrimethamine, a diaminopyridine were introduced in the late 1940s and early
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1950s. They destroy the early tissue stages, particularly in P. falciparum and so 
are used as "casual prophylactics" to prevent blood infection occurring. They 
also act as blood schizonticides, but work more slowly than chloroquine. Both 
have very few side effects; the only known side effect of proguanil to be reported 
is that of mouth ulcers. They both have excellent safety and tolerance records.
Both drugs act by interfering with folic acid metabolism in the parasite, 
and hence they are sometimes known as antifolates. Proguanil, or more 
correctly its metabolite cycloguanil, and pyrimethamine inhibit the bifunctional 
enzyme Dihydrofolate Reductase (DHFR)/Thymidylate Synthase. Other 
antifolate drugs, collectively known as the sulfonamides inhibit Dihydropteroate 
Synthetase.
Within a few years resistance to these drugs was observed. Resistance in 
both P. falciparum and P. vivax limited their usefulness. Resistance to the DHFR 
inhibitors results from reduced affinity of the DHFR-Thymidylate Synthase 
enzyme complex for the drug. This is due to point mutations in the DHFR gene. 
Studies show that several distinct base-pair mutations have been identified which 
result in affinities 100-1000 times less than that of the drug sensitive DHFR 
complex.
Resistance to one antifolate compound does not automatically mean 
resistance to another and so proguanil may be useful in some areas where 
pyrimethamine alone is not and vice versa. These compound are still very useful 
today, especially as chemoprophylactic drugs.6-26
1.6.4 Mefloquine (9)
The racemic drug was introduced in clinical trials in 1975 and was found to 
be an effective therapeutic agent against drug resistant P. falciparum.
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Mefloquine is a 4-quinolinemethanol and is structurally related to quinine 
and halofantrine. It is a blood schizontocide and like chloroquine it appears to 
work by inhibition of haem polymerase.
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Resistance to mefloquine was first reported in parts of Thailand in 1982 
and in other areas in the decade afterwards. The resistance mechanism is at 
present unknown. An added complication is the development of cross 
resistance. There is evidence that mefloquine resistance may drive halofantrine 
and possibly quinine resistance. At present, treatment with mefloquine is not a 
problem except in some parts of Thailand where cure rates have dropped from 
98% in 1986 to 71% in 1990. The figure below shows the cure rates of some 
drugs in Eastern Thailand since 1976.25 Note that all of the antimalarial agents 
in the study have seen a decrease in their effectiveness.6-25
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Antimalarial cure rates in falciparum malaria in Eastern Thailand since 1976. The arrow marks 
the introduction of mefloquine to malaria clinics for the treatm ent of positive-slide P. falciparum  
infections.25
A bigger problem facing mefloquine is reports of its neuropsychiatric 
effects such as psychosis and convulsions. These have been reported in 1 out of 
215 to 1 out of 1700 users. This coupled with the cross resistance with 
halofantrine limit its prescription; thus the future does not look good for 
mefloquine.26
1.7 A Summary of the Causes of Antimalarial Drug Resistance 27
In the previous sections possible mechanisms of antimalarial drug 
resistance were discussed, but how do they develop? Resistance is considered 
to result from spontaneous chromosomal point mutations, a process which is
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believed to be independent of drug pressure. In the case of DHFR inhibitors 
resistance can arise from single point mutations, but epidemiological and 
laboratory observations point to resistance to quinoline compounds requiring a 
series of unlinked additive mutations.
Resistant parasites are more likely to be selected if the population is 
exposed to a sub-therapeutic level of the drug. For resistance to spread, the 
resistant parasites must survive and produce gametocytes and these parasites 
must be transmitted. The female mosquitoes have varying degrees of 
receptiveness to different strains of the parasite. In some instances the vectors 
are more receptive and resistance can arise or they are less receptive to the new 
strain of parasite.
Resistance is known to spread in three circumstances:
1. Large scale antimalarial drug use;
2. Inadequate dosing; and
3. Adequate dosing with drugs that are expelled slowly from the body.
Inadequate dosing can arise in a number of ways, commonly due to the 
patients failing to comply with the prescribed regime of treatment and 
unregulated distribution of the drug. The greatest difficulties arise when a whole 
population is exposed to a low concentration which occurred in population 
experiments in South-east Asia when pyrimethamine or chloroquine was added 
to table salt. Many think this resulted in the development of chloroquine 
resistance in this region.
Drugs that are slowly eliminated from the body, such as chloroquine and 
halofantrine which have a half life of 1-2 months and 3 weeks, respectively, and 
can be detected in the blood months after treatment, will persist in sub- 
therapeutic levels and act as a selective pressure when the patient is reinfected. 
As the level of resistance rises, more parasites escape the first therapeutic 
actions of the drug and the chances of selecting resistant mutagenic strains from 
the initial infection increase and resistance quickens.
These lessons have been learned for treatment today and in the selection 
of new antimalarial drugs. Usage is more strictly controlled and people are 
educated on the need to follow the prescribed treatment methods. New potential 
antimalarial drugs like artemesinin have shorter half lives and are probably 
expelled from the body within hours.6-27
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1.8 The Selection of Antimalarial Agents for Prophylaxis
This is a difficult area and in many cases there are no clear right or wrong 
answers. Any compromise that is reached must be under constant scrutiny and 
open to change when the need arises. One thing certain in all cases is that local 
knowledge of transmission areas and antimalarial drug resistance and sensitivity 
are vital in order to give the appropriate advice and treatment. However, some 
generalities can be made. Where P. vivax or sensitive strains of P. falciparum 
only are found, chloroquine on it own is an appropriate prophylactic. As 
resistance begins the weekly doses of chloroquine are increased from a base 
level of 5 to 10 mg/kg. This will "buy some time". Thereafter it is common to 
recommend chloroquine and proguanil combinations. This will not be totally 
effective everywhere, but it at least prevents severe symptoms arising. This 
combination is well tolerated and is still effective over large parts of Africa, 
Southern Asia and some of the Americas. Multidrug resistance is more wide­
spread in south-east Asia but there are three options for prophylaxis. The first is 
weekly administration of mefloquine or daily use of the antibiotic, doxycycline. 
The final option is to administer mefloquine, halofantrine or quinine with 
tetracycline. An in depth knowledge of the local situation is essential when 
making a decision on which course of therapy to use.6-27
1.9 The Selection of Antimalarial Agents for Treatment
It is unfortunate but for most countries in the tropics, cost is the major 
factor determining what antimalarial drug is prescribed locally. Of course the 
sensitivity of parasites to antimalarial drugs is also taken into account. To treat 
infection successfully health workers need to know the in vivo response to 
antimalarial treatment. This information varies from the reliable and detailed 
assessments of drug efficacy in a particular community to the less than reliable 
observations from health workers that patients seem to be coming back for 
treatment in a few weeks. As there is a limited number of drugs available, their 
efficacy has to be monitored frequently and with a high degree of care and 
attention. The tolerance and effect of different drug therapies must also be 
assessed.6
Failure of a course of treatment can arise due to intrinsic resistance of the 
parasite to the drug in use, or host factors (i.e. pharmacokinetics) which will 
result in an insufficient concentration of the drug in the blood. These two features 
can be distinguished since assays exist to quantify antimalarial drug levels in the 
blood.6- 27
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The classification of in vivo resistance most frequently used is derived for 
evaluation of aminoquinoline resistance (table 2). With some limitations it can be 
applied to other drugs.
As resistance develops, increasing numbers of people with R| 
recrudescence are observed. This means that the initial therapeutic response is 
satisfactory, but infection returns later. As resistance increases, more and more 
patients are seen whose infections are not cured. These are the R|| and R||| high 
grade resistances shown in Table 2.6
Table 2 The World Health Organisation grading of resistance of asexual 
parasites (P. falcipraum) to 'schizontocidal' drugs (4-aminoquinolines).
Response
Sensitivity
Recommending
grading
Low-grade resistance R|
High-grade resistance Rn
Evidence
Clearance of asexual 
parasitaemia within 
seven days of initiation 
of treatment, without 
subsequent 
recrudescence.
Clearance of asexual 
parasitaemia, as in 
sensitivity, followed by 
recrudescence3.
Marked reduction (75%) 
of asexual
parasitaemia, but no 
clearance, i.e. the 
parasitaemia remains 
patent for seven days.
No marked reduction in 
parasitaemia, i.e. the 
parasite count does not 
fall by more than 75% 
within 48 h.
aThe assessment is usually made 28 days after the last treatment, although it is 
known that recrudescences can occur up to ten weeks following drug 
administration. Reinfection cannot be excluded if the patient re-enters an area of 
malaria transmission.6
Ri
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Current treatment strategies can be improved but the underlying problem 
is that not enough new drugs have been developed and not enough research is 
being conducted.
1.10 Antimalarial Drugs - What Next?
Perhaps the future of antimalarial chemotherapy lies in the hands of a 
drug that has been prescribed for over 2000 years. Artemesinin (1), which was 
briefly mentioned in section 1.1, and its derivatives are the most promising drugs 
undergoing development at present. It was isolated in 1972 as the active 
component of Artemisia annua, the Chinese wormwood plant which was 
prescribed as a herbal remedy for fevers. Artemesinin (1) itself is a 
sesquiterpene lactone with an endoperoxide bridge across one of the rings of the 
trioxane structure and is unrelated to any previously known antimalarial agent.6
Three very potent semi-synthetic derivatives of artemesinin have been 
developed. These are a water soluble hemisuccinate salt known as artesunate 
(10), and two compounds that are oil soluble, artemether (11) and arteether 
(12). The latter was studied by WHO for its lipophilic properties which could be 
important when treating cerebral malaria. They all have faster clearance times 
and potency than any other antimalarial agent and are rapidly active against drug 
resistant P. falciparum but there is a high incidence of relapse in pre-clinical trials 
when it is used alone in therapy. This problem appears to be solved by 
administration of the drug in combination with mefloquine. The synthetic 
derivatives have greater potency and stability than artemesinin (sometimes 500% 
more potent), but artemesinin is much cheaper to produce.27
No completely convincing theories exist to account for the antimalarial 
effect of artemesinin and its derivatives. Some reports suggest that activity is in 
part due to activated oxygenated radicals which are toxic and which may react 
with the high concentration of haem within the parasite resulting in selective 
toxicity. What is known for sure is that they are all converted into a common 
biologically active metabolite dihydroartemesinin (13).25
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At present there is no licence for these drugs in Europe or the USA. 
However, artemether and artesunate have been available in China and 
Indochina for a number of years. Some are of the opinion that the widespread 
use of artemesinin and its derivatives is unlikely since a therapeutic dose has 
been seen to induce foetal resorption in rats and that the most probable 
application of these drugs will be in cerebral malaria, where its rapid effects 
make it superior to quinine and mefloquine. This is a worse case scenario, 
since it is clear that at the moment there is insufficient pre-clinical and toxicity 
data to meet the strict requirements necessary for the drugs to be licensed.27
1.11 Other Strategies to Combat Malaria
Two of the most innovative ideas owe their development to advances in 
molecular biology and genetic engineering. Much time and money is being spent 
on the development of transgenic mosquitoes and in the research for vaccines 
against malaria. A brief discussion of each will follow.
1.11.1 Transgenic Mosquitoes
This is a totally new idea in vector control. Past evidence shows that 
mosquitoes have been extraordinarily difficult to control, and have quickly 
developed resistance to most insecticides. Two options are being looked at. The 
first involves creating transgenic mosquitoes incapable of transmitting malaria, 
and finding ways to spread the genes involved in natural resistance throughout 
the indigenous population. The key behind this idea is that many of the 380 
species of mosquito are resistant to Plasmodium parasites. Genes of this type
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have been mapped in a resistant strain of Anopheles gambie at the European 
Molecular Biology Lab. in Heidelberg. The other approach using transgenic 
mosquitoes is to engineer mosquitoes carrying foreign genes that confer 
protection. A mammalian gene for an antibody that attacks an antigen in the 
ookinete phase of the parasite has been cloned successfully.28
The biggest problem in this approach is spreading these new genetically 
engineered traits in nature. Work with Drosophila has shown that releasing a 
relatively small number of transformed mosquitoes should result in spreading the 
"new" genes throughout the wild population 28
At present no one has transformed mosquitoes in a stable manner, but 
researchers believe they are close to achieving it.
Major ethical and safety problems exists with this work and it will 
undoubtedly be a long time, perhaps decades before any genetically engineered 
mosquito could be released into the environment.28-29
1.11.2 Malaria Vaccines
The potential for a malaria vaccine was built upon the observation that 
people who have been repeatedly bitten by infectious mosquitoes gradually 
acquire some form of immunity. This resistance to infection has arisen because 
the immune system has mounted an effective r e s p o n s e . 7 >30
Immunity to infection can occur at three stages of the parasite's life cycle 
and is stage and species specific.
Three types of vaccine are currently under development.
1. Antisporozoite Vaccines - These are designed to prevent infection.
2. Transmission Blocking Vaccines - They retard the development of the 
parasite in the mosquito, in the hope of reducing or preventing transmission of 
the disease.
3. Anti-asexual Blood Stage Vaccines - These are designed to reduce severe 
and complicated symptoms of the disease.
SmithKline Beecham in conjunction with the US army have developed an 
antisporozoite vaccine which protected 6 out of 7 volunteers who had been 
repeatedly bitten by infected mosquitoes. The vaccine is based upon the major 
surface protein of the sporozoites, which helps them infect hepatocytes.
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Previous potential vaccines in this area failed because they did not elicit a 
sufficient immune response. New studies indicate that this can be overcome by 
using adjuvants. These are compounds which enhance an immune response.
Vaccines of the third group have been given priority by WHO as such 
vaccines could lower morbidity and mortality in children under 5 years old in 
Africa, which is the main risk group. At present several such vaccine candidates 
are subject to clinical and field trials.30
This is an exciting area of work. One major drawback is the species 
specificity of any vaccine, This could mean that a vaccine that is effective 
against, for instance, P. falciparum would be useless against any other 
Plasmodium parasite.10-30
1.12 Malaria - Will it Affect Us in the UK?
This may seem like a rather selfish question but some reports claim that 
malaria could return to northern Europe early in the new millennium as a result of 
global warming. The hot and humid conditions are ideal for the spread of 
mosquitoes. A more immediate problem is that of cheaper international travel. 31
Over the past 20 or 30 years there has been a large increase in the 
number of people taking holidays or going on business trips to malaria endemic 
areas such as the Far East, Africa and South America. The highest risk of 
infection by Plasmodium falciparum occurs in areas of West Africa, including 
Ghana and Nigeria. WHO reported in 1991 that the number of imported malaria 
cases had doubled over the past decade, with over 10,000 cases reported in 
Europe and 1000 in North America.5
This way of contracting malaria, can be avoided in most cases if a 
number of precautions are taken and the individual acts in a responsible manner.
Anyone travelling to a known endemic area of the world should see their 
doctor, who will prescribe the appropriate antimalarial drug. The patient must 
follow the prescribed doses and use it for up to 4 weeks after leaving the area.
All reasonable precautions should be taken to minimise contact with 
mosquitoes, such as sleeping under insecticide impregnated bednets and 
wearing clothes that cover arms and legs from dawn to dusk; the times when the 
mosquitoes are most active. It is also wise to apply mosquito repellents such as 
A/,A/'-diethyl-/77-toluamide. Some people may object to these measures, but they 
are a small price to pay when considering the potential consequences.27
Finally no drug is 100% effective, so if symptoms of malaria are noticed 
then immediate medical advice must be sought.5
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1.13 Conclusions
Malaria is still one of the most important public health problems in the 
world today and it is estimated that 1 in 17 of the people alive today will die from 
the disease or effects directly related to it. Science has learned the lessons of 
past mistakes and is fighting the problem on a number of fronts, with chemistry 
having a vital role to play.
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Fungi, Fungicides and Polyamines
2.1 The Effect of Fungal Plant Diseases - Past, Present and Future
Fungal plant diseases have been a constant enemy in man's bid to 
cultivate the land and provide food for himself and the community at large. 
Books of the Bible refer to blights, blasts and mildews and as early as 700 B.C. 
the Romans were making attempts to find favour with Rubigo, their god of 
rusts.32
These diseases are more prevalent and more spectacular amongst 
farmed crops because they are grown as a single cultivar. They are all 
genetically identical so if one is affected they all will be.32
Effects of such diseases have ranged from minor annoyances to major 
famines that have been responsible for millions of deaths, and the movement of 
millions of people trying to escape from the resulting hunger and poverty. One 
well documented example is the Irish potato famine of the 1840s. The potato 
was the major source of food for Irish peasants but the potato blight 
Phytophthora infestans  resulted in much lower than expected yields and 
premature rotting of the stored crop. The food shortage that resulted was 
responsible for around 1.5 million deaths and caused about 1 million people to 
emigrate.32
Just over 100 years later in 1942 a catastrophe of a similar magnitude 
struck in Bengal when favourable weather helped Helminthosporium oryzae to 
decimate the rice crop. The resulting price increase was too much for many and 
about 2 million people died of starvation.32
In more recent times in developed parts of the world plant diseases have 
been seen which did not result in famine but did cause severe economic hardship 
and a reduction in the quality of life of large numbers of people. In 1970 15% of 
the U.S. corn crop was destroyed by southern corn leaf blight, a disease induced 
by Helminthosporium maydis. This resulted in financial loss of about $1 billion.32
The economic effects of plant diseases on crops is enormous. It has been 
calculated that even with the use of crop protection products, around one third of 
the world's food is lost each year to pests and diseases. In 1987 it was estimated 
that plant diseases cost Europe $23 billion and Asia $26 billion.33
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Apart from economic needs new antifungal compounds are needed for a 
number of reasons. Three of the most important are as follows
1. To avoid the famines caused by fungal disease epidemics of the 
nineteenth and twentieth centuries.
2. Urbanisation and the increasing population has put a strain on natural 
resources and decreased the amount of good quality farming land available. 
Farmers will have to increase yields from existing agricultural land. It has been 
estimated that in 1991 there was 0.33 hectares of land to feed each person which 
will shrink to 0.2 hectares per person in 2025 and by 2050 the figure may be as 
low as 0.15 hectares per person.
3. Many crop fungi have developed resistance to common antifungal 
agents. New antifungal agents need to be found to combat this problem.33
2.2 Fungi as Plant Pathogens
As well as fungal diseases, the growth of plants can be affected by 
viruses, bacteria or by a deficiency of essential minerals in the soil. However, it 
is fungi that are by far the most destructive parasites of plants 34
Fungi derive all their nutrients for living from the plant. They share a 
common life, termed a symbiotic relationship. They live together but only the 
fungus derives any benefit. The host is harmed and this relationship is termed 
parasitic symbiosis.34
The fungal kingdom includes the varied and numerous moulds found on 
decaying vegetation and the yeasts found on the surfaces of ripe fruit. Mildews, 
rusts, smuts and many other plant pathogens also belong to this group.
The classification of fungi is to many people subjective and often 
controversial, so any numbers quoted must be treated with caution. A recent 
estimate puts the number of species at over 64,000.34
At the simplest level a fungus consists of a feeding system of threads 
called the mycelium, which produces spores on specialised reproductive 
structures. These spores are liberated and dispersed. The production of spores 
is crucial for the existence of fungi as a fungus can almost limitlessly regenerate 
from only a few surviving spores. This means that if a fungicide is to be of any 
practical use it must be very persistent.34
To pick the correct fungicide for effective control is of course essential. To 
understand which fungi are affected by which fungicide requires a knowledge of 
how the fungus transmits the infection and the life style of the fungus.
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One very useful system was developed by Barnes in 1972. He classified 
pathogenic fungi according to the method by which they reach the plant and their 
reliance on water. Three methods of spreading infection are known. These are 
by airborne pathogens, seedborne pathogens and soilborne pathogens. These 
groups are shown in more detail in the table 3 below.35
Table 3 A simplified classification of pathogenic fungi according to method 
of reaching host plants and reliance on water; examples of effective 
fungicides are included.
AIRBORNE INFECTIONS3
Group 1A. Water dependent at infection stage-motile spores. Mostly 
Oomycetes (e.g. the downy mildews, P y t h i u m , Phytophthora, 
Peronospors, Bremia, Pseudoperonospora)
Fungicides: copper, dithiocarbamates, phthalimides, Dichlorfluanid (most 
systemics are ineffective)
Group 1B Most need water to infect but spores move passively. Mycelium 
hydrophobic and lives under cuticle. Mostly members of Ascomycetes and 
Deuteromycetes (e.g.Septoria, Venturia, Sderotinia, Botrytis)
Fungicides: phthalimides, Dichlorofluanid, some systemic fungicides (e.g. 
benzimidazoles)
Group 2 Not directly dependent on water at infection stage. Live, at 
least initially under the cuticle or deeper. Includes pathogenic 
Ascomycetes, especially all the powdery mildews. Also rusts.
Fungicides: hydroxypyrimidines, Triforine, azole derivatives
SEEDBORNE INFECTIONS
Fungi belong to many different orders. Some live on seeds, others within 
them. They Include some Basidiomycetes (e.g. Ustilago), some 
Ascomycetes (e.g. Pyrenophora) and some Deuteromycetes (e.g. Septoria) 
Fungicides: dithiocarbamates, cuprous oxide, organomercury compounds, 
some systemic compounds (e.g. carboxin, azoles)
SOILBORNE INFECTONS
Fungi belong to many taxonomic groups e.g. Pythium (Oomycetes), 
Fusarium (Deuteromycetes) and Urocystis (Basidiomycetes)
Fungicides: according to the circumstances, need a correct choice from 
nabam, Dichloran, Chloroneb, copper, some systemics (e.g.  
Thiophanate-methyl thiabendazole).
a Seed or soil applications of some systemic fungicides can sometimes 
control airborne infections.
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With the above knowledge in hand a decision on what fungicide to use can 
be made. There are two broad classes of fungicide; these are systemic and 
non-systemic.35
2.3 Non-Systemic and Systemic Fungicides
Non-systemic fungicides were the dominant form of fungicides until the 
late 1960s. They are often referred to as protectant fungicides. They were 
applied as a treatment to prevent or protect against infection. They may be 
applied to seeds, soils or the plant surface but cannot penetrate into the plant 
tissues in effective amounts, hence they have to be applied before infection. This 
is an example of prophylaxis.35
Systemic fungicides can be used as a form of therapy (i.e. they can be 
effective once infection has occurred) and as prophylaxis. These chemicals can 
penetrate the plant cuticle and move through the cell membrane, thus reaching 
fungi within the plant tissue. This movement, or translocation within the plant 
allows systemic fungicides to act at places remote from the site of application and 
to protect new areas of growth. This gives another clear advantages when 
compared to non-systemic compounds. When a non-systemic compound is 
applied to a plant there is no surface redistribution, so areas missed by the first 
application remain unprotected as does any subsequent growth. This means 
repeated applications are necessary to ensure continuous protection.36
Another advantage of the penetrative nature of systemic fungicides is that 
they can be effective for a longer duration as they cannot be washed away by 
rain.35
Non-systemic fungicides do have one big advantage over systemic 
fungicides, in that they appear to be less prone to fungal resistance. One reason 
for this could be due to the high site specificity of systemic fungicides resulting in 
fungi selecting out mutants or favouring rapid gene mutation. Resistance 
persists for many years after the use of the compound has ceased and as the 
use of systemic fungicides increases so does the potential for resistance.
The low inherent toxicity and limited persistence of non-systemic 
compounds may also account for in part the low incidence of resistance among 
these compounds.
Two strategies are commonly used in order to try and reduce the chances 
of resistance developing. The first is to apply a mixture of systemic and non- 
systemic fungicides together or use them in rotation.35
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2.4 Non-Systemic Fungicides - Chemical Aspects
Non-systemic antifungal compounds are most effective when applied 
before infection. An important property of most of them is that they are insoluble 
in water. This gives them some degree of persistence, i.e. they are not washed 
away by rain water. Table 4 shows that organic non-systemic compounds are 
divided into classes that are dependent on their molecular structure.35
This section will begin with a brief discussion of some of the inorganic non- 
systemic fungicides (the only type of fungicides used before 1930), followed by a 
more detailed discussion of some of the more important organic non-systemic 
fungicides.
Table 4 Classification of non-systemic organic fungicides other than 
organometallic compounds.
Group
Organosulfur compounds
1. Dithiocarbamates
2. Phthalimides
Dinitrophenol derivatives
Chlorinated aromatics
1. Chlorinated nitro compounds
2. Chlorinated amino compounds
3. Chlorinated nitriles
4. Chlorinated quinones
Other non-systemic compounds
1. Guanidine Derivatives
2. Dicarboximides
2.4.1 Sulfur
The fungicidal effects of sulfur were known to the ancient Greeks. They 
were forgotten during the middle ages only to be rediscovered again around 1800 
when mixtures of sulfur lime were used to suppress powdery mildew on tree 
fruits. The efficacy of elemental sulfur was recognised in 1850 when it was used 
to protect grapes against powdery mildew. Sulfur was used to such an extent 
that even in the 1970s elemental sulfur was used more than any other fungicide 
in the U.S.A. This was because of its broad spectrum of activity (but it is most 
effective against powdery mildews) and its low cost. Usually it is dusted onto 
plants but it has been mixed with surfactants in sprays. For adequate effect it 
has to be used in large amounts. The mechanism by which sulfur displays its 
fungitoxicity is still uncertain and even the identity of the active form is unclear.32
Examples
Thiram, Zuneb, Mancozeb 
Captan, Folpet, Captofol
Dinocap, binapacryl
Quinozene
Dichloran
Chlorthalonil
Dichlone
Dodine acetate 
Iprodione, Vinclozolin
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2.4.2 Copper
In the Medoc region of France in 1882 it was noticed by Millardet that a 
mixture of copper sulfate and lime on the surface of grapes suppressed powdery 
mildew. Publication of his results led to extensive testing of many related 
mixtures and the widespread use of Bordeaux mixture began. Until the middle of 
the twentieth century copper-based compounds accounted for the vast majority 
of fungicides. Bordeaux mix is used extensively in the tropics where other 
fungicides are quickly washed away.32
Bordeaux mixture is toxic because copper ions from water insoluble 
deposits are chelated by fungal metabolites and absorbed into fungal cells until 
toxic concentrations of copper are accumulated. The insoluble copper sulfate 
mixture is formed via the following reaction.
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2.4.3 Organic Mercury Fungicides
Compounds of this type were first used in 1913 to control diseases of 
seeds which were spread by soil-borne pathogens. Compounds used include 
phenyl mercury acetate (14) and methyloxyethyl mercury silicate (15).37
HgOAc
The use of mercury based compounds is now decreasing due to their 
general toxicity. Mercury concentrations have increased in the food chain and 
there were reports of human poisonings resulting from the consumption of 
treated seeds 35> 38
2.4.4 Other Organometallic Fungicides
A variety of other organometallic fungicides have been used, mostly 
based on cadmium, copper and tin. They have been found to be more fungitoxic 
than inorganic metal but their use is limited due to fears about toxicity in the 
environment.35
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2.5 Non-Systemic Organic Fungicides
Organosulfur compounds are the most widely used fungicides on a 
tonnage scale today. There are two main classes of organosulfur compounds; 
the dithiocarbamates and the phthalimides.35
2.5.1 Dithiocarbamates
These compounds can be divided into two distinct groups. Type one 
compounds have no hydrogen atom attached to the carbamate nitrogen and are 
called dimethyldithiocarbamates. Type two compounds do have a hydrogen 
atom attached to the carbamate nitrogen and are referred to as 
bisdithiocarbamates. The general structures of dimethyldithiocarbamates and 
bisdithiocarbamates are represented below as (16) and (17) respectively.35
SH
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Most of the dimethyldithiocarbamates in commercial use are metallic 
complexes such as the iron complex, Febram (18) (M=Fe) and the zinc complex, 
Ziram (18) (M=Zn).
Both these compounds have limited use. For instance Febram is used 
successfully against apple scab mildew but it gives poor control of powdery 
mildew.
In contrast the disulphide oxidation product of dimethyldithiocarbamates 
Thiram (19) is successful in many areas.35
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The mode of action of type 1 compounds is unclear. It has been 
suggested that they may form toxic complexes with copper or that they may 
sequester essential trace metals from the fungus (by co-ordination). 
Dithiocarbamate ions can inactivate thiol groups and so are toxic in their own 
right.
Type two dithiocarbamates have different fungicidal properties, and many 
of them are important in treating potato and tomato blight.
The mode of action of such fungicides is associated with the labile 
hydrogen on the nitrogen; it makes the compounds unstable. They react with 
thiol groups in essential biological components and then break down to give 
products including isothiocyanates and thioureas which react with enzymes and 
proteins. It has also been proposed that ethylenethiran disulfide (20), a common 
breakdown product of all these fungicides is the actual fungitoxic agent.35
2.5.2 Phthalimide
The first phthalimide fungicide was introduced in 1952 as Captan (21). 
Although it is a broad spectrum protective fungicide it has mainly been used to 
prevent fruit damage.35- 39
S
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It is synthesised by reacting maleic anhydride with buta-1,3-diene and 
condensing the product with ammonia to produce 1,2,3,6-tetrahydrophthalimide. 
This is treated with trichloromethanesulfenyl chloride to give Captan.
Derivatives of Captan such as its analogue Captafol (22) have been 
developed and have found to be more effective.
The exact details of the mode of action of captan are unclear. One theory 
is that Captan reacts with thiol groups in fungi and is converted into thiophosgene 
which can react with thiol groups starting a chain of events that blocks enzyme 
synthesis.35
N-S-C C IoC C I
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2.5.3 Chlorine-Substituted Aromatic Fungicides
There are many examples of chlorinated aromatic fungicides. They are 
commonly used for soil or seed treatment and until recently they were of local but 
limited importance. Interest in this type of compound, such as Chlorthalonil (23) 
increased when it was used as a non-systemic component of a mixed formulation 
of systemic and non-systemic compounds in attempts to decrease the risk of 
systemic compounds causing resistance to develop. It was found to work well 
and widen its spectrum of action.35
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Chlorthalonil is made by the addition of chlorine to isophthalonitrile. It is 
believed that this type of compound may display their fungicidal activity by 
interfering with chitin synthesis in fungi cell walls.35> 40
A more detailed review of non systemic fungicides has been published 
(see reference 35, chapter 11.)
2.6 Systemic Fungicides
Systemic fungicides were first developed in the mid 1960s because it was 
felt that they would be able to attack internal mycelium thus overcoming the 
problem that arises from small surviving pieces of mycelium regenerating. It was 
also expected that systemic fungicides would reduce the need for non-systemic 
fungicides which suffer the twin problems of being subject to weathering and 
being unable to protect new areas of growth after the plant has been sprayed. In 
many instances this proved to be the case but non-systemic fungicides are still 
widely used.35
The main types are divided into groups distinguished by their molecular 
structure and mode of action. Most of the main classes of plant pathogen are 
attacked in varying degrees by one or more of these groups. Table 5 shows 
some of the commonly used systemic fungicides and their trivial names.35
Table 5 Classification of some systemic fungicides.
Group Examples
Benzimidazoles Benomyl, Carbendazim,
Thiophanate, Thiabendazole
Oxathins or carboxamides Carboxin, Oxycarboxin
Morpholines Tridemorph, Dodemorph
Inhibitors of C-14 demethylation
(a) Triazoles Triadimefon, Triadimenol,
Diclobutazole
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(b) Pyrimidines Fenarimol, Nuarimol
(c) Pyridines Buthiobate
(d) Piperazines Triforine
(e) Imidazoles Imazalil, Prochloraz, Ketoconazole
Hydroxyaminopyridines Ethirimol, Bupirimate, Dimethirimol
Antibiotics Kasugamycin, Streptomycin
Phenylamides that target Metalxyl, Ofurace, Oxadixyl
Oomycetes
The majority of systemic fungicides seem to exhibit their fungitoxic activity 
by attacking specific processes in the fungi. Site specific activities such as these 
are usually influenced by either single gene selection, amplification or 
modification. Some of the specific activities that have been attributed to systemic 
compounds include interference with nucleotide base synthesis, and with 
polynucleotide and protein formation and the synthesis of steroids.35
Systemic compounds do have the disadvantage of being more prone to 
fungal resistance than non-systemic compounds. Possible reasons for this were 
discussed in section 2.3. More resistance was reported in the decade after they 
were introduced than in the previous 50 years when only non-systemic fungicides 
were used, hence the need for new systemic fungicides.35- 36
A brief discussion of some of the important systemic fungicides will follow. 
For a fuller review see reference 35 chapter 11 and reference 36 chapter 13.
2.6.1 Benzimidazoles
Systemic fungicides of this group have had a great effect on disease 
management. They all have a wide spectrum of activity, being particularly useful 
against Ascomycetes and Basidomycetes. The benzimidazoles can be 
subdivided into three groups: the carbamates, the non-carbamates, and 
thiophanates. The benzimidazole carbamates are formed by replacing one of the 
hydrogens of the amino group of carbamic acid with the benzimidazole radical. 
The thiophanates only become benzimidazoles after application.
Benomyl (24) is synthesised by condensing o-phenylenediamine with 
methyl cyanocarbamate and then treating the product with butyl isocyanate. 
Upon uptake into the root of the plant Benomyl is hydrolysed to Carbendazim 
(25) and this moves upwards through the plant. It has been suggested that no 
matter which of the benzimidazoles is used Carbendazim is the active antifungal 
agent. Carbendazim is itself a commercial fungicide; it has developed a
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widespread resistance with several types of fungi, but it can still be effective in 
very large doses.35
NHBu
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2.6.2 Morpholines
One of the most important morpholine fungicides is Tridemorph (26). It is 
effective against powdery mildew and various other fungi. It is often used in 
mixtures with non-systemic fungicides in order to increase its spectrum of activity.
CH
CH26
Like other morpholines it exhibits its fungicidal action by inhibiting sterol 
synthesis in the fungi but the exact mechanism is not known due to the problems 
with sterol identification.35’ 36
A large number of sterol inhibitors have been used as antifungal agents, 
many of them based around nitrogen containing heterocycles such as pyridine, 
pyrimidine and triazole. They work by inhibiting the demethylation of sterols.35
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2.6.3 Hydroxyaminopyrimidine
Compounds such as Ethirimol (27) were developed in the late 1960s 
specifically to control powdery mildews and consequently are of little use against 
other fungi.35
HO
NHCpH
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Their use has declined in recent years due to high levels of resistance that 
have developed against them. Many theories have been suggested to explain 
the mode of action of Ethirimol. The current theory is that it interferes with the 
enzyme adenosine deaminase.35
2.7 Polyamines
Polyamines are simple polycationic molecules, some of which are 
abundant in cells. These include the diamines putrescine (28) and cadaverine 
(29), the triamine spermidine (30) and the tetraamine spermine (31).
Spermidine (30) and spermine (31) bearing three and four net positive 
charges respectively at physiological pH are the most cationic small molecules of 
cells which means that they bind to polyanionic molecules such as DNA, RNA 
and phospholipids. The distribution of charge in these basic polyamines may 
allow them to interact more flexibly with the acidic phosphate groups of nucleic 
acids than multivalent cations such as Mg2+, where the charge is localised.41’ 42
It is now clear that polyamines have a number of important physiological 
roles but in particular their involvement in growth and cell replication is gaining 
increasing attention. Their role in cancer development is one of a number of 
areas where the roles of polyamines has been explored.43- 44 This section will 
be concerned with their relevance with fungal diseases and malaria.
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2.7.1 Polyamine Biosynthesis
It is now known that changes in the level of putrescine (28) and 
spermidine (30) in fungi are associated with a number of morphological events. 
For example, polyamine biosynthesis increased during zoospore germination in 
Blastocladiella emersonii and morphogenesis of Mucor racemosus. The need 
for polyamines has also been considered vital in the dimorphic transition of 
Mucor species. In the yeast to mycelium conversion of M. racemosus, 
polyamine biosynthesis increases, while monomorphic mutants of M. baciliformis 
possessing low levels of the polyamine biosynthetic enzyme ornithine 
decarboxylase (ODC) cannot grow mycelially.41
Numerous studies with mutants and inhibitors of polyamine biosynthesis 
have proved that polyamines are essential for normal growth.41- 45> 46 To 
examine the possibilities of controlling fungal disease by interfering with 
polyamine metabolism it is necessary to discuss polyamine biosynthesis in plants 
and fungi.
In mammalian cells, protozoa and fungi the first step in the synthesis of 
polyamines is the decarboxylation of the amino acid, ornithine to form 
putrescine, catalysed by the enzyme ornithine decarboxylase. Putrescine is the 
precursor for further polyamine synthesis.41- 46
In plants and bacteria, putrescine can also be synthesised indirectly from 
arginine; decarboxylation with the enzyme, arginine decarboxylase gives 
agmatine which is converted into /V-carbamoylputrescine by agmatine 
iminohydrolase. The final step is completed with the help of the enzyme, N- 
carbamoylputrescine amidohydrolase (Scheme 1).41
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The polyamines spermidine and spermine are synthesised by the 
subsequent additions of aminopropyl groups donated by S-adenosylmethionine 
(AdoMet)The addition of the aminopropyl groups are catalysed by the enzymes 
spermidine and spermine synthase to give spermidine (30) and spermine (31) 
respectively.
The two pathways shown for the synthesis of putrescine and further 
polyamines are the basis for many approaches to the control of fungi. Plants and 
bacteria may synthesise polyamines essential for normal growth directly via the 
ODC pathway or indirectly via the ADC pathway. However the vast majority of 
fungi possess only the ODC pathway (it was believed until quite recently that all 
fungi synthesised putrescine via the ODC route, but there is evidence for the 
operation of the ADC route in a small number of fungi). Inhibition of the ODC 
route should be fatal to most fungi but plants should be unaffected as they have 
the alternative route to polyamine synthesis.41- 46
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2.8 Ornithine Decarboxylase and its Mode of Action
The ODC enzyme is a dimer of molecular weight 80000 to 82000. 
Problems with the isolation and purification of a significant amount of ODC has 
meant that direct mechanistic studies of ODC have been limited. It has been 
shown to deplete rapidly the polyamines putrescine, spermidine and spermine 
and to slow the proliferation rate in a number of tumour cells and parasitic 
protozoa.
ODC activity has been found in plants, protozoa, fungi and mammalian 
tissue. The enzymes will differ in each case but all ODC enzymes that have 
been investigated require pyridoxal phosphate (PLP) (32) as a co-factor for 
activity. PLP is likely to sit in a 'pocket' of the enzyme so ornithine can approach 
and undergo decarboxylation with the minimum of hindrance. ODC exhibits a 
high degree of selectivity for ornithine as a substrate. Putrescine, the product of 
the reaction, spermidine and spermine are all weak competitive inhibitors of 
ODC.47
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The mechanism for the action of ODC on ornithine is shown in Scheme 
2 47 The co-factor decarboxylates ornithine with retention of configuration. The 
hydrogen ( H e ) introduced by the conversion has the same stereochemical 
position as the carboxyl group. PLP is shown linked to the terminal amino group 
of a lysine residue of the enzyme. When a substrate appears the lysine detaches 
to leave the aldehyde and a Schiff's base is formed between the amino group 
ornithine and the aldehyde group of PLP. The bonds to the a-carbon of ornithine 
are weakened due to the attraction of the electrons towards the cationic nitrogen 
in the pyridoxal ring system and cleavage of the carboxyl group releases carbon 
dioxide; this reaction is irreversible. The resulting intermediate has extended 
conjugation. Protonation of the a-carbon gives an imine which is hydrolysed to 
give putrescine and regenerate PLP enzyme complex.47
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2.9 ODC Inhibitors
Since the first publication dealing with ODC inhibitors by Skinner and 
Johansson in 1972,48 three approaches have been investigated in order to try to 
inhibit ODC.41
1. Synthesis of analogues of the substrate ornithine and the product putrescine 
as potential competitive inhibitors.
2 . Synthesis of compounds capable of interacting or combining with the enzyme 
co-factor (PLP).
3. Design and synthesis of enzyme activated inhibitors.
The compounds of the first two areas are reversible inhibitors, while those 
in group three are irreversible inhibitors.
Most success has been achieved with the third group, enzyme activated 
inhibitors. Each group will be discussed briefly in turn.
2.9.1. Reversible Inhibition with Analogues of Ornithine and 
Putrescine
The first compound to be reported of this class was a-methylornithine 
(33).49 It is decarboxylated 6000 times slower than ornithine and also produces 
gradual inactivation of ODC. The inactivation of ODC is achieved by converting 
PLP Into pyridoxamine phosphate.
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The only compounds of this class that have shown a greater inhibitory 
effect are (£)-dehydro-analogues of ornithine and putrescine.41’ 47> 50 The (£)- 
dehydro-analogues have the carbon -carbon double bond between carbon atom 
three and carbon atom four.
2.9.2 Reversible Inhibitors that Interact with the PLP Co-factor
The target for this area of work is the first step in Scheme 2, i.e. the 
reversible formation of a Schiff's base between the a-amino carbon of ornithine 
and the aldehyde group of PLP.
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One of the most potent ODC inhibitors of rat liver ODC is 1-aminooxy-3- 
aminopropane (34). However, it also inactivates S-adenosylmethionine 
decarboxylase and spermidine synthase indicating a lack of specificity for ODC. 
a-hydrazinoornithine (35) is another potent ODC inhibitor but again it shows a 
lack of specificity as it also inhibits a number of other PLP dependent enzymes.51
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The origin of the inhibitory effect of these compounds is unclear but it may 
be due to them forming a stable adduct with PLP and thereby mimicking some 
transition state along the reaction co-ordinate.51
The problems associated with lack of specificity and the inability of these 
compounds to block polyamine biosynthesis in vivo as well as they do in cell 
cultures means less attention is now being paid to reversible inhibitors. Most 
current work is being focused in the area of enzyme-activated inhibitors.51
2.9.3. Irreversible Enzyme-Activated Inhibitors
The above nomenclature was coined by Merrell Dow chemists who took 
the initiative in this area. Enzyme-activated inhibitors are chemically inert 
pseudosubstrates of the target enzyme. Incorporated into their structure is a 
latent group that is transformed by catalytic turnover into a species that 
eventually inactivates the enzyme.41
Irrefutable proof that a compound is an enzyme-activated inhibitor requires 
the agreement of a number of pieces of evidence which are difficult, but not 
impossible to collect. However, reasonable evidence can be obtained from 
simple kinetic experiments on the crude enzyme.41- 47
Several enzyme-activated inhibitors of ODC have now been prepared, the 
most important being a-difluoromethylornithine (DFMO) (36). It was synthesised 
in the early 1970s and initially it was used in studies on animal tumours and it 
was also found to be a highly effective treatment of all stages of sleeping 
sickness caused by Trypanosoma brucei gambinese. It has been found to be an
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effective antifungal agent in many situations. Most of the important studies on 
the inhibition of ODC over the past decade have been carried out using DFMO.47
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Both enantiomers of DFMO inhibit mammalian ODC, but (-)-DFMO is 
much more potent than the corresponding (+)-DFMO enantiomer.
The in vitro reduction of fungal growth by DFMO has been reported by a 
number of workers, but many fungi appeared to be relatively insensitive to it. A 
variety of explanations has been proposed to account for this insensitivity. Two 
of the most convincing are as follows.41
1. A large intracellular concentration of DFMO results in a reduced 
effectiveness of the inhibitor due to competition for ODC.
2. Alternatively a different route for putrescine biosynthesis exists. This 
has been suggested for the insensitivity of the fungus Ceratocycstis uimi in 
Dutch Elm disease which has been attributed to ADC activity.
This can be misleading as in vitro growth of fungi on a cell culture and in 
vivo work on a plant are two very different situations. In in vitro work fungal 
mycelia are exposed to the inhibitors, on the plant. The inhibitor may affect 
germination and subsequent early development of the fungus on the plant.
Studies have shown that DFMO has powerful fungicidal activity. It is most 
active against rusts and powdery mildews and it has also shown good activity 
against Botrytis cinera. It has been shown that as little as 25 g of DFMO per acre 
would be sufficient to protect bean plants from the rust fungus Uromcyces 
phaseoli41
The mechanism by which DFMO inactivates ODC is unclear. Two 
alternative mechanisms have been suggested (Scheme 3). The original 
mechanism is shown in path a. If this was the correct mechanism then the 
enzyme-inhibitor adduct should be stable under dialysis conditions. The 
alternative pathway, path b was suggested by Likos in 1982. If inactivation of
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ODC occurred by this mechanism the enzyme-inhibitor adduct formed should 
easily be hydrolysed during dialysis.52
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2.10 Use of Polyamine Analogues to Inhibit Fungal Growth
Some of the physiological effects of polyamines were outlined in section
2.7. These led some to believe that polyamine analogues varying slightly from 
the naturally occurring compounds might be able to reduce cell growth by one or 
more of the following mechanisms: (1) inhibiting polyamine biosynthesis; (2) 
regulating biosynthetic enzymes; (3) competing for polyamine binding sites 
related to cell proliferation; and (4) binding at polyamine sites with the resultant 
disruption of macromolecular structure and proliferation.41
A number of papers have reported polyamine analogues which possess 
antitumour and antiprotozoal activity-43- 44> 53 Of more relevance here are 
reports of polyamine analogues inhibiting fungal growth.
Compounds based on putrescine have shown considerable fungicidal 
activity. It was noted that the commercially available compound keto-putrescine 
controlled a number of economically important plant pathogens. The synthetic 
putrescine analogues (E)-/V, N, A/', /V-tetraethyl-1,4-diamino-2-butene (E-TED) 
(37) and the (Z) isomer (Z-TED) and BED (38) were among a group of polyamine 
analogues that controlled at least five important crop fungi including Erysiphe 
graminis64 and Phytophthora infestans$5\n both glasshouse and field conditions. 
A number of alicyclic diamine analogues of putrescine have shown excellent 
results in reducing mildew infections on barley seedlings 41
NEt
37 38
2.11 Polyamines in Antimalarial Chemotherapy
The discovery of classes of active chemical compounds radically different 
from those used in the past to treat malaria is an exciting prospect. They may 
prevent the problems caused by cross-resistance between antimalarial drugs. 
The strategies described in sections 2.9 and 2.10 to control fungi have also been
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investigated for applications in malarial chemotherapy. Each will be discussed 
briefly.
2.11.1 The Use of Inhibitors of Polyamine Biosynthesis and Function 
as Antimalarial Agents
ODC inhibitors are being investigated as potential antimalarial agents. It 
was found that DFMO, a-monofluoromethyl-3,4-dehydroornithine methyl ester 
(39), its ethyl ester and (1 R, 4fl)-&-methyl-oc-ethynyl putrescine (40) could all 
inhibit erythrocytic schizogony of P. falciparum in vivo. Only DFMO was 
effective at limiting erythrocyctic schizogony of P. berghi in vivo. The effects 
were due to the rapid depletion of putrescine, spermidine and spermine which 
slowed proliferation rates in these cells. Results showed that the greater the 
reduction in spermine, the greater the reduction in parasitaemia. Although 
parasitaemia levels could be decreased by as much as 55% there was no 
increase in the survival times of the mice used in the experiments.56
NH
H?N
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Gillet et al. examined the effects of DFMO on exoerythrocytic schizogony 
using P. berghei as a model. They found that it could inhibit exoerythrocytic 
schizogony in mice and would also completely inhibit the sporogonous life cycle 
in the mosquito.57
The inhibition of other polyamine biosynthetic enzymes is being looked at 
as potential targets for antimalarial chemotherapy. Irreversible inhibitors of S- 
adenosylmethionine can inhibit the growth of chloroquine-sensitive and 
chloroquine-resistant P. falciparum in equal measures. These drugs worked 
during the erythrocytic cycle.58
Some very encouraging results have been obtained in these areas, which 
suggest that agents that deplete the parasite's polyamine levels may be a viable 
form of chemotherapy. Work in this area has led to the development of novel 
treatments for Trypanosoma gambiense infections in humans.58
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2.11.2 Polyamine Analogues as Potential Antimalarial Agents
Some excellent results have been obtained from the screening of a 
number of polyamines against P. falciparum and P. berghei. Perhaps the most 
important leads have been synthesised by Bitonti et al. at the Merrell Dow 
research institute, Cincinnati. They have shown that a number of 
bis(benzyl)polyamine analogues are potent inhibitors of both chloroquine- 
resistant and chloroquine-sensitive strains of P. falciparum and P. berghei in vitro 
and in vivo. 59< 60
All the compounds tested were spermine analogues that have elongated 
central polymethylene chains and either benzyl substituents or terminal free 
amines. The activity of the analogues against P. falciparum increased as the 
length of the central polymethylene chain was lengthened from 4 to 12 carbon 
atoms. The general structure of the spermine bis(benzyl)analogues is shown 
below, the greatest activity was shown when X = 7; this compound (41) was as 
potent as quinine.
Importantly it was found that combination therapy with (41) and DFMO 
resulted in cures for 47 out of 54 mice infected with P. berghei. Cured mice were 
found to be immune to reinfection with the same strain of parasite four months 
after the initial infection and drug-induced cure. The combined treatment was 
also found to be effective against severe and established infections of P. berghei 
in mice.60
P h ^ ^  N N N Ph
H H H H
41 (x= 7)
Studies involving DNA and RNA synthesis indicated that the major 
cytotoxic event may be the direct binding of the compound to DNA with the 
subsequent disruption of macromolecular synthesis and cell death. Inhibition of 
ODC activity may also in part account for the action of compounds such as (41).
It was found that the more water soluble polyamine analogues with free 
amine ends are at least 1000 times less potent than their bis(benzyl) 
counterparts. The increased lipophilic nature of the bis(benzyl) compounds may 
explain their greater efficacy as antimalarial agents as they will be more able to 
be carried into the human erythrocytes.61
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A great deal of work has to be completed before compounds of this type 
could be used in the treatment of malaria. They are, however, producing a 
number of exciting leads.
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3
Synthesis of 2-(Aminomethyl)pyridines and 2- 
(Aminoethyl)pyridines.
3.1 Introduction
The direction taken in this work was mainly as a consequence of the 
encouraging antifungal testing results obtained by Dr Dale Walters. Initial 
leads were established from a selection of diamines synthesised by Dr Steven 
Gavin, who was a past worker in the polyamine group.62
Gavin's work involved investigations of the enzyme diamine oxidase 
(DAO). This enzyme catalyses the oxidative deamination of diamines to their 
corresponding aminoaldehydes (Scheme 4).
Scheme 4
NH
CHO
NHo
Diamine O xidas^
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Two areas of his work were of particular relevance to this project:
1. oxidation of aromatic compounds with amine side chains by pea
seedling diamine oxidase; and
2 . inhibition of pea seedling diamine oxidase.
The first area involved the synthesis of a range of pyridine, quinoline, 
thiophene and pyrrole derivatives with amine side chains and testing them as 
substrates for pea seedling diamine oxidase. From a spectrophotometric 
assay values of Vmax and Km were obtained for the oxidation of each substrate 
using pea seedling DAO. The value of Vmax is the maximal rate of oxidation 
and is an indicator of the ease of oxidation rate of various substrates. The Km 
is a measure of the strength of the enzyme-substrate complex and indicates 
the binding efficiency of the substrate to the enzyme. This gave information on
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the enzymatic process and the nature of the enzyme's binding site. More 
importantly for our work was that a comparison of the kinetic data obtained 
from the various aromatic substrates allowed for studies on how the binding 
affinity and the rate of oxidation changed with the structures of the 
substrates.62 This led into work in the second area and consequently to the 
synthesis of the compounds discussed in this chapter.
As indicated in chapter 2 polyamines are known to be essential for 
normal growth and replication and diamine oxidase is vital in polyamine 
metabolism. Inhibition of DAO could therefore have a dramatic effect on 
polyamine metabolism and hence cell growth.
A number of the compounds that were shown to bind efficiently to pea 
seedling diamine oxidase were tested as inhibitors. The majority of the 
compounds tested were found to inhibit the DAO-catalysed deamination of 
putrescine (Scheme 4, (n=1)) and were shown to be competitive 
inhibitors.62
Of the compounds screened for antifungal activity by Dr Dale Walters 
the following were chosen as lead compounds: 2-(aminomethyl)pyridine (42); 
2-(aminoethyl)pyridine (43); and (±)-2-hydroxy-2-(2'-pyridyl)ethylam ine 
(44). All of Gavin's samples were tested as their dihydrochloride salt .
NH
NH NH
OH42 43 44
In this chapter substitution of the terminal nitrogen of each of the lead 
compounds will be discussed together with future work to be considered in 
this area.
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3.2 Synthesis of 2-Substituted Aminomethylpyridines
The choice of method for the synthesis of the above compounds was 
straightforward. Earlier experience within our group and numerous examples 
in the literature suggested that reductive amination would give the desired 
compounds easily and in high yield and this proved to be the case. 63> 64
Four compounds were synthesised by the route shown below in 
scheme 5.
Scheme 5
N 
45
II
O
1.RNH2, Et20
2. NaBH4, MeOH NHR
46 R = benzyl
47 R = cyclohexylmethyl
48 R = tbutyl,
49 R = nbutyl
All starting materials were commercially available and needed no 
further purification. It was found that the reaction went in highest yield when 
dry ether was used as the solvent for intermediate imine formation. The 
reaction also proceeded in dry benzene using a Dean and Stark apparatus to 
remove the water formed in the reaction. However, the reaction was 
considerably slower in this solvent.64
The yield of free base isolated after working up the reaction was 
typically between 78-85%. When the intermediate imine was dried with 
Drierite™ before treatment with sodium borohydride the yield rose to 92%. 
Drierite™ is anhydrous calcium sulfate which is available from the Aldrich 
Chemical company.
It was envisaged that purification could best be achieved by forming 
the corresponding dihydrochloride salts and recrystallising them to remove 
impurities. This however was not possible as the dihydrochlorde salts were 
very hygroscopic. In order to avoid this problem the oxalate salts were formed 
by treating the appropriate diamine with one equivalent of oxalic acid. One
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recrystallisation from water or ethanol gave the oxalate salts in an analytically 
pure form.
The compounds synthesised were screened for antifungal and 
antimalarial activity. To increase the chances of observing antimalarial activity 
we chose to synthesise diamines (46) and (47) as earlier work within the 
group and the literature suggested that optimal in vivo antimalarial activity 
was displayed when the diamine contained these large hydrophobic moieties. 
It is believed that the lipophilic character of these groups allows the 
compounds to pass into the parasitised erythrocyte more easily.
3.3 Attempted Synthesis of 2-(/V,/V-Dialkylamino)methylpyridines
Attempts were made to synthesise the corresponding diamines with two 
alkyl groups instead of one, i.e. 2-(A/,A/-dialkylamino)methylpyridines. A 
literature precedent suggested we could use commercially available 2- 
(chloromethyl)pyridine (50) to make the desired product (51) by a simple 
Sn2 displacement by heating one equivalent of the appropriate secondary 
amine and an excess of triethylamine in ethanol at 80 °C for 48 hours.65 This 
reaction was tried a number of times with the reagents used in the original 
paper, but each time the reaction ended in failure, even after correction of the 
errors in the quantities made in the paper. 2-(Chloromethyl)pyridine (50) was 
used as its hydrochloride salt and as soon as base was added a red colour 
developed in the flask which persisted. TLC of the reaction mixture and 1H 
NMR spectra of the crude products indicated a large number of products had 
been formed on each occasion. An example of the reactions attempted is 
shown in Scheme 6 below.
Scheme 6
HNPr2 1
Et3N, EtOH 
80 °C, 48 h
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3.4 Synthesis of 2-Substituted Aminoethylpyridines
Initial investigations in this area were carried out by Kieron Brear, 
another PhD student in our group.66 His strategy to synthesise compounds of
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this class was to start from 2-pyridylacetic acid and convert it into the mixed 
anhydride which was then cleaved by an amine to form the amide, which after 
reduction with BH3 yielded the desired diamine. This is shown in Scheme 7.
Scheme 7
isobutylchloroformat^ 
NEto, 0 °C
OH
5352
NHRR
BHo/THF
Reflux
NRR' NRR
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Brear experienced difficulty with this route, most commonly at the 
second stage, namely the conversion of the mixed anhydride (53) into the 
corresponding amide. This could have been due to conducting this reaction at 
room temperature. With greater experience we found it was best to carry out 
this reaction at 0 °C.
Brear tried two further methods to make amide (54). Both routes 
involved making the corresponding acid chloride. Using thionyl chloride as 
the chlorinating agent led to a complex mixture of products after the amidation 
step and using freshly distilled oxalyl chloride as the chlorinating agent also 
proved unsuccessful.
The solution to this problem lay in a reaction that is well known in the 
literature, namely the pyridylethylation of active hydrogen compounds.67- 68 
The reaction has been shown to work for the condensation of 2-vinylpyridine 
with ketones. This is a Michael condensation reaction.
The reaction is also possible between 2-vinylpyridine and primary or 
secondary amines using acetic acid as the condensing agent (Scheme 8).
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All three reactions were first reported by Levine and co-workers in the 
mid 1950s.67 It was found that amines such as pyrrole and 2,5-dimethypyrrole 
were too weakly basic to be pyridylethylated under acidic conditions but the 
condensation reaction with 2-vinylpyridine can be achieved by using sodium.
Scheme 8
N 
55
NHRR1 
AcOH, EtOH
N ^  NRR'
56 R = benzyl, R1 = H
57 R =cyclohexylmethyl,R'= H
58 R = 'butyl, R '= H
59 R = "butyl, R'=H
60 R = ethyl, R1 = ethyl
We believe that the reaction follows the mechanism outlined in 
Scheme 9. Initially 2-vinylpyridine is protonated on nitrogen by acetic acid 
then undergoes the Michael reaction with either a primary or secondary amine 
thereby reducing the aromatic character of the molecule. Full aromaticity is 
regenerated by a proton transfer reaction. A basic work-up affords the 
compound as the free base.
Scheme 9
RR'NH
NRR'
Basic work-up
NRR NRR1
R = alkyl, benzyl or cyclohexylmethyl 
R' = alkyl or hydrogen
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In order to carry out this reaction we decided to use the method of 
Shiozawa and co-workers.69 They were investigating analogues of 
betahistidine (61) as potential antivertigo agents. Betahistidine has a 
histamine like action and has found clinical use as an antivertigo agent. A 
number of analogues of betahistidine have been synthesised to investigate 
their biological effects. Some analogues have also been found to possess 
tranquillising or a antihypertensive action.
Shiozawa and co-workers found that the 4-(2-methoxyphenyl) 
piperazine (62) group was the most effective amine moiety for activity in their 
study. A number of structure-activity relationships are discussed in their 
paper.
MeO
NHCH
62
A typical procedure by Shiozawa and co-workers involved heating an 
equimolar solution of 2-vinylpyridine, amine, and acetic acid in ethanol at 
reflux for 5 hours. The reaction was worked up by evaporation of the solvent 
in vacuo followed by basification of the residue by treatment with 5 M NaOH 
and extraction with chloroform. After drying and removal of the solvent the 
product was purified by recrystallisation from an appropriate solvent.
When attempting this reaction we found that five hours was not long 
enough to allow the reaction to reach completion. TLC analysis indicated the 
presence of product after five hours but not all of the 2-vinylpyridine had been 
consumed and excess of primary or secondary amine remained. An older 
reference suggested heating the reactants at reflux for a period of eight hours, 
whether using a primary or secondary amine.67 However TLC again indicated 
that the reaction had not reached completion and even heating overnight at 
reflux did not consume all the reactants.
It was decided to allow the reaction to proceed for an appropriate length 
of time, as judged by TLC, which was typically 18-20 hours and any 
unreacted starting material was removed by flash column chromatography.
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Obviously as the reaction did not go to completion a lower yield was 
expected. The work of Shiozawa and co-workers indicated that the yield of 
the reaction was highly dependent on the structure of the amine to be 
pyridylethylated, with a range between 41-73%. Our work would also suggest 
this to be the case. A yield of 54% was achieved for the pyridylethylation of 
benzylamine to give (56) and the lowest yield was 35% in the preparation of 
(60) using the secondary amine, diethylamine. A brief survey of the literature 
suggests that the pyridylethylation reaction works best for primary rather than 
secondary amines and our work supports that observation.
It should be noted here that in going from 2 -substituted 
aminomethylpyridines (46-49), via a reductive amination reaction to 2- 
substituted aminoethylpyridines (56-60), via a Michael reaction, i.e. the 
addition of one methylene unit we see a decrease in yields from over 90% to 
less than 40% in some cases. Purification is also more time consuming and 
expensive as compounds (56-60) have to be subjected to column 
chromatography, whereas compounds (46-49) can be purified by 
crystallisation.
Compounds such as (56) and (57) can be made by the reductive 
amination route using commercially available 2-(2-aminoethyl)pyridine and 
the appropriate aldehyde. As a comparison of the Michael type reaction with 
the reductive amination, compound (57) was synthesised by both routes. 
The yield achieved by the reductive amination route (Scheme 10) was 95% 
as compared to 36% from the Michael reaction.
Scheme 10
1. CeHnCHO, EtOH
2. NaBH4, MeOH
NH
5743
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3.5 Synthesis of (±)-2-Hydroxy-2-(2'-pyridyl)ethylamine (44)
NH
OH
44
After initial evaluation of the antifungal properties of (±)-2-hydroxy-2-(2‘- 
pyridyl)ethylamine hydrochloride (44) larger quantities were required by Dr. 
Dale Walters for further assays and testing. We also devised a route to 
prepare substituted analogues.
We decided to synthesise (44) by much the same method as Gavin as 
he found the reaction reasonably efficient with an overall yield of 54% for two 
steps.
3.6 Synthesis of (±)-2-Hydroxy-2-(2'-pyridyl)nitroethane (63)
The first step in our synthesis involved the condensation of 2- 
pyridinecarbaldehyde (45) with nitromethane, using potassium fluoride as a 
base to give (±)-2 -hydroxy-2 -(2 '-pyridyl)nitroethane.70 The reactants were 
stirred at room temperature for three hours, then at 40 °C for one hour. After 
purification by silica gel chromatography and crystallisation, the product, a p- 
nitroalcohol was isolated in 60% yield (Scheme 11).
Scheme 11
c h 3n o 2
KF, propan-2-ol
NO
OH45 63
The above reaction is an example of the Henry reaction, or as it is 
sometimes known the nitroaldol addition reaction.71 Deprotonation at the 
carbon adjacent to the nitro group can be achieved with a number of bases
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(the pKa of nitromethane is 10.2). The resultant anion is nucleophilic and 
hence will add to an aldehyde or ketone. This is one of the classical C-C bond 
forming processes.
Often the corresponding nitroalkene can be generated in situ under the 
reaction conditions.72 There was no evidence of this reaction occurring under 
our conditions. This dehydration reaction can also be facilitated by a number 
of reagents including A/,A/'-dicyclohexylcarbodiimide (DCC)73, pivaloyl 
chloride,74 and phthalic anhydride.75 A combination of the Henry reaction 
followed by dehydration to form the alkene is known as a Knoevenagel 
reaction.72
As well as being a classical C-C bond forming reaction the nitro group 
introduced via a Henry reaction is extremely versatile in synthesis as it can be 
transformed into a number of other functional groups. 76
The nitro group can be replaced by hydrogen in a denitration reaction 
or converted into a carbonyl group by the classical Nef reaction (Scheme 
12).76 This reaction requires vigorous conditions and reductive hydrolysis 
with TiCl3 (aq) is usually a better way of generating the aldehyde or ketone. 76 
Nitro groups can be reduced to generate oximes ,77 ketones ,72 
hydroxylamines78 or amines.76 Primary nitro groups can be dehydrated to 
produce nitrile oxides, which are important compounds in cycloaddition 
reactions. 79
Scheme 12
n o 2 NaOH (aa), ^ /  H20 Ph\ ^ .C H O
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3.7 Reduction of (±)-2-Hydroxy-2-(2,-pyridyl)nitroethane (63)
NO.
OH
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The conversion of the (3-nitroalcohol (63) to the corresponding (3- 
aminoalcohol (44) could have been achieved by a number of reagents 
including lithium aluminium hydride.76 We chose to use a method based on 
catalytic hydrogenation. We investigated two possibilities: catalytic 
hydrogenation of the substrate at medium pressure;80 and transfer 
hydrogenation at atmospheric pressure using ammonium formate as the 
source of hydrogen.81 These reactions are shown in Scheme 13.
Initially transfer hydrogenation using ammonium formate found use in 
peptide synthesis for the rapid removal of hydrogenolysable protecting groups 
under mild conditions. A variety of protecting groups including benzyl, tbutyl 
and nitro were removed in under 10 minutes in yields above 90%.82
This work was exploited by a number of people including Barrett and 
Spilling who converted a series of p-nitroalcohols into the corresponding p - 
aminoalcohols with retention of configuration by transfer hydrogenation using 
ammonium formate and palladium on carbon.83 Reductions of this type had 
usually been carried out with hydrogenation over Raney nickel or platinum. In 
most cases the reaction was complete well within an hour.82
The major advantage of this method for reducing a nitro group is that it 
is rapid and selective in the presence of other functional groups such as 
nitriles and carbonyl groups. Ammonium formate is inexpensive, stable and 
non-toxic and can be used with either palladium-carbon or Raney-nickel 
catalysts.81
Scheme 13
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It is believed that the active species in the process is the formate anion 
and the various systems developed use ammonium formate as the hydrogen 
donor and palladium on carbon as the heterogeneous catalyst.84
We attempted the reaction a number of times on (63) using ammonium 
formate with palladium-carbon for various time periods between 1-48 hours 
without success. A typical procedure involved dissolving the nitroalcohol (63) 
in methanol and then adding 50 mg of palladium on carbon followed by 5 
equivalents of ammonium formate and stirring the resultant mixture at ambient 
temperature. We expected the reaction if successful to be complete within a 
few minutes, but TLC indicated only the presence of starting material. This 
was unexpected as examples of the reaction with benzyl compounds are 
found in the literature.85 However, we could not find any examples with 
pyridyl substrates.
As Gavin had completed the transformation successfully using catalytic 
hydrogenation with palladium on carbon at 3.5 atm we decided to synthesise 
the desired p-aminoalcohol by this method. This reaction is operationally 
simple. A mixture of the p-nitroalcohol and palladium on carbon dissolved in 
methanol was hydrogenated for 17 hours at ambient temperature. The 
product was separated from the palladium on carbon by filtering the reaction 
mixture through a plug of Celite.62 Purification of the product was achieved by 
formation of the corresponding oxalate salt and its subsequent crystallisation.
3.8 Synthesis of Substituted (±)-2-Hydroxy-2-(2'-pyridyl)ethylamines
N ^ iT ^ ^ N R R 1
OH
R = alkyl, benzyl, cyclohexylmethyl
R' = hydrogen
The route used to synthesise (44) gave us the desired compound in 
reasonable yield. However, it was not amenable to the synthesis of the 
analogues we required for evaluation as antifungal and antimalarial agents.
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We of course wanted a route that would allow us to synthesise a range 
of analogues. We believed this could be best achieved by the regioselective 
opening of the epoxide (64) with the appropriate nucleophile (Scheme 14).
Scheme 14
1.Nu
Nu
64 OH
3.8.1 Synthesis of 1-(2-Pyridyl)oxirane
A number of methods exist for the synthesis of epoxides some of which 
could be applied to synthesise (64) and others which could not. A brief 
discussion of possible methods will follow.
3.8.2 Electrophilic Reagents
In the laboratory epoxides are usually prepared by the treatment of an 
alkene with a peroxyacid such as m-chloroperoxybenzoic acid, m-cpba 
(65)86 The alkene, 2-vinylpyridine (55), is available but we believed that 
the reaction between it and electrophilic reagents such as m-cpba (65) would 
result in A/-oxide formation.
Scheme 15
55 65
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3.8.3 Sulfonium Methylides
Corey and Chaykovsky showed that the dimethyloxosulfonium 
methylide and the dimethylsulfonium methylide are nucleophiles that transfer 
a methylene moiety to a number of electrophilic unsaturated linkages such as 
C=N, C=S and in some cases C=0 .87
The oxosulfonium methylide is less reactive and interacts with the 
carbonyl group of aromatic and non-conjugated aldehydes and ketones to 
form oxiranes. It reacts with a,(3-unsaturated Michael acceptors to form 
cyclopropyl ketones.87
The sulfonium methylide reacts with both types of substrate to give 
oxiranes exclusively.87
Our desired epoxide (64) has been synthesised using either methylide 
and 2-pyridinecarbaldehyde. With the dimethylsulfonium methylide (66) a 
yield of 3% was reported (Scheme 16). The dimethyloxosulfonium 
methylide gave an improved yield of epoxide, but it was still relatively poor at 
17%.88
Both methylides can be purchased commercially or synthesised from 
the corresponding chloride or iodide. Dimethyloxosulfonium methylide can be 
synthesised by treatment of trimethylsulfonium chloride or iodide in dry 
dimethyl sulfoxide with sodium hydride. The reaction is carried out under 
nitrogen and proceeds rapidly with the evolution of hydrogen to give the ylide 
and sodium halide. 87
The poor yields and the possible problems controlling odorous by­
products such as dimethylsufide (67) meant other routes were examined.
Scheme 16
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3.8.4 Lithiation of 2-Chloromethylpyridine
A short paper appeared in the literature detailing the synthesis of 
oxiranyl pyridines by lithiation of 2 -chloromethylpyridines and their 
subsequent reaction with carbonyl compounds. We did not follow this 
procedure as experimental detail was sparse and the reaction appeared only 
to be applicable to the synthesis of oxiranes substituted with bulky groups.89
3.8.5 Enzymatic Methods
Imiuta and co-workers synthesised epoxide (64) in high enantiomeric 
excess while examining the product stereoselectivity in the microbial reduction 
of a-haloaryl ketones. 90
The a-haloaryl ketone (68) was shaken with a two-day-old culture of 
Cryptococcus macaerans to give the bromohydrin (69) in enantiomeric 
excess of 80% or greater. Treatment of the bromohydrin with base gave the 
(S)-(-) enantiomer (Scheme 17).
At this point we wanted to develop a synthesis of racemic p -  
aminoalcohols. However, the synthesis we did use to make racemic 1-(2- 
pyridyl)oxirane did rely on intermediate bromhydrin formation.
Scheme 17
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Reduction
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3.8.6 Epoxide Synthesis via a Bromhydrin
Bromohydrins can be prepared by the electrophilic addition of HO-Br to 
alkenes using Br2 and water but in practice very few alkenes are soluble in 
water.91
We chose to synthesise (64) by adapting the methods of Hanzlik and 
co-workers92 and those of Thurkauf and co-workers93 who both synthesised 
1-(2-pyridyl)oxirane. The reaction is shown below in Scheme 18.
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dioxane: water (3:7)
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We synthesised the epoxide by treating 2-vinylpyridine with acetic acid 
in a 3:7 mixture of dioxane and water and then adding A/-bromosuccinimide in 
small portions. The bromohydrin was not isolated, but reacted with sodium 
carbonate and the reaction was stirred overnight during which time the mixture 
became very viscous. The reaction was worked-up in a similar manner to that 
of Thurkauf and co-workers. When purifying the product by distillation we 
found it was better not to precipitate excess succinimide beforehand as this 
led to problems. The crude epoxide was very viscous and stuck to the sinter 
and to the precipitated succinimide. Distillation gave a clear oil that yellowed 
on standing after a few days, even when refrigerated. 1H NMR spectroscopy 
indicated that the purity was unaffected. Thurkauf and co-workers claimed to 
achieve a yield of 66% for this synthesis. Typically our yield was between 45 
and 55%. Our lower yield may have been a consequence of not removing the 
succinimide before distillation.
Synthesis of (64) by this method allows us to overcome the problems 
associated with the poor solubility of alkenes. We carried out the reaction in 
aqueous dioxane (other solvents commonly employed with water in this type 
of reaction include tetrahydrofuran92 and dimethylsulfoxide94) using N- 
bromosuccinimide (NBS) as the bromine source. NBS slowly decomposes in 
water to generate Br2 at a controlled rate. 96< 96 Another advantage of using 
NBS is that it is stable and easy to handle. Bromine could be used to form the 
intermediate bromonium ion but as a reagent bromine is more dangerous and 
difficult to handle.
The bromonium ion is attacked by water to generate the bromohydrin. 
Treatment of the bromohydrin with a base effects an intramolecular 
substitution to afford the epoxide. 96 This final step, the synthesis of epoxides 
by base treatment of halohydrins, is in fact an intramolecular Williamson ether 
synthesis. The nucleophilic oxygen atom and the electrophilic carbon atom 
are in the same molecule.96
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Having found a reliable method to synthesise large amounts of epoxide 
(64), its reaction with the appropriate amine gave the p-aminoalcohols we 
desired.
3.8.7 Regiochemistry of Epoxide Ring Opening
The direction in which unsymmetrical epoxides are opened is 
dependent on the conditions used. We wanted to open the oxide with a basic, 
nitrogen nucleophile and under these conditions a typical Sn2 type reaction 
takes place at the less hindered epoxide carbon.97 This is shown in Scheme 
19.
Scheme 19
o
N
64
RR'NH
OH
NRR'
70 R = benzyl, R'= H
71 R =cyclohexylmethyl, R' =H
72 R =nbutyl, R'=H
In contrast if acidic conditions are employed attack of the nucleophile 
occurs primarily at the more substituted carbon atom. The mechanism for acid 
catalysed opening of an epoxide is interesting as it appears to be midway 
between an Sn1 and an Sn2 reaction. Studies have shown that the transition 
state has an Sn2 like geometry but a high degree of S |\|1 carbocation 
character. The protonated epoxide is not a full carbocation but it is strongly 
polarised so that the positive charge is shared by the more highly substituted 
carbon atom. Therefore, the nucleophile attacks this more highly substituted 
site (Scheme 20).98
Scheme 20
RNH
OH
NHR
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We wanted to synthesise p-aminoalcohols so we chose to use basic 
conditions to open the epoxide. We found it best to heat a solution of the 
epoxide at reflux in methanol with the appropriate secondary amine until all 
the epoxide had been consumed. Typically this took about eight hours and 
then the mixture was stirred at room temperature overnight. TLC indicated that 
an excess of secondary amine remained at completion of the reaction.
The first of the p-aminoalcohols synthesised by this method was the 
benzylated analogue (70). We worked up the reaction by dissolving the 
residue in ether and extracting with acid, washing the solution with ether and 
then adding sodium hydroxide pellets until the solution was basic. This 
solution was extracted with chloroform and dried with potassium carbonate. 
1H NMR spectra of the concentrated extract indicated that an excess of 
benzylamine remained. We removed this excess by distillation. The 
benzylamine distilled first and our desired p-aminoalcohol (70) remained. 
After recovery of the free base we converted it into the corresponding oxalate 
salt by dissolving it in a small amount of methanol and treating it with one 
equivalent of oxalic acid dissolved in methanol. We expected precipitation of 
the salt to occur rapidly, but this was only achieved by vigorous scratching of 
the solution with a glass rod. The product was purified by crystallisation from 
water.
Compounds (71) and (72) were synthesised in the same manner but 
in these cases it was found that the excess of amine was removed during the 
work-up of the reaction and there was no need for further purification before 
salt formation, except for (72) which unfortunately was destroyed when we 
attempted purification by distillation.
The 1H NMR spectra of compounds (70), (71) and (72) were as 
expected for compounds with a typical ABX system. For instance the 
diastereotopic methylene group of (70) appeared as two doublets of doublets 
at 8 3.25 (J9.3 and 3.7) and 83.42 (J 9.7 and 3.4). The proton on the carbon 
of the secondary alcohol, at the chiral centre couples differently to each of the 
diastereotopic protons of the methylene, and it comes into resonance at 8 
5.20 (J 5.9 and 3.3).
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3.9 Studies Towards an Enantioselective Synthesis of 2-Hydroxy-2- 
(2'-pyridyl)ethylamines
While awaiting both antifungal and antimalarial evaluation of our 
racemic p-aminoalcohols, we turned our attention towards developing a 
route to synthesise these compounds in an enantiomerically pure form.
Biological systems are usually homochiral. So, it is probable that 
enantiomers will have different biological effects. In general three types of 
activity are observed.98
1. All the desired activity belongs to one enantiomer and the other 
enantiomer is inactive or has a different activity. This is commonly observed. 
This means that separation of the racemic mixture into a single enantiomer 
should give us a more potent agent, which should also be less toxic than 
using the racemate.
2 . The enantiomers differ in potency. In this case most of the activity is 
in one enantiomer and the other displays weaker activity. The less potent 
enantiomer has some binding with the biological site but it is a weaker 
interaction. This is also a common occurrence.
3. Both enantiomers have the same activity. This is rarely seen and not 
expected since activity depends on the agent interacting with a homochiral 
biological site.
In terms of potency and selectivity and reducing toxicity there is a 
strong case to develop drugs as single enantiomers.98
We believed that we could resolve the racemic mixtures of p -  
aminoalcohols by classical techniques. This could be achieved by making 
diastereoisomeric salts, separating them by fractional crystallisation and then 
regenerating each enantiomer. So, ideally any route we considered should 
have a small number of high yielding steps.
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3.9.1 Synthesis via Regioselective Opening of Chiral Epoxides
Our original idea was to utilise the powerful regioselectivity displayed 
when opening epoxide (64) with an amine. We needed a method to 
synthesise both enantiomers of the epoxide selectively.
We knew that the a-brom oketone (68) could be subjected to a 
microbial reduction to give the enantiomerically enriched bromohydrin (69), 
which in turn could be cyclised to give the (F?)-(-)-enantiomer of epoxide (64). 
However, this would only give us access to one enantiomer. Fortunately a 
number of reagents for reducing a-bromoketones to either enantiomer of the 
corresponding bromohydrin are commercially available. Many are homochiral 
organoboranes based on a-pinene (7 3 )."  Other reagents that can perform 
such reductions include Corey's oxazaborolidine,100 and its variants101 as 
well as binaphthyl-modified lithium aluminium hydride reagents.102
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Our first idea involved bromination of the appropriate ketone (74) to 
form a-brom oketone (6 8 ) and reduce it to either enantiomer of the 
corresponding bromohydrin (69) using the appropriate organoborane 
reagent. Treatment of the bromohydrin with base should give an 
enantiomerically enriched epoxide which should be opened regioselectively 
with an amine such as benzylamine, in the manner discussed in section
3.8.7. The overall method is shown in Scheme 21 .
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The reagent we proposed to use for the reduction of the bromoketone 
(68) was p-chlorodiisopinocamphenylborane (IC2BCI) which is commercially 
available in both of its enantiomeric forms, known as DIP-CI™. It has been 
found to reduce substituted aryl alkylketones with "extraordinary" efficiency, 
with enantiomeric excesses of greater than 97% not being uncommon. 
Another advantage of using this reagent is that the stereochemistry of the 
product is highly predictable."
The reduction sequence, including the synthesis of the reagent 
involves four s teps."
Step 1 - Formation of the reagent by treatment of BH3.SMe2 and a-pinene 
with H2BCI. SMe2 or H2BCI.OEt2 (eq 1).
2/3 BHo.SMe
1/3 BCU.SMe.
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Step 2 -Asymmetric reduction of the ketone (eq 2).
(eq 2)
Step 3- Treatment with acetaldehyde with the subsequent elimination of the 
other unit of a-pinene (eq 3).
Cl1 I Cl1
CH3CHO 
H o ' Ipc -----2----- ►
XRs Rl
Bv
H o ' 0E t
■ X nRs Ri_ / b L (eq 3)
Step 4-Hydrolysis of the product mixture (eq 4).
Cl
i
H o  0E t Na0H H« P HV.'"  ► V  EtOH + Na[B(OH)4] +NaCI
Rs Rl Rs Rl
(eq 4)
Overall one equivalent of the ketone is reduced by two equivalents of 
a-pinene and one equivalent of BHCI2. The a-pinene can be recovered 
without loss of optical activity and can be re-used. 1.5 moles of ketone are 
reduced per mole of BH3.99
The route shown in Scheme 21 appeared a good choice as it was 
relatively short; there was a literature precedent for the first step: and it took 
advantage of chemistry we already had shown worked. However, on further 
investigation we believed we could shorten the route by using the set of
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reactions shown in Scheme 22. By reacting the a-bromoketone (68) 
directly with an amine such as benzylamine to make the keto-diamine (75) 
and then reduction with DIP-CI™ we believed that we could synthesise our 
desired product without the need to synthesise the epoxide. Another 
advantage of this scheme was that we would isolate ketodiamines such as 
(75). Foster and Walters showed that ketoputrescine controlled a number of 
economically important plant pathogens.41
Scheme 22
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3.9.2 a-Bromination of Ketones
The reagent of choice for the a-bromination of ketones is molecular 
bromine. Two sets of conditions can be employed, base catalysed103 
bromination and acid catalysed bromination.104 Base catalysis is rarely used 
as the reaction is very difficult to stop after mono-bromination. Typically the 
product of the reaction is bromoform and the salt of the corresponding 
carboxylic acid. This reaction is known as the bromoform reaction and is often 
used to produce carboxylic acids with one less carbon atom than the starting 
ketone (Scheme 23).103
72
Scheme 23
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CH
CHBr.
a-Bromination of ketones is usually achieved under conditions of acid 
catalysis (Scheme 24). The reaction proceeds via enol intermediates. The 
first step is an acid-base reaction between the catalyst and the carbonyl group 
of the ketone to form a protonated carbonyl compound. This loses an acidic 
proton from the a-carbon to yield an enol intermediate, which attacks the 
positively polarised bromine atom to give an intermediate cation. The cation 
loses a proton to form the halogenated adduct.104
Scheme 24
Commonly used catalysts for the bromination reaction are acetic 
acid104 and hydrobromic acid.105 In our attempts to synthesise (68) we 
investigated the use of them separately and together.
We purchased our ketone (74) from Lancaster synthesis Ltd. It was a 
light brown liquid and 1H NMR spectroscopy indicated that it was impure. We 
purified it by distillation to afford a colourless starting material.
We attempted the reaction using acetic acid as the catalyst a number of 
times without success. A typical procedure involved the dropwise addition of a 
small excess of neat bromine to a stirred solution of 2-acetylpyridine (74) and 
acetic acid containing 48% HBr at 0°C and then raising the temperature to 
40°C for 1.5 hours and to 75°C for 1 hour, cooling, filtering and washing the
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product.106 These conditions were unsatisfactory. The 13C NMR spectrum of 
the product indicated a number of products had been produced and low 
resolution mass spectrometry indicated the presence of the dibrominated 
ketone.
Alterations were made to the experimental procedure such as adding 
the bromine as a solution in acetic acid, carrying out the entire reaction at 
0°C, room temperature and 75°C as well as varying the reaction times, but 
all proved unsuccessful.
Applying the method of Taurins and Blaga105 we obtained the 
compound in a yield of 75%. Operationally this method was very simple. One 
equivalent of the ketone was dissolved in 48% hydrobromic acid at 70 °C a 
solution of one equivalent of bromine in the same acid was added slowly with 
vigorous stirring. The temperature and the vigorous stirring was maintained 
for three hours. Upon cooling a crystalline product dropped out of solution 
which was washed, filtered and dried in vacuo. Crystallisation from 20% 
hydrobromic acid gave the a-bromoketone as the pyridinium salt.
3.9.3 Nucleophilic Substitution of 2-Bromoacetylpyridine
We believed that the displacement of bromide by a nitrogen 
nucleophile in a typical Sn2 reaction would be straightforward. Unfortunately 
this did not prove to be the case. Despite repeated efforts we failed to isolate 
the desired product. Much is known about the Sn2 reaction as it is important 
in organic synthesis. We don't intend to cover the topic in great depth, but 
Table 6 details the favourable conditions for a successful Sn2 nucleophilic 
displacement.107
Table 6 Effect of reaction variables on nucleophilic substitution
Solvent Nucleophile/base Leaving group Substrate structure
Strong effect Strong effect Strong effect Strong effect
Reaction favoured 
by polar aprotic 
solvents
Favoured by good
nucleophile/weak
base
Favoured by good 
leaving group
favoured by 1° 
substrates
When carrying out the reaction we took each of these factors into 
account where possible. The structure of the substrate was fixed and we had
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in mind two products in particular, those being the enantiomerically pure 
forms of (70) and (71), so this limited the choice of nucleophiles we could 
employ.
HO HO
70
If we consider the substrate the ideal structure should allow for the easy 
approach of an incoming nucleophile. The transition state of the Sn2 reaction 
involves partial bonding between the attacking nucleophile and the substrate 
and the transition state is co-planar. Bulky substrates which shield the carbon 
atom to be attacked by the incoming nucleophile react more slowly than less 
hindered substrates because the transition state is sterically hindered and 
consequently of a higher energy. The presence of the large pyridine ring of 
the a-bromoketone may contribute to a degree of steric congestion, but there 
should be sufficient room to allow the nucleophile, substrate and leaving 
group to reach a co-planar arrangement.108
The leaving group is another very important consideration in an Sn2 
reaction. The leaving group in most reactions is expelled with a negative 
charge, so, it follows that the best leaving groups are those that best stabilise 
the negative charge. The most stable anions (weak bases) also make the best 
leaving groups. This can be rationalised by again looking at the transition 
state of an Sn2 reaction. The charge is distributed over both the attacking 
nucleophile and the leaving group. This means that the transition state is more 
stable and thus the reaction is faster. The bromide ion is an excellent leaving 
group, the pKa of the conjugate acid is -9 and it has a relative reactivity of 
10,000. The iodide ion is a better leaving group as the pKa of the conjugate 
acid is -9.5 and it has a relative activity of 30,000. The chloride ion is the 
strongest base with the pKa of the conjugate acid being -7 and is the poorest 
nucleophile of the three and it has a relative reactivity of 200.109
Another important variable in the Sn2 reaction is the nature of the 
attacking nucleophile. As we mentioned earlier we wanted to synthesise the 
benzyl (70) and cyclohexylmethyl analogues (71). This limited our choice of
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nucleophiles to benzylamine and cyclohexylmethylamine. In our studies we 
exclusively investigated the reaction with benzylamine.
When trying to explain the role of the nucleophile in the Sn2 reaction it 
is best to think of it in terms of the nucleophilicity of the attacking species. 
Nucleophilicity has been defined as the relative attraction of the attacking 
species in the Sn2 reaction for the carbon atom bearing the leaving group. 
Under a set of standard conditions, the stronger the nucleophile the faster the 
reaction.110
No single factor can be used to explain nucleophilicity, however, we 
can make a number of broad generalisations. It must be remembered that the 
following rules are not invariant but depend on a number of factors including 
the substrate, solvent and leaving group.
With the above proviso there are four main principles that govern 
nucleophilicity for the Sn2 reaction in solution.111
1. A nucleophile with a negative charge is a more powerful nucleophile than 
its conjugate acid.
2. In comparing nucleophilicites of species whose attacking atom is in the 
same row of the periodic table, nucleophilicity is approximately in order of 
basicity.
3. Going down the periodic table, nucleophilicity increases. For instance a 
sulfur nucleophile is more powerful than its oxygen analogue and any 
phosphorus nucleophile is more potent than its nitrogen counterpart.
4. The freer the nucleophile, the greater the rate of reaction. Solvents that 
poorly solvate the nucleophile lead to faster reaction and solvent free or gas 
phase reactions are even faster.
This is only a very basic description of a very complex topic For more 
detail see reference 111 pages 348-352 and references therein.
The first solvent we looked at for the reaction was DMF. As a polar 
aprotic solvent this should be an ideal solvent for an S n2 reaction. 
Unfortunately when we attempted the reaction we isolated a brown oil which 
1H NMR spectra and TLC indicated was a complex mixture of products and a
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white solid which 1H NMR spectroscopy proved to be benzylamine 
hydrobromide. The reaction was attempted a number of times varying the 
amount of benzylamine and temperature, but the results were always similar.
Other solvents investigated were ethanol, water, acetone and DMSO, 
all without success. With each of the other solvents, under various conditions 
a similar outcome to that described above was achieved, namely the isolation 
of a brown oil which could not be purified and benzylamine hydrobromide.
We decided to investigate the number of equivalents of benzylamine 
used in the reaction. Initially we used two equivalents, one to act as 
nucleophile and one to mop up the hydrogen bromide by-product formed. We 
increased the number of equivalents of benzylamine from two through to five 
but without success. Instead of using benzylamine as a base as well as 
nucleophile in the reaction we used various amounts of triethylamine but 
again this proved fruitless. Again a complex brown oil was isolated, this time 
with solid triethylamine hydrobromide.
We can give no reason for the failure of this reaction, but it is possible 
that contrary to our initial belief the large pyridyl group of the substrate 
prevented the nucleophile approaching the substrate with the correct 
geometry.
Unfortunately time constraints meant we did not investigate this area 
any further.
3.10 Future Work
The work presented in this chapter could be extended in a number of 
ways. The most obvious and straightforward way would be to alter the 
position of the substituent on the aromatic ring of the most active compounds.
3.10.1 Synthesis of 3- and 4- Substituted Aminomethylpyridines
3-Pyridinecarbaldehyde and 4-pyridinecarbaldehyde are both 
commercially available. By using the reaction described in section 3.12 we 
would get compounds such as (76) and (77). These are putrescine 
analogues.
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NRR'
NRR'
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R=H, R'=H or alkyl, benzyl or cyclohexylmethyl
3.10.2 Synthesis of 3- and 4- Substituted Aminoethylpyridine
3-Vinylpyridine and 4-vinylpyridine are commercially available. Using 
the Michael type reaction described in section 3.14 we would be able to 
examine compounds of the type (78) and (79). Compounds (78) are 
putrescine analogues whereas compounds such as (79) are cadaverine 
analogues.
NRR
NRR
78 79
R=H, R'=H or alkyl, benzyl or cyclohexylmethyl
3.10.3 Synthesis of 3- and 4-substituted (± ) -H y d r o x y -2 - (2 '-  
pyridyl)ethylamines
The availability of 3-vinylpyridine and 4-vinylpyridine also makes it 
viable to make compounds such as the putrescine analogues (80) and the 
cadverine analogues (81) by the reactions discussed in section 3.17.
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R=H, R'=H or alkyl, benzyl or cyclohexylmethyl
3.10.4 Synthesis of Analogues of ( ± ) - 2 - H y d r o x y - 2 - ( 2 ‘ - 
pyridyl)ethylamines
A number of structural alterations could be investigated and a few are 
indicated below.
1. Extension of the carbon chain by one unit (Scheme 25).
Literature precedent exists for the synthesis of 2-allylpyridine (82).112 
from which we could synthesise the corresponding epoxide. This would give 
rise to a new class of homo-putrescine analogues (83).
Scheme 25
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R=H, R'=H or alkyl or benzyl or cyclohexylmethyl
2. Replacement of the hydroxy group by chlorine or bromine.
Treatment of the hydroxy compound with phosphorus trichloride113 or 
thionyl chloride114 should give rise to the chlorinated analogue (84).
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R=H, R'=H or alkyl, benzyl or cyclohexylmethyl
In an analogous fashion treatment of the alcohol with phosphorus 
tribromide115 or thionyl bromide116 would give the corresponding bromide 
(85).
NRR
Br85
R=H, R'=H or alkyl, benzyl or cyclohexylmethyl
Further investigations into the synthesis of enantiomerically pure 2- 
hydroxy-2-(2'-pyridyl)ethylamines could be undertaken. It may be more viable 
to synthesise them via the route outlined in Scheme 22 which does not 
involve an Sn2 reaction on a 2-bromoalkylpyridine.
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4
Investigations Towards Cyclic and Bicyclic 
Putrescine Analogues
This chapter will be split into two sections; the first will deal with our 
experiences in the area of six-membered cyclic putrescine analogues, and 
the second will detail our work in the field of bicyclic putrescine analogues.
4.1.1 Cyclic Putrescine Analogues
The lead compound for work in this area was 1,2-bis(aminomethyl)-4,5- 
dimethylcyclohexa-1,4-diene dihydrochloride (86) which is known as BAD.
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This compound had previously been synthesised within the group and 
was found to have excellent antifungal properties and indeed had been 
patented for this purpose.117 It was found to reduce powdery mildew infection 
of barley seedlings by 93%. As was shown in chapters one and two 
polyamines can show antifungal and antimalarial activity by similar 
mechanisms. The co-sponsors of this work required a sample of BAD to test 
for in vivo antimalarial activity.
4.1.2 Synthesis of BAD
We synthesised BAD from commercially available starting materials in 
an overall yield of 12%, as indicated in Scheme 26. A brief discussion of the 
reactions employed follows.
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4.1.3 Diels-Alder Cycloaddition
The first stage in the synthesis was a Diels-Alder reaction between 2,3- 
dimethyl-1,3-butadiene (87) and dimethyl acetylenedicarboxylate (88) to give 
the cyclic diester (89). The reaction proceeds smoothly in a yield of 80%.118 
The electron withdrawing substituents on the dienophile and the electron 
donating substituents on the diene are responsible for an accelerated reaction 
rate.
The Diels-Alder reaction is also influenced by the choice of solvent. 
Many have been used successfully in the reaction, including benzene, 
toluene, ether and ethanol. We carried out this Diels-Alder reaction in water 
to take advantage of the hydrophobic effect to increase the rate of reaction.119
The hydrophobic effect was first explored by Breslow and co-workers, 
although it had previously been noted that water can have a remarkable effect 
on the rate of the Diels-Alder reaction.119 Breslow et a l conducted a number 
of experiments and concluded that the rate enhancement was not due to 
solvent polarity effects. Breslow proposed that the rate acceleration displayed 
in water was due to the promotion of hydrophobic packing of the reactants.119
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Evidence for the hydrophobic effect was gathered by conducting a 
number of experiments in which reaction rates were increased in the presence 
of additives such as lithium chloride which increase hydrophobic effects and 
guanidinium salts that decrease the hydrophobic effect.119
A variety of other methods have been used to accelerate the Diels- 
Alder reaction such as the use of microwave radiation120 and 
ultracentrifugation.121
4.1.4 Synthesis of Diol (90)
The second stage of the synthesis was the reduction of diester (89) to 
the corresponding diol (90). This reaction proved more testing than the 
previous one. A number of reducing conditions had been investigated by a 
previous worker within the group in an attempt to achieve this transformation. 
Most were based on diisobutylaluminium hydride (DIBAL-H) in either DCM or 
toluene.122 These were either unsuccessful or gave the product in an impure 
form and in no better than 10% yield.
We found that it was best to do the reaction in THF with four 
equivalents of lithium aluminium hydride. The yield of the reaction was a 
significant improvement at 35% and after one recrystallisation from ethyl 
acetate the diol (90) was isolated in an analytically pure form.
No attempt was made to optimise the yield of the reaction. We could 
easily make large amounts of the diester (89) and so could synthesise a 
reasonable amount of the diol by carrying out the reduction on a large scale.
4.1.5 Conversion of Diol (90) into Diamine (86)
The conversion of the diol (90) into the diamine (86) involved the 
combination of three known reactions; the Mitsunobu,123 the Staudinger124 
and acid hydrolysis as shown in Scheme 27. Our procedure was adapted 
from that of Fabiano and co-workers.125
The first reaction in Scheme 27, the Mitsunobu, was developed in the 
early 1980s by Oyo Mitsunobu and has found a number of synthetic 
applications, and is used routinely to invert the stereochemistry at a chiral
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centre containing a hydroxyl group.123 It has also found widespread use in 
the transformation of natural products as it can be carried out under mild, 
neutral conditions and exhibits stereospecificity, regioselectivity and functional 
selectivity.123
Scheme 27
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The Mitsunobu reaction converts the diol (90) into the diazide (91) via a 
stabilisation process. Triphenylphosphine is oxidised to triphenylphosphine 
oxide and diisopropyl azodicarboxylate (DPAD) is reduced to diisopropyl 
hydrazinedicarboxylate.123
The second reaction in the synthesis, the Staudinger reaction involves 
an in situ reaction of the diazide with triphenylphosphine produces the 
iminophosphorane intermediate (92). This reaction occurs via a 3-membered 
transition state and the loss of diatomic nitrogen and is therefore 
irreversible.124
The final step is a simple hydrolysis of (92) by dilute hydrochloric acid 
to give the dihydrochloride salt (86).
The yield for the conversion of the diol (90) into the diamine 
dihydrochloride of (86) was 43%. We did not try and optimise the yield for two 
reasons. We had made the product before and work within the group and in
84
the literature suggested that simple dihydrochloride salts such as (86) would 
not exhibit good antimalarial properties. 59> 60 It was felt that the dibenzyl 
derivative of (86 ) with the lipophilic benzyl groups would show better 
antimalarial activity. Possible reasons for this were discussed in chapter 2.
A sample of (86) was sent to the World Health Organisation (W.H.O.), 
who assessed it for in vitro antimalarial activity. As expected no activity was 
observed. We then turned our attention to substituted BAD derivatives, in 
particular dibenzyl BAD (93).
4.1.6 Approaches towards Dibenzyl BAD (93)
Our initial plan to synthesise dibenzyl BAD is outlined in Scheme 28. 
Successful hydrolysis of diester (89) would yield the corresponding diacid 
(94), activation of the diacid followed by reaction with benzylamine would 
produce the diamide (95). Reduction of (95) would give the desired diamine 
(93).
Scheme 28
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4.1.7 Investigations towards the Synthesis of Diacid (94)
Being able to produce diester (89) easily and in high yield meant that 
reactions involving its hydrolysis to give the diacid (94) were important. The 
traditional methods of hydrolysing methyl esters are with acid or alkali. Of 
these two methods alkaline hydrolysis is most often favoured as it is 
essentially irreversible as the resonance stabilised carboxylate anion does not 
react with the alcohol formed.126 Alkaline hydrolysis gives the acid as its salt, 
from which it can be liberated by the addition of acid (Scheme 29).
Scheme 29
O 0 01
R -C -O R '
I
OH
R - C X
.0
O
G
OA + R'OHR OH'
The first method we investigated for alkaline hydrolysis of the diester 
was an adaptation of that reported by Corey and co-workers.127 This method 
employed lithium hydroxide monohydrate in a methanol: water (3:1) system.
Initial attempts were all done at room temperature using between five 
and ten equivalents of UOH.H2O. A typical procedure involved dissolving the 
diester in methanol and adding UOH.H2O in methanol: water with stirring. As 
the addition proceeded the solution became yellow in colour. The resulting 
solution was stirred at room temperature for 24 hours after which time TLC in 
methanol : DCM (4:1) and two drops of acetic acid indicated all the starting 
material had been consumed and a single more polar product had been 
formed. After acidification, extraction and drying, a sparingly soluble white 
solid was obtained. A 1H NMR spectrum strongly suggested the presence of 
ester functionality, the desired acidic protons as well as aromatic and olefinic 
protons.
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This situation can be explained by partial hydrolysis of the ester to give 
the half ester (96).
OMe
OH
96
In addition, oxidation of the 1,4-diene to give a more stable aromatic 
system is not an unexpected reaction. Isomerisation of double bonds with 
alkali to give the conjugated diacid has been reported for the similar diacid 
(97) to give (98) as shown in Scheme 30,118 and this may also have 
happened within our system.
Scheme 30
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As well as carrying out the reaction at room temperature we tried to 
achieve the transformation at 6°C by the use of a cyclohexene/dry ice bath. 
This was in order to mimic the conditions employed by Corey and co-workers 
as closely as possible. Unfortunately this proved to be no more successful 
than when carrying out the reaction at ambient temperature or 0 °C.
4.1.8 Attempted Hydrolysis of (89) with Sodium Hydroxide
We also attempted to synthesise diacid (94) from diester (89) by 
hydrolysis with aqueous sodium hydroxide solutions of various concentrations 
at either room temperature or reflux. All the methods gave similar results to 
those described above for UOH.H2O.
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Two other methods were investigated to hydrolyse the diester (89). 
These are briefly discussed.
4.1.9 Alkali Metal Silanolates
Metal silanolates such as potassium trimethylsilanolate (99) and lithium 
trimethyl silanolate have been found to convert carboxylic acid derivatives 
including esters into their corresponding anhydrous acid salts under mild 
conditions (Scheme 31).128
Scheme 31
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Metal silanolates are organic soluble equivalents for O2-. They have 
two advantages over other oxygen anions; they have appreciable solubility in 
organic solvents, and the silicon oxygen bond may be cleaved under mild 
reaction conditions. The reagents are soluble in solvents such as ether, THF, 
toluene and dichloromethane.
We adapted the procedure of Laganis and Chenard with diester (89) in 
dry THF using 2.2 equivalents of potassium trimethylsilanolate under nitrogen 
at room temperature.128 TLC of the reaction mixture at regular intervals over 
24 hours indicated only starting material was present.
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4.1.10 Neutral Conditions with Trimethylsilyl Iodide
As well as hydrolysis of alkyl carboxylic esters under acidic or basic 
conditions it is also possible to achieve hydrolysis under neutral conditions. 
Many of these procedures require the use of strong nucleophiles and high 
temperatures to achieve dealkylation.
Treatment of alkyl carboxylic esters with trimethylsilyl iodide (100) 
followed by aqueous hydrolysis has been shown to be a very mild method for 
the dealkylation under neutral conditions in almost quantitative yield (Scheme 
32).129
As suggested above the high bond energy of the silicon-oxygen bond 
makes it thermodynamically very favourable to use a reagent with a weak Si-I 
bond and react it with an appropriate oxygen-containing organic compound to 
form a silicon-oxygen bonded intermediate such as (101) which can be 
transformed to another product in a subsequent step.130 The by-products of 
this reaction are the alkyl iodide (102) and hexamethyldisiloxane (103).
Scheme 32
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As well as being used to cleave esters, trimethylsilyl iodide has been 
shown to cleave lactones to carboxylic acids, ethers to alcohols and 
carbamates to amines under various conditions in high yield.130
Trimethylsilyl iodide is a commercially available reagent but it is 
extremely air sensitive due to the hydrolytic susceptibility of the Si-I bond. We
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chose to synthesise it in situ by the reaction of sodium iodide with the more 
stable trimethylsilyl chloride.130
We attempted the reaction on diester (89) by adapting the procedures 
of two papers published by Olah and co-workers.129- 130 Typically the 
reaction is carried out in a polar aprotic solvent such as acetonitrile or carbon 
tetrachloride. We carried out the reaction by treating diester (89) with 2.4 
equivalents of dry sodium iodide and 2 equivalents of trimethylsilyl chloride in 
acetonitrile. The reaction time was decided upon by comparison with the time 
given to hydrolyse similar esters that were investigated by Olah and co­
workers. After work-up we only succeeded in isolating a small amount of 
starting material.
We were unsuccessful in all the methods we employed to hydrolyse 
diester (89) to the corresponding diacid. Aromatisation and double bond shifts 
were problems that could be expected. In all the methods employed we feel 
that the 1,2-relationship of the diester functionality may have contributed to a 
degree of steric hindrance which ultimately prevented the desired reaction.
The desired diacid was synthesised by a return to the Diels-Alder 
reaction.
4.1.11 Synthesis of Diacid (94) via the Diels-Alder Reaction
The diacid (94) was synthesised by the Diels-Alder reaction reported 
by Kucherov and co-workers in 1960 as illustrated in Scheme 33.118
Scheme 32
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The reaction involved heating acetylenedicarboxylic acid (104) and 2.1 
equivalents of diene (87) and 0.1 equivalent of pyrogallol in dioxane at 65-75 
°C. After removal of the dioxane and excess diene we should have been left
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with the crude anhydride (105) which can be converted into the diacid (94) 
with dilute sodium hydroxide solution. However, when we carried out the 
cyclisation we always isolated a mixture of the anhydride and the diacid even 
when using rigorously dried dioxane and glassware and under nitrogen.
Carboxylic acids are notorious for there ability to absorb water. We 
obtained our reagent from the Aldrich chemical company. It may be that we 
have to sublime the material to get it completely dry. At this stage this was 
not a problem as we desired the diacid (92) and the mixture could be 
converted exclusively into this by treatment with a dilute sodium hydroxide 
solution. We obtained the diacid in an overall yield of 60%.
Presumably the pyrogallol (106) is used as an anti-oxidant. It is 
oxidised to the orf/70-quinone (107) in preference to oxidation of the anhydride
(105) or diacid (94) (Scheme 34).
Scheme 34
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4.1.12 Attempted Synthesis of Diamide (95)
We believed we could synthesise diamide (95) by activating diacid (94) 
with thionyl chloride to yield the corresponding diacid chloride which after 
reaction with benzylamine would furnish us with our target compound.
The first procedure attempted had been successfully applied to a 
number of other diacids our group had investigated.122 Typically it involved 
heating the appropriate diacid at reflux in six equivalents of thionyl chloride for 
six hours. After removal of the excess thionyl chloride the oil obtained was 
dissolved in an organic solvent such as ether and stirred at 0 °C and eight 
equivalents of the appropriate amine was added dropwise. After removal of 
the precipitated amine hydrochloride by-product the desired diamide was 
obtained.
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When we applied this method to this diacid we encountered a problem. 
Heating the diacid at reflux in thionyl chloride proceeded normally. However, 
when the excess reagent was evaporated instead of being left with an oil a 
white solid was obtained which was insoluble in common organic solvents.
1H NMR spectroscopy indicated that the solid was a mixture of the 
starting diacid and anhydride (105). We believe that the diacid was formed by 
the mechanism shown in Scheme 35.
Scheme 35
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The reaction conditions were varied in an attempt to achieve a more 
favourable outcome. The number of equivalents of thionyl chloride used 
were reduced and the reaction mixture was stirred at ambient temperature 
instead of reflux temperature. It soon became apparent that this was not a 
viable method to synthesise diamide (95).
4.1.13 Coupling Reaction with N,  AT-Dicyclohexylcarbodiimide 
(DCC)
We briefly looked at the possibility of using DCC (108) as a reagent to 
couple diacid (94) with benzylamine to generate the corresponding 
diamide.131
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DCC is one of the most widely used reagents for preparing 
amides/peptides and it can also be used to make esters.131
The reaction has been studied in depth and the mechanism for amide 
formation is shown below in Scheme 36. It follows a very similar path to that 
typically shown when thionyl chloride is used to form amides. The carboxylic 
acid is activated by the addition of DCC. The adduct (109) is attacked by the 
amine to generate an amide and A/,A/'-dicyclohexylurea (DCU) (110). The 
DCU can be precipitated out of the reaction mixture and the amide recovered 
relatively easily.131
When this reagent was applied to our substrate a white solid 
precipitated out almost immediately, but we only succeeded in protonating the 
benzylamine. The order of addition of the reagents was altered but the same 
result occurred. We quickly abandoned this idea.
Scheme 36
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We felt the close proximity of the acid functionality in our diamide 
adversely affected the outcome of both these attempts and we looked at other 
methods to synthesise dibenzyl BAD. The one we felt most likely to succeed 
is discussed briefly below.
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4.1.14 Attempted Synthesis of (93) via Acetylenedicarboxamide
In our earlier work we had shown that we could carry out the Diels 
Alder reaction and reductive amination in high yield. We thought it might have 
been feasible to incorporate these reactions into the synthesis of dibenzyl 
BAD by the route shown in Scheme 37.
Scheme 37
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The procedure of Saggiomo to synthesise acetylenedicarboxamide was 
followed. This procedure involved treating an excess of aqueous ammonia 
solution at -10 °C with the diester (88), then filtering and washing the 
precipitated solid (111).132
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The reaction was also carried out under anhydrous conditions by 
condensing gaseous ammonia, cooling it to -78 °C and adding to it a solution 
of diester (88 ) in methanol. This method also proved successful but the 
quality of the product was inferior to that produced by the first method and it 
was operationally more involved.
The diamide (111) produced by this method is an antibiotic substance 
produced by Streptomcyes chibaensis from soil collected in Japan.133
Unfortunately when the Diels Alder reaction between the butadiene 
(87) and acetylenedicarboxamide (111) was attempted to form the cyclic 
diamide (112) the diamide (111) was very insoluble in all common organic 
solvents investigated and consequently the proposed cyclisation could not be 
carried out. We also investigated the solubility of diamide (109) in water, but 
as expected it was insoluble.
Instead of converting diester (86) into diamide (111) and then into the 
cyclic diamide (112) we investigated the possibility of converting the cyclic 
diester (89) into the cyclic diamide (112). This would mean the Diels Alder 
reaction with the insoluble diamide would no longer be required. We thought 
it would be possible to do this in an analogous way to that used to convert 
diester (88) into diamide (111) as shown in Scheme 38.
Scheme 38
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Unfortunately when this reaction was tried on the cyclic diester we were 
unsuccessful. Regular TLC analysis of the reaction mixture showed that only 
unreacted diester (89) was present. We tried the reaction again under 
anhydrous conditions but the results were the same.
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4.1.15 Synthesis of Diamide (95)
By applying some of the experience gained in trying to synthesise 
anhydride (105) and that obtained in our work with bicyclic compounds, which 
we will discussed later, it was felt that it would have been possible to 
synthesise diamide (95) and thence dibenzyl BAD (93) by the reactions shown 
in Scheme 39.
Scheme 39
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As was documented earlier our attempts to synthesise anhydride (105) 
by the Diels Alder reaction of (87) with (104) in the presence of pyrogallol
(106) resulted in isolation of a mixture of the anhydride and the corresponding 
diacid.118 This problem may have been due to moisture present in the 
reaction or in the subsequent work-up. In order to try and minimise this
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problem the cycloaddition was carried out uinder under a dry nitrogen 
atmosphere using dry solvent and the product was isolated without 
purification. The subsequent opening of the anhydride was performed with
1.1 equivalents of benzylamine as soon as the crude product was isolated 
from the first step. The analogous reaction was carried out on a similar 
anhydride in high yield. With this substrate the desired product (113) was 
isolated but in a much lower yield of 19%. This was almost certainly a 
consequence of not purifying the product of the first step.
When we attempted to purify the crude mixture isolated in the synthesis 
of (113) by crystallisation in ethanol - water a cyclisation reaction took place to 
give a mixture of (95) and the diimide (114), Scheme 39. As the crude 
product containing (113) was very insoluble in most organic solvents, (it was 
sparingly soluble in DMSO) we chose not to purify it by column 
chromatography.
We chose to convert a crude sample of (113) into the diamide (95) via 
a mixed anhydride. This involves activation of the carbonyl group to make it 
more susceptible to nucleophilic attack. The mechanism is well know and 
shown in Scheme 40. Deprotonation of the carboxylic acid with a non- 
nucleophilic base such as triethylamine generates the carboxylate anion 
which reacts with an alkyl chloroformate suclh as ethyl chloroformate to 
generate the mixed anhydride (115). The anhydride is cleaved by a 
nucleophile, in this case an amine, to generate the amide.134 The reaction is 
irreversible as one of the by-products is carbon dioxide. The reaction is best 
carried out at 0 °C, and the desired amide was isolated in a yield of 39%.
Scheme 40
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4.1.16 Attempted Reduction of Diamide (95) to Diamine (93)
The reduction of diamide (95) with lithium aluminium hydride was 
attempted without success and due to a shortage of (95) the reaction could 
not be repeated. It is possible that lithium aluminium hydride is too harsh a 
reagent to complete this transformation. It is known that reduction of 
carboxylic amides with metal hydride reagents are prone to problems, the 
main one being cleavage of the C - N  bond to form the alcohol as opposed to 
the desired C - 0  bond cleavage to generate the amide (Scheme 41 ).135
It may be possible to achieve the desired reduction using a milder 
reducing agent such as sodium bis(2-methoxyethoxy)aluminium hydride 
(116), which is commercially available as a solution in toluene and is known 
as Red-AI®.136
116 [(CH30CH2CH20 )2AIH2]Na
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4.2.1 Studies towards the Synthesis of Bicyclic Putrescine 
Analogues
Our studies in this area arose for two main reasons. Firstly, a study of 
the literature indicated that compounds containing the bicyclo-[2.2.1]-heptane 
skeleton had been found to a have a wide range of biological activity137 and a 
number had been incorporated in pharmaceutical agents138 As far as we 
were aware they had not been investigated as antimalarial agents.
Secondly, we were having difficulty synthesising dibenzyl BAD and we 
could easily synthesise a number of norbornyl compounds which had similar 
structures to some of the possible precursors of dibenzyl BAD. This gave us 
the chance to try and synthesise a number of relevant compounds for 
antimalarial and antifungal evaluation and the chance to develop methods that 
we might be able to use in the synthesis of dibenzyl BAD.
4.2.2 Disubstituted Bis-(aminomethyl)-bicyclo-[2.2.1 ]-endo-cis-5- 
heptenes
When we began our work in this area the compounds we desired to 
make were disubstituted bis-(aminomethyl)-bicyclo-[2.2.1]-eA7do-c/s-5- 
heptenes, and their general structure is shown below.
NRR
NRR1
This type of compound was chosen for four main reasons.
1. The carbon framework can be constructed easily, cheaply and in high 
yield.
2. They are similar to dibenzyl BAD and related compounds.
3. They contain a putrescine portion within the molecule.
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4. The method we selected to synthesise them should have made it possible 
to synthesise diamines bearing different amino substituents in the same 
molecule. There is evidence within the literature that suggests that putrescine 
analogues bearing different amino substituents are more potent antimalarial 
agents than their symmetrical counterparts.139
The method chosen for the synthesis of these compounds is shown in 
Scheme 42.
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4.2.3 Synthesis of enc/o-c/s-anhydride (119)
The first reaction in Scheme 42, the synthesis of the endo-cis- 
anhydride (119) via the Diels Alder reaction between cyclopentadiene (117) 
and maleic anhydride (118) is well documented in the literature.140 It is a 
classic example of the effect of secondary orbital overlap on the cycloaddition 
reaction.141
There are two possible modes of addition of diene (117) to dienophile
(118); endo and exo, of these the endo geometry predominates by far.
For endo overlap there are two possibilities; the highest occupied 
molecular orbital (HOMO) of the diene overlaps with the lowest unoccupied 
molecular orbital (LUMO) of the dienophile, or the LUMO of the diene 
overlaps with HOMO of the dienophile. In both cases the endo orientation is 
stabilised by additional overlap. There is no such stabilisation when addition 
is from the exo position.142
The anhydride (119) is commercially available but as it is quick and 
easy to synthesise it was made in the laboratory. The reaction proceeded 
smoothly in a yield of 85%.
4.2.4 Reactions of Anhydride (119)
The opening of the anhydride (119) with the appropriate amine to give
(120) was one we had already shown to have carried out on an impure 
sample of anhydride (105). As we could isolate the anhydride (119) in a pure 
form the yield and purity of (120) was significantly higher than that for (113). 
The yield was 72% .
There was a choice of methods to convert (120) into the diamides
(121), (122) and (123). To prepare the dibenzyl diamide (121) the mixed 
anhydride method was selected, and this gave the desired product in a yield 
of 71 %.
To synthesise compounds (122) an d (123) the reagents 
hexamethylphosphorus triamide, HMPT (125, R'=CH3 )143 and the analogous 
reagent hexaethylphosphorus triamide, HEPT (126, R'=C2 H5 )144, were 
chosen respectively.
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HMPT is prepared by the reaction of phosphorus (III) chloride with 
anhydrous dimethylamine and then purified by distillation.145 The same 
procedure can be used to prepare the higher alkyl homologues. Both HMPT 
and HEPT are commercially available.
HMPT has found most of its applications in the synthesis of epoxides 
from aldehydes and arene oxides from aryldialdehydes.143 It has also been 
used to replace triphenylphosphine in the Wittig and the Horner-Wittig 
reaction.143 In all cases one of the main benefits of the reaction is that the by­
product, hexamethylphosphoric triamide is water soluble and hence easily 
removable.143
The method reported by Quin et al. was followed to take advantage of 
the short reaction time and simple isolation and purification of the product.146
We believe the reaction to proceed by the mechanism outlined in 
Scheme 43. Protonation of HMPT by the carboxylic acid gives the 
intermediate (127) which eliminates a molecule of diethylamine to form the 
charged species (128) which reacts with the carboxylic acid or its carboxylate 
equivalent to form the ester (129) which is attacked by a molecule of 
diethylamine released in a previous step to give the protonated amide (130) 
which is neutralised by (131) to give the desired product. The mechanism for 
HMPT would follow an analogous path.
Both (122) and (123) as expected exist as rotamers and the 1 H NMR 
spectrum of (122) shows the two inequivalent methyl groups as two distinct 
singlets. The 1 H NMR spectrum also clearly shows the two doublets of 
doublets of the diastereotopic protons of the methylene carbon of the benzyl 
group.
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4.2.5 Attem pted Reduction of (121)
The reduction of the diamides (121), (122) and (123) to the 
corresponding diamines was investigated by working with (121) as this 
compound was available in the largest quantity and the diamine that would 
result from its successful reduction was of most interest.
The reduction was attempted by heating (121) with four equivalents of 
lithium aluminium hydride at reflux in THF and monitoring the reaction by 
TLC.146 The procedure was carried out a number of times and on most 
occasions either starting material, or a complex mixture of products were
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isolated, among which seemed to be the diol (132). This would be the result 
of C-N bond cleavage as opposed to the desired C-0 bond cleavage as 
shown by the method outlined in Scheme 41.
OH
OH
132
On one occasion TLC indicated the consumption of all the starting 
diamide and the appearance of a single product spot. 1H NMR and 13C NMR 
spectra of the isolated material suggested that instead of the desired product 
we may have obtained the half-reduced product (133) or possibly the lactam 
(134). They are presumably formed by the mechanism shown in Scheme 44. 
This material was subjected to further reduction with lithium aluminium hydride 
and a brown oil was isolated which 1H NMR spectroscopy showed to be a 
complex mixture.
Scheme 44
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4.2.6 Synthesis of A/,/\/,-Dibenzyl-bicyclo[2.2.1]heptane-2,3-enc/o- 
c/s-diamine Dihydrochloride (138)
After considering the problems encountered in synthesising dibenzyl 
BAD (93) it was decided to remove the double bond from the norbornyl ring to 
allow the use of borane-THF as the reducing agent.135 We could not use 
borane-THF on the alkene as hydroboration would almost certainly result. We 
went back to the anhydride (119) and subjected it to hydrogenation at one 
atmosphere using 5% palladium on charcoal, by the method of Ohtani et 
a lM 1 The reaction went smoothly in a yield of 98%. At this point we decided 
to concentrate on the synthesis of the dibenzylated diamine (138) and 
synthesised it by the method outlined in Scheme 45.
Scheme 45
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The conversion of anhydride (135) into the dibenzylated diamide (137) 
went smoothly and in a similar yield to that recorded for the conversion of
(119) into (121). Reduction of diamide (137) into diamine (138) went in 75% 
yield after we dissolved the crude dihydrochloride salt in ethanol and 
precipitated it out with ethereal hydrochloric acid.
4.2.7 Future work
Now that we have developed a route to synthesis bicyclic putrescine 
analogues it would be prudent to investigate the antimalarial and antifungal 
activity of a carefully chosen selection of analogues. The two compounds that 
we would be most interested in are the dicyclohexylmethyl analogue (139) 
and the unsymmetrical analogue containing benzyl and cyclohexylmethyl 
moieties (140). These groups have displayed the most potent antimalarial 
and antifungal activity in our work so far.
NH NH
NH NH
139 140
As discussed in section 4.1.16 it may be possible to reduce diamide 
(95) to dibenzyl BAD (93) with RED-AI®. We may investigate that possibility 
in the future (Scheme 46).
Scheme 46
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5
Polyamine Analogues
5.1 Synthesis of Polyamine Analogues
As we discussed in section 2.10 polyamine analogues have been 
shown to inhibit fungal growth and have a possible use in the area of 
antimalarial chemotherapy.
Past workers within our group had shown that synthetic putrescine 
analogues such as (E)-BED (38) could control important harmful fungi on 
crops.41 This compound became one of our lead compounds into the area 
of antimalarial chemotherapy.41
38
We have also discussed in sections 2.11 to 2.11.2 how polyamine 
analogues can be used in antimalarial chemotherapy and in particular the 
effectiveness of the bis(benzyl)polyamine analogues, such as (41) 
developed by Bitonti et al. at the Merrell Dow institute in Cincinnati, 
USA.59’ 60
H H H H
___________________ 41 (x=7)_________________
In this area of work it was decided to synthesise a number of 
polyamine analogues by simple, high yielding reactions to investigate how 
the spacing between the nitrogen atoms affected both the antimalarial and 
antifungal activity. The imine formation reaction and subsequent reduction
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was used and a brief discussion of these reactions will be given in the 
following two sections.
5.2 Synthesis of Imines
Imines can be synthesised by a large variety of methods including 
the addition of Grignard reagents to nitriles148 and the reduction of 
oximes.149 By far the most common and simple method is by the addition 
of ammonia or amines to aldehydes150-151 and ketones 152. An example 
with cyclohexanone and benzylamine is shown below (Scheme 47).
Scheme 47
PhCH2NH2 + O
PhHoC
The C=N 7i bond is weak and so the equilibrium of the above 
reaction lies to the left if there is excess water present. This does not 
present much of a problem when coupling aldehydes and amines as the 
reaction is fast, but the reaction is much slower with the corresponding 
amine and ketone and often longer reaction times and higher temperatures 
are required.76 When using a ketone, in order to obtain a good yield of the 
imine it is often necessary to remove the water formed in the reaction. This 
can be done by azeotropic distillation, the use of molecular sieves153 or 
drying agents such as titanium (IV) chloride.154
If the imine is conjugated to an aromatic ring then it is known as a 
Schiff's base and is more stable than a simple aliphatic imine. However, in 
most cases the imines are used immediately as they have a limited stability 
on storage. The diimines made in the synthesis of compounds discussed in 
section 5.4 are Schiff bases.
5.3 Reduction Of Imines
Imines can be reduced to the corresponding amines with a large 
number of reducing agents including aluminium hydride155 and
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diborane.156 The two most common reagents are catalytic hydrogenation 
(H2/Pd/C)157 or sodium borohydride.151
We were unable to use catalytic hydrogenation with the dibenzyl 
diimines generated in section 5.4 as cleavage of the benzyl group would 
have resulted to regenerate starting material.
Sodium borohydride was used as this reagent is known to be easy to 
use and effective in high yield, and this proved to be the case in our studies. 
Our target compounds were prepared in essentially quantitative yields 
(Scheme 48).
Scheme 48
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5.4 Synthesis of A/,/V'-Bis(benzyl)diaminoalkane Dihydrochlorides
The synthesis of these compounds is very straightforward and goes 
in almost quantitative yield (Scheme 49). The appropriate diamine was 
coupled with benzaldehyde to give the diimine which was reduced with 
sodium borohydride to give the corresponding diamine which was 
converted into the dihydrochloride salt upon the addition of concentrated 
hydrochloric acid.
The diimine from each reaction was not purified. It is possible to 
crystallise the diimine but this was only done on one occasion. In general 
they were isolated as oils and treated with sodium borohydride almost 
immediately. These compounds were prepared by the method of Lee et 
al.' 51
As well as the method reported by Lee et al. we also investigated the 
procedure reported by Sclafani et al. 152 This method involved reacting the 
diamine and aldehyde in chloroform in the presence of molecular sieves. 
The molecular sieves are there to absorb the water given off in the 
formation of the imine in order to drive the reaction to completion. We found
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that this gave no benefit in terms of yield and made the work up of the 
reaction more complex.
Scheme 49
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Bitonti worked mainly with spermidine analogues but we decided to 
work with commercially available diamines. We began our studies with 
putrescine (141) (n=4) and cadaverine (142) (n=5) (Scheme 49). Both 
the in vitro antimalarial and antifungal testing results of these compounds 
were very encouraging and we decided to extend the chain length in order 
to see if this would increase the biological activity. We synthesised N,N'- 
bis(benzyl)diaminoalkanes with a chain length from 2 to 10 to give a 
complete set of compounds.
5.5 Synthesis of /V,/V-Bis(2-chloroethyl)-/V,/V-dibenzylaminoalkane 
Dihdrochlorides
Fiona Anderson, a co-worker in our group had obtained some 
encouraging in vivo antifungal testing results with a number of nitrogen 
mustards incorporating an A/,A/-bis(2-chloroethyl) moiety.158 We prepared 
a small number of A/,A/'-bis(2-chloroethyl)-A/,A/'-dibenzylaminoalkanes as 
they would be easily accessible and might provide us with further leads.
We chose to extend compounds (144), (145) and (146) by the 
method reported by Lee et al. as shown in Scheme 50.
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Hydroxyethylation of these compounds presented two difficulties. 
Initially each N ,A/'-bis(benzyl)diaminoalkane was treated with 20 
equivalents of ethylene oxide at 0 °C. The desired product was obtained 
each time but yields were lower than those quoted and the purity was poor. 
These problems were solved by carrying out the reaction at -78 °C. Twenty 
equivalents of ethylene oxide was used and the corresponding A/;A/'-bis(2- 
hydroxyethyl)-/V,A/'-bis(benzyl)diaminoalkane was isolated in a yield of 
about 75% and used in the subsequent step without purification.
The final step was also problematic. Firstly the thionyl chloride must 
be distilled from quinoline in order to remove any acidic impurities 
otherwise the starting material precipitates out of solution as the 
hydrochloride salt. Isolation of the pure final product was a problem in 
some cases. TLC indicated that each reaction gave one product but initially 
they were extremely sticky and getting them pure was time consuming. The 
problem was believed to be due to the large excess of thionyl chloride used 
and the hygroscopic nature of the compounds. Another method using only
2.2 equivalents of thionyl chloride has been found.159
It is difficult to distinguish between an A/,A/'-bis(2-hydroxyethyl)-A/,A/- 
bis(benzyl)diaminoalkane and its corresponding A/,A/-bis(2-chloroethyl)- 
N,N' -bis(benzyl)aminoalkane by 1H NMR spectroscopy but a difference 
can be distinguished in the 13C NMR spectra. The methylene attached to 
the hydroxyl group has a chemical shift 8 of about 40 whereas the 
methylene attached to a chlorine atom comes into resonance at about 8
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6 4 .160 This difference is apparent in the 13 C NMR spectra of our 
compounds.
5.6 Synthesis of At/V-Bis-p-pyridylmethyOdiaminoalkane Oxalates
To investigate the effect of introducing more nitrogen atoms into the 
compounds and hence increase the charge on each molecule the /V,A/'-bis- 
(2-pyridylmethyl)diaminoalkanes were prepared.
These compounds were synthesised in a similar route to that shown 
in Scheme 51 except that the formation of the intermediate imine had to 
be done in rigorously dry ethanol under an inert nitrogen atmosphere. The 
reduction of the imine was achieved using NaBhU in ethanol. The 
hydrochloride salts were converted into the corresponding dioxalate salts 
for the purpose of testing as the pyridyl compounds we made previously 
had been converted into their oxalate salts due to their hygroscopic nature.
Scheme 51
C x  Ht*-i ’ n ' c h o  ,eioh, n,
" NH“ 2. N,BH4, E.OH, N, (I J  H* II J
3. (COOH)2
2(COO j 2 158 (n=2), 159 (n=3)
160 (n=4), 161 (n=5) 
and 162 (n=6)
5.7 Synthesis of /V,A/l-B is (cyc lohexylm ethy l)d iam inoa lkane  
Dihydrochlorides
The literature suggested that polyamines bearing cyclohexylmethyl 
groups exhibited good antiparasitic activity161 and this was confirmed with 
the antimalarial testing results of some of the compounds synthesised by 
Brear.66
We decided to identify the most active polyamines we had 
synthesised and make the cyclohexylmethyl analogues. These compounds 
were made by coupling cyclohexanecarbaldehyde with the appropriate 
amine to form the imine which was reduced with NaBHU to give the desired 
compound as the tree base. Subsequent treatment with concentrated
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hydrochloric acid generated the dihydrochloride salt for biological testing. 
(Scheme 52).
Scheme 52
1. CgH^CHO, MeOH,
HoN nNH- 2. NaBH4, EtOH, N2
3. c.HCI
h 2 h 2
2CI©
163 n=3
164 n=7
165 n=8
5.8 Future Work
Future work in this area is governed by the results of biological 
testing. Our testing results which are documented in chapter 6 suggest that 
an important factor in the antimalarial activity of our compounds is the 
distance between the nitrogen atoms. If this is the case then it would be 
prudent to continue with the synthesis of N, A/-bis(benzyl)diaminoalkane 
dihydrochlorides, increasing the chain length until we observe a drop in 
activity.
It may also be worthwhile to examine the introduction of an extra 
methylene group into the most active bis(benzyl) analogues to make the 
corresponding aminoethylbenzenes (Scheme 53).
Scheme 53
nN2. NaBH4, EtOH, N
3. c.HCI '2 2CI
A similar reaction can be used to prepare the corresponding 
aminoethylpyridines. This introduces another methylene group between 
the nitrogen of the pyridyl ring and those of the main chain (Scheme 54).
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Scheme 54
nNH2 2. NaBH4, EtOH, N
Examining other ring systems is another area worth investigating. 
The most obvious starting point would be the introduction of the quinoline 
ring system (Scheme 55).
Scheme 55
nNH
v  N CHO 
2. NaBH4, EtOH, N2
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Antimalarial and Antifungal Testing Results
6.1 Biological Evaluation
This chapter will be split into two sections. The first will detail the 
testing regime and results of the testing of a number of those compounds for 
antimalarial activity. The second will deal with antifungal evaluation.
6.2 Antimalarial Evaluation
This work was carried out by Professor Stephen Phillips and Fiona 
McMonagle in the Institute of Biomedical and Life Sciences, University of 
Glasgow. Initially compounds were tested in vitro and if appropriate in vivo 
tests were carried out.
6.3 In vitro Testing against P. falciparum  Asexual Erythrocytic 
Stages
Two P. falciparum culture adapted stains were used; these were 
FCR (Gambia) and JS (Zimbabwe). Both of these strains are chloroquine 
sensitive and were grown as stock cultures in vitro in petri dishes by 
modifying the candle jar technique of Trager and Jensen.162 In culture the 
parasites were asynchronous in their growth and therefore all stages in the 
48 hour asexual erythrocytic cycle were represented at any one time. The 
assay system for screening compounds for activity against P. falciparum 
was that described by Desjardins et a/.163 Each test was carried out as a 
minimum in triplicate. After 24 hours incubation in a candle jar 100 pi were 
removed from each well and replaced with 100 pi of fresh medium containing 
1 pCi 3H-hypoxanthine164 The plate was incubated for a further 18 hours 
after which the parasites were harvested and parasite growth was measured 
as the incorporation of the radioisotope, using liquid scintillation counting. 
The mean and standard deviation of the counts per minute for each dilution 
of the test compounds and the control culture were calculated and the results 
displayed using Cricket Graph. The results were analysed using a standard 
t-test.
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The activity of the compounds was shown as the lowest concentration 
in pg ml-1 where the compound under testing showed any significant activity. 
For a further comparison this lowest activity was converted into a lowest 
effective concentration (LEC) which in pM takes into account the molecular 
weight of the test compound. The LEC is not an accurate IC50 value but it 
does represent a good guide to the compound's activity. We assessed the 
data using an activity scale (Table 7) which was designed to help determine 
whether certain analogues were appropriate for in vivo testing and/or further 
structural modifications. Chloroquine is greater than nine on this scale. Any 
compound that had an activity of less than four was not pursued.
Activity
Scale
1 2 3 4 5 6 7 8 9
Lowest
Activity
(mgml'1)
(Table 7
1000 
1 vitro c
500
intimak
100 
arial ev<
50
aluation
10
scale)
5 1 0.5 0.05
6.4 In vivo activity against P. chabaudi
Plasmodium chabaudi AS strain, in inbred NIH mice, was handled 
as described by McDonald and Phillips.165 In brief three months old male 
inbred NIH mice were infected intravenously with 1x105 infected erythrocytes 
and groups of five mice immediately afterwards were injected with either the 
test compound or chloroquine at 50mg/kg body weight. The compounds 
were dissolved in physiological saline and injected intraperitoneally. A 
control group of mice were given saline only.
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6.5 In vitro Activity of Compounds Discussed in chapter 3
6.5.1 2-Substituted Aminomethylpyridine Oxalates
These are compounds of the general structure shown below.
The activities of compounds (46), (47), (48) and (49) were measured 
in vitro against one of the P. falciparum chloroquine sensitive cultures 
named in section 6.3. Chloroquine was used as a positive control (Table 8).
compound R Activity (pg ml*1) LEC (pM)
46 benzyl 5-10 17-35
47 cyclohexylmethyl 5-10 17-34
48 tbutyl 50 197
49 nbutyl 50 197
control Chloroquine <1 <1.9
(Table 8 in vitro results for 2-substituted aminomethylpyridine oxalates)
The biological activity for these four compounds was mixed but none 
of the compounds came near to the activity of chloroquine. The tbutyl and 
the nbutyl analogues showed reasonable activity at 50 pg m l'1. The benzyl 
and cyclohexylmethyl analogues showed promising in vitro activity and in 
fact have slightly lower LEC values than (£ )-BED (38) (LEC 18-36 pM) which 
was one of the lead compounds when our group moved into the area of 
antimalarial chemotherapy.
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6.5.2 2-Substituted Aminoethylpyridine Oxalates
NHRR'
By inserting an additional methylene group into the compounds we 
had increased the distance between the nitrogen atoms. This resulted in an 
improvem ent in the activity of the most potent compounds discussed in 
section 6.5.1 above. The most marked effect was seen in (57), the analogue 
containing the cyclohexylm ethyl moiety. The in vitro results for this 
compound showed it to have comparable activity and LEC value to those of 
chloroquine. We also recorded a large improvement in the performance of 
the benzyl analogue (56).The tbutyl and nbutyl analogues were disappointing 
and at this point we decided not to investigate these groups any further 
(Table 9).
compound R O'n Activity (jig  m l’1) LECfciM)
56 benzyl H 5 16
57 cyclohexylmethyl H 0.1-10 0.32-32
58 tbutyl H 50-100 187-383
59 n butyl H 10-100 37-186
60 ethyl ethyl to go in to go in
control Chloroquine <1 <1.9
(Table 9 in vitro results for 2-substituted aminoethylpyridine oxalates)
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6.5.3 (± )-2 -H yd ro xy-2 -(2 '-pyridy l)e thy lam ine  Oxalates
NHRR'
OH
We were mainly interested in these compounds as potential antifungal 
compounds, but we also screened then for antimalarial activity. Results 
from these compounds were disappointing (Table 10). The unsubstituted 
amino compound (44) showed no activity. This was expected and helps to 
confirm  the hypothesis that to exhibit activity any potential antimalarial 
compound should possess hydrophobic groups to enable it to have sufficient 
lipophillicity to pass through the red cell membrane. This observation is 
backed up with the result obtained for the benzyl analogue (70). Although 
this compound had reasonable activity it was signifcantly less active than the 
corresponding benzyl analogues (46) and (56). At present we have no 
results for the cyclohexylmethyl analogue (71).
compound Q nin, ri Activity frig m H ) LEC (pM)
44 H, H no activity N/A
70 benzyl, H 10 31
71 cyclohexylmethyl, H not tested not tested
control Chloroquine <1 <1.9
(Table 10 in vitro results for (± )-2 -H yd ro xy -2 -(2 l-pyridyl)ethylamines)
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6.6 Antimalarial Activity of Compounds discussed in Chapter 4
Due to the problems encountered in this area of our work we have 
very little to report in the way of antimalarial testing results.
6.6.1 BAD (86)
A sample of this was sent to the WHO and it was shown to have no in 
vivo activity. For the reason outlined earlier this result was not unexpected. 
It became apparent to us from a survey of the literature and from our own 
work that to exhibit antimalarial activity compounds need to possess 
hydrophobic moieties such as the benzyl group to give them sufficient 
lipophillicity to pass through parasitized red blood cell walls. This result 
backs up this hypothesis.
6.6.2 /V,/V'-Dibenzyl-bicyclo[2.2.1]heptane-2;3-e/7c/o-c/s-diamine 
Dihydrochloride (138)
The dibenzyl compound (138) has been synthesised and has been 
made available for antimalarial evaluation.
NH
NH
2CI
138
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6.7 In vitro Activity of Com pounds Discussed in Chapter 5
6.7.1 A/,/V'-Bis(benzyl)diaminoalkane Dihydrochlorides
This set of compounds gave us our most promising results. It is clear 
that as the d istance between the nitrogen atoms increases the LEC 
decreases and from n=7 to n=10 the activity and LEC are better than those 
for chloroquine. From n=2 to n=6 the activity is also very promising and this 
is matched by a more gradual decrease in the LEC (Table 11).
com pound n * ■ Activity (jig ml-1) LEC (pM)
143 2 10 32
144 3 10 30
145 4 10 29
146 5 5 14
147 6 1 2.7
148 7 0.1 0.26
149 8 <0.1 -0.5 <0.25-1.26
150 9 0.1 0.24
151 10 0.1 0.23
Control Chloroquine <1 <1.9
(Table 11 in vitro results for A/,A/'-Bis(benzyl)diaminoalkane dihydrochlorides)
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6.7.2 A/,A/,-8/s(2-chloroethyl)-A/,A/,-dibenzyldiaminoalkane 
dihydrochlorides
NH
The results obtained for these compounds are also very promising 
and those tested showed good activity down to 5 pg m l-1 (Table 12). We 
have not exploited this work any further.
com pound n Activity (p g m h 1) LEC (pM)
155 3 not tested N/A
156 4 5 11
157 5 5 11
control Chloroquine <1 <1.9
(Table 12 in vitro results forA/,A/'-B/s(2-chloroethyl)-N,N- 
dibenzyldiaminoalkane dihydrochlorides)
6.7.3 A/,A/,-B is(2-pyridylm ethyl)d iam inoalkane oxalates
Like the ir bisbenzyl counterparts these compounds also showed a 
relationship between the value of n and activity. However, on this occasion 
as n decreased the activity of the compound increased. When the distance 
between the two nitrogen atoms was at its smallest the compound exhibited 
greater activity and a lower LEC in vitro than those values for chloroquine 
(Table 13).
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com pound n Activity (p g m l-1) LEC (pM)
158 2 0.1 0.28
159 3 0.5 1.34
160 4 10 26
161 5 10 25
162 6 10 24
control Chloroquine <1 <1.9
(Table 13 in vitro results for A/,A/'-Bis(2-pyridyl)diaminoalkane oxalates)
6.7.4 A/,/V-Bis(cyclohexylm ethyl)diam inoalkane dihydrochlorides
We prepared these compounds to compare them with the most active 
A/,/V'-bis(2-pyridyl)diaminoalkane oxalates and A/./V-bisbenzyldiaminoalkanes 
we had at that time. Subsequent testing would uncover more potent 
analogues. We prepared (163) with n=3 to compare with the analogous 
dipyridyl compounds (159), (164) and (165) to compare them with the
corresponding dibenzyl compounds (148) and (149). At present we have no 
data for the cyclohexylmethyl analogue (163). Compounds (164) and (165) 
have a similar activity profile to their bisbenzyl counterparts (Table 14).
compound n Activity (p g m h 1) LEC (pM)
163 3 not tested N/A
164 7 0.1 0.25
165 8 0.1 0.24
control Chloroquine <1 <1.9
(Table 14 in vitro results fo r A/,/V'-Bis(cyclohexylmethyl)diaminoalkane 
dihydrochlorides).
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6.7.5 Results of in vivo Testing against P. chabaudi
Three of our compounds were considered good enough candidates to 
be investigated further and were screened form in vivo activity. The 
compounds screened were the cylclohexylmethyl analogue (57) and the 
bis(benzyl) analogues (146) and (147).
Each of the compounds were tested in mice infected with the rodent 
malaria P. chabaudi. Administering a 50 mg kg'1 dose of chloroquine was 
curative and no parasitaemia was detected in mice over 14 days. Our 
compounds showed no significant antimalarial activity at doses of 100 mg 
kg1 and 300 mg kg-1. Unfortunately none of these compounds showed in 
vivo antimalarial activity.
6.7.6 Summary of Antimalarial Testing Results
Our antimalarial work gave us some extremely active compounds in 
vitro, some with activity comparable to chloroquine. We have identified a 
number of promising new leads. It also supports the hypothesis that large 
hydrophobic moieties such as benzyl groups are required for antimalarial 
activity.59- 60
The in vitro results also strongly suggest a relationship between the 
distance separating nitrogen atoms in polyamines and activity. This was 
seen most d ram atica lly  with the A/j/V-bistbenzylJaminoalkane 
dihydrochlorides where activity increased 10 fold and the LEC decreased 
more than 100 fold in moving from the compound with the smallest N-N 
distance (143) to that with the longest N-N distance (151) in our study.
As we indicated in section 2 .11.2 the action of bis(benzyl)polyamines 
has been attributed to the direct binding of the compound to DNA with the 
subsequent disruption of macromolecular synthesis and cell death. It is 
possible that this mechanism is occurring with our compounds. Inhibition of 
ODC activity has also been suggested as a reason for the action of 
compounds similar to ours.
The dependence on nitrogen-nitrogen distance was also clearly seen 
in the 2 -substituted aminomethylpyridine oxalates and the 2-substituted 
aminoethylpyridine oxalates, where the most potent analogues with the extra
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methylene between the nitrogen atoms was substantially more active. It 
would appear that the introduction of a hydroxyl group into the 2-substituted 
am inoe thy lpyrid ines to produce (±)-2-hydroxy-2-(2 '-pyridyl)e thylam ines 
resulted in a decrease in activity.
It has also become clear that polyamines bearing cyclohexylmethyl 
substituents can show excellent in vitro activity. It would be interesting to 
examine them for in vivo activity.
In vivo testing results so far have been disappointing, unfortunately 
this is a common occurrence in the area of antimalarial research.
6.8 Antifungal Testing Results
Antifungal testing was carried out by Dr Dale Walters, Department of 
Plant Sciences, The Scottish Agricultural College, Auchincruive.
The first group of com pounds supplied to W alters for in vitro 
evaluation were the 2-substituted aminomethylpyridine oxalates (46), (48) 
and (49) , the N, /V-'bis(benzyl)diaminoalkane dihydrochlorides (144) - (147), 
the A/,A/'-bis(2-chloroethyl)-A/,A/'-dibenzylaminoalkane dihydochlorides (155) - 
(157) and finally the /V,/V-bis(2-pyridyl)diaminoalkane oxalates (159) and 
(160).
Each of the compounds was assessed for its ability to inhibit in vitro 
mycelial growth of Pyrenophora avenae. Only compounds (146), (147) and 
(159) at 0.1 mM concentration were effective at reducing mycelial growth. 
The reduction of mycelial growth after seven days is shown in Table 15.
Compound % inhibition of mycelial growth
146 45
147 36
159 55
(Table 15 in vitro inhibition of mycelial growth for selected polyamines)
These com pounds all significantly reduced the in vitro growth of 
Pyrenophora avenae on solid media although interestingly they all affected 
enzyme activities and polyamine concentrations in different ways. A brief
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description of the results and a discussion of some of their implications will 
follow.
6.8.1 ODC and AdoM etDC Actvity
The activity of the enzymes ODC and AdoMetDC was measured in 
the presence of compounds (146), (147) and (159). Compounds (147) and 
(159) were assayed in a different group from (146) hence the need for two 
controls (Table 16).
Enzyme Activity (pmol CO 2 ) 
(mg protein)"1 hr-1
Enzyme Activity (pmol CO2 ) 
(mg protein)”1 hr-1
Treatment ODC Activity AdometDC Activity
control 906.8 ±105.8 110.6±19.8
159 1043.6±342.5 70.6±19.8
147 907.2±106.6 80.4±33.6
Control 801.6±377.0 49.1±9.5
146 1897.3±294.0* 51.4±6.0
(Table 16 Effects of (159), (147) and (146) on ODC and AdoMetDC
activities in P. avenae values are means of 4 replicates ± standard errors)
Statistical differences shown at * P < 0.05
We can see from the table that ODC activity in (147) and (159) was 
not increased but in the presence of (146) there was a 2.4 fold increase in its 
activity. AdoMetDC activity was reduced by both (147) and (159) but there 
was no difference in AdoMetDC activity in the presence of (146).
6.8.2 DAO and PAO Activity
DAO activity was increased by 33% by (146) but not at all by (147) 
and only a slight increase was observed in the presence of (159). PAO 
activity doubled in the presence of (158), while a 66% increase was noted in 
the presence of (146) no effect was observed with (146) (Table 17).
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Enzyme Activity (pmol CO 2) 
(mg protein)*1 hr-1
Enzyme Activity (pmol CO2 ) 
(mg protein)”1 hr-1
Treatment DAO Activity PAO Activity
control 100.1 ±32.1 32.8±5.8
146 133.2±17.6 54.519.9**
147 103.2±12.4 32.6±2.9
159 114.9±15.8 68.3±5.0
(Table 17 Effects of (146), (147) and (159) on DAO and PAO activities in P. 
avenae values are means of 4 replicates ± standard errors).
Statistical differences shown at **P <0.01
6.9 Polyam ine Concentrations
The effects of our compounds on polyamine concentrations are shown 
in Table 18. Spermine concentration was reduced by 30-40% in the 
presence of all the test compounds. Compounds (147) and (159) did not 
alter sperm idine levels but (146) led to a 32% decrease in spermidine 
concentration. All three of the compounds caused a reduction in the level of 
cadaverine recorded in the fungus while (146) and (147) reduced the 
putrescine levels, and (159) caused a slight increase.
Polyamine Concentration (pM/gf.wt)
Treatment Spermine Spermidine Cadaverine Putrescine
Control 210.0±12.3 182.314.4 314.1121.4 355.9119.0
159 143.1111.6** 186.116.4 258.9127.6 410.0177.9
147 145.9123.9 188.3113.1 221.6168.9 317.3147.1
Control 157.7120.1 173.3121.1 546.7128.1 683.3183.6
146 93.1110.9* 117.419.7 268.4119.7*** 416.8129.1*
(Table 18 Effects of (159), (147) and (146) on polyamine concentrations in 
P. avenae values are means of 4 replicates ± standard errors), 
statistical differences shown at *P < 0.05. **P  < 0.01 and***P  < 0..001
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6.10 Discussion of Biological Testing Results
As we said in section 6.8 (146), (147) and (159) all significantly 
reduced in vitro mycelical growth of P. avenae and as we have shown with 
a selection of our biological testing results they all affected enzyme activities 
and polyamine activities in different ways.
Perhaps the most interesting results were demonstrated by (146). In 
our studies ODC activity more than doubled in the presence of (146). This 
should have led to an increase in the polyamine concentrations, but there 
were significant reductions in the levels of putrescine, cadaverine, spermine 
and spermidine (Table 18). AdometDC activity was not altered and this 
coupled with the reduction in putrescine levels could account for the 
reduction in spermine and spermidine levels. One possible reason for the 
reduced putrescine levels is that there may have been an increased efflux of 
putrescine from the cells, or putrescine may have been acetylated to form N- 
acetylputrescine.166 Similar results have been seen when the in vitro 
growth of P. avenae was inhibited by (£)-TED (38). The reasons outlined 
above may also account for the large reduction in cadaverine concentration.
It is clear that for whatever reason polyamine concentrations were 
reduced by (146) and this correlates with the observed reduction in mycelial 
growth. It is well established that polyamines are essential for normal growth 
so reducing their levels should repress the growth of fungi. The results 
discussed show that it is possible that perturbation of polyamine biosynthesis 
in the presence of (146) could be the cause of the observed fungicidal 
effect.167
Compound (147) differs from (146) by the addition of one methylene 
group in the diamine chain. The effects shown for (147) were not as 
pronounced as those for (146) and (159). It induced insignificant reductions 
in amounts of putrescine and cadaverine. No change was observed in 
spermidine levels, but there was a reduction in spermine levels. The 
reduction of putrescine levels was not matched by a decrease in ODC 
activity and there was no increase in DAO. The inhibition of mycelial growth 
by (147) cannot be correlated with inhibition of polyamine biosynthesis.
The tetraamine (159) induced putrescine levels higher than the 
control, even though there was only a small increase in ODC activity. The
128
increased putrescine levels may be due to the substantial increase in PAO 
activity. Although spermine levels were significantly reduced, spermidine 
levels were similar to control levels. The large increase in PAO activity may 
account for the fungicidal activity displayed.
It is probable that closely related compounds, particularly (146) and 
(147) are displaying powerful antifungal activity by different mechanisms. 
Further work, such as in vivo studies, is required to determine if 
perturbation of polyamine metabolism and/or function is responsible for the 
antifungal activities displayed.
At present we are awaiting in vitro results for twenty compounds.
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F u rth e r A n tifu n g a l T e s tin g  R esu lts
Prelim inary data are presented for the following compounds
The effects of a 0.25mM solution of the following compounds on powdery 
mildew infection of barley seedlings were recorded. Measurements were 
taken seven days after inoculation and are displayed in the table below.
Compound % Infection
control 34 ± 1.9
70 11 ±1.2
71 16 ± 1.3
143 10± 1.2
151 6 ±0.9
163 15 ± 1.2
164 10± 1.2
165 12 ± 1.9
It is clear from these results that all of the compounds substantially 
inhibited fungal growth.
The A/,A/’-bis(benzyl)diam inoalkanes (143) and (151) showed a 
possible correlation with activity and the distance between the nitrogen 
atoms. The activity of the compounds increased as the distance between the 
nitrogen atoms increased. The % infection nearly halved when going from 
(143) n=2 to (151) n=10. This is in agreement with our previous work.
The A/,A/'-bis(cyclohexylmethyl)diaminoalkanes (163), (164) and (165) 
also showed encouraging antifungal activity although the activity does not 
appear to related to the distance between the nitrogen atoms.
The final group of compounds in this section are the (±)-2-hydroxy-2- 
(2 '-pyridyl)ethylam ines. These compounds showed good activity at 0.25 
mM. The benzyl deriva tive  (70) was s ligh tly  more active than the 
cyclohexylmethyl derivative (71).
130
All the compounds in this section are being investigated for their 
effects on enzyme activity and polyamine concentrations.
(143) n=2 
(151) n=10
©.
N
H 0 
2COO
(163) n=3
(164) n=7
(165) n=8
0
NHR
OH
70 R =benzyl
71 R =cyclohexylmethyl
131
Experimental to Chapters 3 - 5
7
7.1 General Experimental Section
All chemicals were purchased either from the Aldrich Chemical Co. 
(Gillingham, Dorset, U.K.) or Lancaster Synthesis Ltd (Eastgate, White Lund, 
Morecambe, U.K.). The chemicals were used without further purification except 
where stated.
Commercially available solvents were used without further purification 
except those detailed below. Methanol and ethanol were dried by distilling from 
magnesium filings. Ether, tetrahydrofuran (THF), dioxane and benzene were 
dried by distillation from sodium and benzophenone.
All melting points (mp) were measured with a Gallencamp apparatus and 
are uncorrected.
All NMR spectra were obtained either on Bruker AM200-SY, AM360-SY or 
AM400-SY spectrometers operating at 200 MHz for 1H NMR spectra and 50 MHz 
for 13C NMR spectra, 360 MHz for 1H NMR spectra and 90 MHz for 13C NMR 
spectra and 400 MHz fo r 1H NMR spectra and 100 MHz for 13C NMR spectra, 
respectively. All coupling constants quoted are given in Hz. The numbering 
system used is solely to aid NMR characterisation, and does not reflect IUPC rules.
Mass spectra were recorded on AEI MS12 or a VG updated MS 902 mass 
spectrometer.
Infrared spectra were recorded using a Perkin Elmer 500 
spectrophotometer.
Thin layer chromatography (TLC) was carried out on silica gel G plates of 
0.25 mm thickness. Compounds were visualised by UV, iodine or with the 
dragendorff reagent. Column chromatography was carried out on silica gel, 70- 
230 mesh, 60 A.
Section 7.2 Experimental to Chapter 3
General Procedure A - Synthesis of 2-substituted aminomethylpyridines
Dry ether was added to a dry 3-necked flask fitted with a condenser, stirring 
bar, septum and N2 balloon. With stirring 2-pyridinecarbaldehyde was added and 
the resulting solution was stirred for 10 min. One equivalent of the appropriate 
primary amine was added dropwise and the solution became cloudy. The solution 
was stirred at room temperature for a period of 3-16 h. Solvent was removed under 
reduced pressure to give the imine as a yellow oil.
The imine was dissolved in dry ethanol and added to a dry flask as above 
and 2 equivalents of NaBhU were added slowly. After addition was complete the 
solution was stirred at room temperature overnight. The reaction mixture was 
washed with brine ( 1 x 1 5  cm3) and extracted with chloroform (3 x 50 cm3). The 
organic extracts were dried with anhydrous sodium sulfate, filtered and 
concentrated to leave the crude free base. A sample of the free base was 
converted into its oxalate salt by dissolving it in methanol (5 cm3) and 1 equivalent 
of oxalic acid dissolved in methanol (5 cm3) was added. The precipitate was dried 
and recrystallised from water or 95% aqueous ethanol.
The yields are based on the crude free base as not all of each sample was 
converted into its oxalate salt.
2-Benzylaminomethy!pyridine (46)168
General procedure A was used on a 14 mmol scale to give (46) as a yellow 
oil (1.81 g, 11 mmol, 78%); oxalate salt (white crystals) mp 202-204 °C; 5h (200 
M H z ,  D 2O ) ;0 6 8 )  4.11 (2 H, s, 8-H2), 4.16 (2 H, s, 7-H2), 7.25 (7 H, m, 3-H, 5-H,
10-H, 11-Hand 12-H), 7.69(1 H, dt, J7.8, 1.7, 4-H) and 8 . 38 (1H, d, J4.0, 6-H); 
Oxalate salt, new data: vmax(KBr)/cm"’*; 3436, 3036, 2849, 1716, 1590, 1445
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and 942; ( m/ z  )(+CI/NH3) 198 (M +H)+(%) 199 (100), 197 (12), 96 (30) and 79 
(20).
2-Cyclohexylmethyaminoethylpyridine(47)
The title compound was prepared by general procedure A on a 28 mmol 
scale (5 .2g, 25.5 mmol, 91%); (Oxalate Salt) mp 207-210 °C; Vmax (KBr disc/cnr 
1) 3438, 3049, 2926, 1719, 1593, 1473, 1200, 764 and 720; (Found: C, 61.26; 
H, 7.53; N, 9.61 C15H22N2O4 requires C, 61.22;H, 7.48; N, 9.52); 8h (400 MHz, 
D20); 0.96 (2 H, m, 11-H2), 1.15(4-H, m, 10-H2), 1.53(1 H, m, 9-H), 1.65 (4 H, 
m, 12-H2), 2.88 (2 H, d, J 8.0 , 8-H2), 4.28 (2 H, s, 7-H2), 7.44 (2 H, m, 3 and 5- 
H2), 7.88(1 H, m, 4-H2) and 8.50(1 H, d, J4.0, 6-H); 8C (100 MHz, D20); 25.3 
(CH2), 25.8 (CH2), 30.1 (CH2), 34.8 (CH), 51.3 (CH2), 53.8 (CH2), 124.9 (CH),
125.1 (CH), 139.6 (CH), 149.2 (CH), 150.0 (C) and 166.4 (C=0); (m/z) (+CI/NH3) 
204 (M+H)+ (%) 205 (100), 121 (2.5) and 93 (2.5); (Found (M+H)+ 205.1705 
C13H20N2 requires 205.1705).
2-Butylaminomethylpyridine (48)168
5 / ^ . 3
General procedure A was used on a 14 mmol scale except that the imine 
was dried with Drierite® before treatment with sodium borohydride to give (48) as 
a yellow oil (2.1 g, 12.9 mmol, 92%); oxalate salt data (white crystals); mp 198- 
200 °C. (lit.168 199-200 °C); 8H (400 MHz, D20) 0.74 (3 H, t , J, 7.4, H -H 3), 1.21 
(2 H, m, 10-H2), 1.52 (2 H, m, 9-H2), 2.96 (2 H, m, 8-H2), 4.21 (2 H, s, 7-H2), 
7.37 (2 H, m, 3 and 5-H2), 7.80(1 H, td, J  7.8, 1.7, 4-H) and 8.43 (1 H, d, J 
4.3, 6-H); New data, vmax(KBr)/cnrr1 3436, 3051, 2870, 1716, 1654, 1473 and
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865; 8C (100 MHz, D20); 13.0 (CH3), 19.4 (CH2), 27.7 (CH2), 47.6 (CH2), 51.0 
(CH2), 124.7 (CH), 125.0 (CH), 139.5 (CH), 149.1 (CH), 150.1 (C) and 166.4 
(C=0); (m/z) (+CI/NH3) 164 (M +H)+ (%) 165 (100), 163 (5), 96 (5) and 79 (5).
2-tert-Butylaminomethylpyridine (49)169
General procedure A was used on a 14 mmol scale to give (49) as a yellow 
oil (1.9 g, 11.6 mmol, 83%); Free base; 8h (400 MHz, CDCI3); 1.00 (9 H, s, 9-H3) 
3.70 (2  H, s, 7-H2); 6 .96(1 H, m, 5-H); 7.16(1 H, m, 3-H), 7.40(1 H, m, 4-H) 
and 8.35 ( 1 H, m, 6-H); oxalate salt data (white crystals) mp 119-120 °C; New 
data, vmax(KBr)/cm-1 3345, 2771, 2462, 1719, 1609, 1383 and 980; 5C (100 
MHz, D20 ) 25.1 (CH3), 45.5 (CH2), 58.0 (C), 124.6 (CH), 125.0 (CH), 139.5 
(CH), 149.0 (CH), 150.5 (C) and 166.5 (C=0); (m/z )(+Ci/NH3) 164 (M +H)+ (%) 
165 (100), 149(5), 96 (22) and 79 (15)
2-BenzylaminoethyIpyridine (56)170
Dry ethanol (20 cm3) was added to an oven-dried 3-necked flask fitted with a 
condenser, septum and nitrogen balloon. 2-Vinylpyridine (2 g, 19 mmol) and 
acetic acid (1.14 g, 19 mmol) was added and the solution was stirred. Benzylamine 
(1.38 g, 19 mmol) was added and the solution brought to reflux temperature which 
was maintained for 5 h. The solution was allowed to cool and stirred at room 
temperature for 14 h. The solvent was removed in vacuo to give 3.2 g of a white 
solid which was dissolved in 5 M NaOH (50 cm3) and extracted with chloroform (3 
x50 cm3). The organic extracts were dried (K2C 0 3), filtered and evaporated in 
vacuo to give a brown oil. The title compound was obtained by silica gel
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chromatography of the oil (hexane - ethyl acetate, 7:2). The free base was 
converted into the oxalate salt in a manner similar to that outlined in general 
procedure A. The precipitate was filtered, dried and recrystallised from 95% 
aqueous ethanol.(1.61 g, 7.6 mmol, 54%); (Found : C, 63.69; H, 6.10; N, 9.27% 
requires C, 63.58; H, 5.96; N, 9.27%); 8H (400 MHz, D20); (17°) 3.27 (2 H, m, 
7-H2), 3.38 (2 H, m, 8-H2), 4.18 (2 H, s, 9-H2), 7.36 (5 H, m, 11, 12 and 13 
-H), 7.60 (2 H, m, 3 and 5-H), 7.60 (2 H, m, 3 and 5-H), 8.13(1 H, dt, J8.0, 1.7, 
4-H), 8.49(1 H, d, J 4.0, 6-H); (m/z) (+CI/NH3), 212 (M+H)+(%) 213 (100), 211 
(2 .8) and 121 (2).
2-Cyclohexylmethylaminoethylpyridine (57)
Compound (57) was prepared on a 15 mmol scale and purified in a similar 
manner to that of (56) (1.18 g, 5.4 mmol, 36%); oxalate salt data; mp 178-180°C; 
(Found: C, 58.23; H, 7.58; N, 10.45. C-|3H2oN204 requires C, 58.21; H, 7.46; 
N, 10.45); Vmax (KBr)/cm-13059, 3013, 2927, 2852, 2810, 1718, 1701, 1475, 
1217, 770, 720 and 709; SH (400 MHz, D20); 0.88 (2 H, m, 13-H2), 1.08 (4 H, 
m, 12-H2), 1.52(1 H, m, 10-H), 1.59 (4 H, broad signal, 11-H2), 2.84 (2 H, d, J 
6 .6 , 9-H), 3.33 (4 H, m, 7 and 8-H2), 7.67 (2 H, m, 3 and 5-H), 8.22 (1 H, 
distorted dd, J  7.8, 4-H), 8.52(1 H, d, J  5.4, 6-H); 8C (100 MHz, D20); 25.2 
(CH2), 25.7 (CH2), 30.1 (CH2), 30.7 (CH2), 34.9 (CH), 46.4 (CH2), 54.0 (CH2), 
125.4 (CH), 126.7 (CH), 144.0 (CH), 144.9 (CH) 152.8(C), 168.9 (C=0); (m/z) 
218 (%) (+CI/NH3) (M+H)+ 219 (100), 135 (5) and 14 (5); (Found: (M+H)+ 
219.1860 C14H22N2 requires 219.1861).
2-tert-Butylaminoethylpyridine (58)171
The title compound (58) was prepared on a 19 mmol scale and purified in a 
manner similar to that described for (56), (1.33 g, 7.4 mmol, 39%); Oxalate salt 
data; Vmax (KBr)/cm1; 3421, 3036, 2977,2794, 1590, 794, 706 and 486; 6H 
(400 MHz, D20); 1.29 (9-H, m, 10-H3), 4.19 (6-H, s, 7 and 8-H2), 7.33(1 H, dd, 
J 7.0, 5.3, 5-H), 7 .39(1 H, d, J 8.0, 3-H); 8.18(1 H, dt, J, 7.9, 1.6, 4-H); 8.41 
(1 H, d, J 4.0, 6-H); 8C (100 MHz, D20); 25.1 (CH3), 31.6 (CH2), 40.2 (CH2), 
57.9(C), 125.3 (CH), 126.7 (CH), 144.4 (CH), 144.6 (CH), 153.1 (C) and 170.2 
(C=0); (m/z) (+CI/NH3) 179, (M+H)+(%) 179 (100).
2-Butylaminomethylpyridine (59)67
The title compound (59) was prepared on an 19 mmol scale and purified in 
a manner similar to that described for (56) (1.43 g, 42%, 8 mmol), Oxalate salt 
data; (Found: C, 58.23; H, 7.58; N, 10.45%. C i3H2oN204 requires C, 58.21; H, 
7.46; N, 10.45%) New data: Vmax (KBr)/cm-1, 3078, 2964, 2934,1719, 1578, 
1214, 751 and 705I 5h (400 MHz, D20), 0.80 (3 H, t, J7.4, 12-H3), 1.26 (2 H, m,
11-H2), 1.55 (2 H, m, 10-H2), 2.99 (2 H, t, J 7A,  9-H2), 3.31 (2 H, m, 8-H2), 
3.36 (2 H, m, 9-H2), 7.65 (2 H, m, 3 and 5-H), 8.18(1 H, dt, J, 7.9, 1.6, 4-H) 
and 8.51 (1 H, d, J  0.5, 6-H); 8c (100 MHz, D20) 13.1 (CH3), 19.5 (CH2), 27.8 
(CH2), 31.2 (CH2), 46. 1 (CH2), 48.0 (CH2), 125.2 (CH), 126.7 (CH), 144.4 (CH),
144.6 (CH), 153.2 (C) and 170. 5 (C=0); mp 176-177 °C (m/z) (+CI/NH3) 178, (M +
H)+(%) 179 (100).
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2-Diethylaminoethyl pyridine (60)172
The title compound (60) was prepared on a 19 mmol scale and purified in a 
manner similar to that described for (56) (1.05 g, 5.9 mmol, 31%); Oxalate salt 
data, mp 93-95 °C. (Found: C, 57.06; H, 7.22; N, 10.15%. C13H2oN2 0 4 
requires C, 57.21; H, 7.46; N, 10.45 %); Vmax (KBr)/cm-1, 3049, 2853, 1718, 
1475,1209, 789, 754 and 701; SH (400 MHz, D20); 1.21 (6 H, t, J 7 .3, 10-H3), 
3.19 (4 H, q, J 7.3, 9-H2), 3.31 (2 H, m, 8-H2), 3.45 (2 H, m, 7-H2), 7.63 (2 H, 
m, 3 and 5-H), 8.16(1 H, td, J8.0, 1.6, 4-H) and 8.50 (1 H, d, J 4.0, 6-H); 8c 
(100 MHz, D20) 8.4 (CH3), 29.3 (CH2), 47.8 (CH2), 50.2 (CH2), 125.2 (CH),
126.6 (CH), 144.2 (CH), 144.8 (CH), 153.0 (C) and 170.2 (C=0); (m/z) (+CI/NH3) 
178 (M+H)+ (%) 179 (100) and 86 (12).
(±)-2-(1-Hydroxy-2-nitroethyl)pyridine (63)173
NO
OH
The title compound (63) was prepared on a 23 mmol scale by the method of 
Gavin and purified by silica gel chromatography (hexane - ethyl acetate, 2:3), 
(1.69 g, 9.9 mmol, 43%) The 1H NMR, 13C NMR, IR and MS spectral data were 
in good agreement with those reported.66 (Found: C, 50.20; H, 4.83; N, 16.62 
% requires C, 50.00; H, 4.76; N, 16.67%).
(±)-2-(1-Hydroxy-2-aminoethyl)pyridine (44)174
The title compound was prepared by the method of Gavin on an 7.7 mmol 
scale, (80%). 1H NMR and 13C NMR data were in good agreement with those 
reported.66
1-(2-pyridyl)oxirane (64)93
The title compound was made by adapting the procedures of Thurkauf et 
a/93 and Hanzlik et al.92
To a 3-necked flask at 0 °C containing a solution of dioxane - water (3:7, 
148 cm3) was added 2-vinylpyridine (5.5 g, 52.3 mmol) and acetic acid (2.75 g,
45.8 mmol) and the solution was stirred for 10 min. A/-Bromosuccinimide* (9.9 g,
55.6 mmol, 1.1 eq) was added in portions over 30 min and the resulting solution 
was stirred at 0 °C for 1 h then sodium carbonate (11 g, 103.8 mmol) was added in 
portions over 45 min and the solution was stirred for 15 h.
The solution which had become very viscous was extracted with diethyl 
ether (4 x30 cm3). The ether extracts were dried with sodium sulfate, filtered and 
the solvent evaporated in vacuo to give a dark brown oil.
The residue was distilled (bp 58 °C, 0.2 Torr)93 to give the title compound 
as a colourless oil, which darkened on standing after two d (2.48 g, 20.5 mmol, 
39%). New data v max (thin film)/crrr1 3404, 3057, 3012, 2992, 1593, 14378, 
878, 780, 581 and 541; 5C (50 MHz, CDCI3) 50.2 (CH2), 52.7 (CH), 119.6 (CH),
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123.0 (CH), 136.7 (CH), 149.2 (CH) and 157.0 (C); (m/z) (+EI) 121 (M+H)+ (%) 
122 (10), 121 (30), 120 (100).
* /V-bromosuccinimde was purified by the method outlined by D.D. Perrin and 
W.L.F. Armarego, Purification of Laboratory Chemicals, 3rd Edition, Pergamon 
Press, 1992.
(±)-2-(Benzylamino-1-hydroxyethyl)pyridine (70)
OH
The following procedure was adapted from that published by that of Backvall 
and Bjorkmann.175
To a dry 3-necked flask fitted with a condenser, septum and stopper was 
added methanol (5 cm3) and benzylamine (1.71 g, 16 mmol). With stirring, 
epoxide (64) (0.5 g, 4.1 mmol) was added and the solution was brought to reflux 
temperature which was maintained for 8 h. The solution was stirred at ambient 
temperature for 14 h.
The reaction mixture was poured into ether (12 cm3) and extracted with 2 M 
HCI (3x10 cm3). The aqueous extracts were washed with ether ( 2 x 1 5  cm3).. 
NaOH pellets were added until the solution was basic (pH =14) and the solution 
was extracted with chloroform (3 x 50 cm3) and extracts dried with K2 CO3. 
Filtration and evaporation of the solvent afforded 1.62g of a brown oil. Distillation 
gave (70) (0.5g, 2.21 mmol, 54%).
The free base was converted to the corresponding oxalate salt by dissolving 
the free base in methanol (3 cm3) and adding it to a solution of 1 equivalent of 
oxalic acid in methanol (3 cm3). Vigorous scratching of the solution gave a white 
precipitate of the salt, which was crystallised from water
mp 186-187°C (decomp); Vmax (KBr)/cm'1 3402, 3062, 2851, 1772, 1595, 
1474, 1213, 1116, 998, 758 and 700; (Found : C, 60.35; H, 5.77, N, 8.81%
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C16H18N2O5 requires C, 60.38, H, 5.66; N, 8.80%); 8h (400 MHz, D2O); 3.25 
(1H, dd, J  9.3, 3.7, 8-H), 3.42(1 H, dd, J 9.7, 3.4, 8-H'), 4.25 (2 H, s, 9-H2), 
5.20(1 H, dd, J  5.9, 3.3, 7-H), 7.40 (5 H, m, 11, 12 and 13-H), 7.58(1 H, 
overlapping dd, J 8.0, 5-H), 7.65(1 H, d, J 8.0, 3-H), 8.12(1 H, m, 4-H) and 
8.51 (1 H, d, J  5.0, 6-H); 8C (100MHz, D20);51.1 (CH2), 51.5 (CH2), 67.8 (CH),
123.2 (CH), 125.7 (CH), 129.6 (CH), 130.1 (CH), 130.3 (CH), 130.6(C), 142.7 
(CH), 145.9 (CH), 156.1 (C) and 168.6 (C=0); (m/z) (+CI/NH3), 228, (M + H)+ (%) 
229 (100), 227 (5), 108 (15), 96 (5) and 79 (5); (Found (M+H)+ 229.1340 
C i4H-|7N20  requires 229.1341).
()-2-(C yclohexylam i no-1-hydroxyethyl)py rid ine (71)
OH
The title compound (71) was prepared as described for (70), except that
(71) was not purified by distillation, mp 178-180°C; Vmax (KBr)/cm‘1 3410, 2927, 
2853, 1596, 1439, 1216, 1080, 720 and 498; 8H (400 MHz, D20); 0.92 (2 H, m, 
13-H2), 1.12 (4 H, m, 12-H2), 1.54 (1 H, broad signal, 10-H), 1.63 (4 H, broad 
signal, 11 -H2), 2.89 (2 H, d, J6.2, 9-H2), 3.23(1 H, dd, J9.4, 3.6, 8-H), 3.39(1 
H, dd, J 9.8, 3.3, 8 '-H), 5.10(1 H, dd, J  6.1, 3.2, 7-H), 7.56(1 H, m, 3-H), 
7.67(1 H, m, 5-H), 8.09(1 H, td, J  7.8, 1.5, 4-H) and 8.51 (1 H, d, J 5.1, 6-H); 
8C (100 MHz, D20); 25.3 (CH2), 25.8 (CH2), 30.1 (CH2), 34.6 (CH), 52.0 (CH2),
54.0 (CH2), 67.4 (CH), 123.5 (CH), 125.9 (CH), 143.4 (CH), 145.4 (CH), 156.0 
(C) and 168.1 (C=0); (m/z) (+CI/NH3), 234 (M+H)+(%) 235 (100), 217 (2), 126 (9) 
and 109 (12) (Found (M+H)+ 235.1809 C i4H23N20  requires 235.1810).
(±)-2-(Butylamino-1-hydroxyethyl)pyridine (72)
OH
The title compound (72) was prepared as described for (70), except that
(72) decomposed upon distillation. 5h (400 MHz, CDCI3); 0.89 (3 H, t, J7.3, 12- 
H3), 1.37-1.41 (2 H, m, 11 -H2), 1.44-1.55 (2 H, m, 10-H2), 2.67-2.71 (2 H, m, 9- 
H2), 2.78 (1 H, dd, J  7.0, 3.3 8-H), 2.97 (1 H, dd, J 9.9, 4.3, 8 '-H), 4.82 (1 H, 
dd, J 4.7, 3.6, 7-H), 7.18 (1H, m, 3-H or 5-H), 7.43 (1H, m, 3-H or 5-H), 7.63 
(1H, m, 4-H) and 8.52 (1H, d, J4.8, 6-H); 5C(100 MHz, CDCI3); 14.3 (12-CH3), 
20.7 (11-CH2), 32.5 (10-CH2), 49.7 (9-CH2), 56.5 (8-CH2), 72.1 (7-CH), 121.0 
(3CH or 5CH), 122.7 (3-CH or 5-CH), 137.0 (6-CH) 148.8 (4-CH) and 162.5 (2-C). 
Plus impurities.
2-Bromoacetylpyridine Hydrobromide (74)
The title compound was prepared on a 20 mmol scale and isolated in a yield 
of 85% following the method of Taurins and Blaga.105 The 1H NMR spectrum and 
melting point are in good agreement with the published data.106
O O
Section 7.3 Experimental to chapter 4 
Dimethyl 4,5-dimethylcyclohexa-1,4-diene-1,2-dicarboxylate (89)118
Compound (89) was prepared on a 30 mmol scale by the method of 
Kucherov and Grigovera. 118 (80%); mp 75-76°C (lit118 75-76°C); §h (200 MHz, 
CDCI3); 1.66 (3 H, s, I-H 3); 2.92 (2 H, s, 3-H2) and 3.78 ( 3 H, s, 6-H3).
1,2-Bis(hydroxymethyl)-4,5-dimethylcyclohexa-1,4-diene (90)176
Compound (90) was prepared on a 50 mmol scale by the method of 
Martin176 and was recrystallised from ethyl acetate (35%); mp 147-149°C 
(lit. 177 146-148 °C); 8H (200 MHz, D6 DMSO); 1.65 (3 H, s, 1-H3); 2.68 (2 H, 
s, 3-H2); 4.00 (2 H, s, 5-H2) and 4.53 (2 H, s, OH).
1,2-Bis(aminomethyl)-4,5-dimethylcyclohexa-1,4-diene 
dihydrochloride (86)176
©w<
”
<CMJ
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The title compound was prepared on a 40 mmol scale by the method of 
Fabiano et a /.12® (43%); 8H (200 MHz, D20)(176); 1.50 (3 H, s, 1-H3); 2.58 
(2 H, s, 3-H2) and 3.57 (2 H, s, 5-H2).
A ttem pted synthes is  of 4 ,5 -D im eth y lcyc lo hexa-1 ,4 -d ien e-1 ,2 - 
dicarboxylic acid (94)
0
V  2 J L  4 J -L
f l  If j 5 OHI LL'0H
0
The following procedure was adapted from that of Corey et al. 127 
Diester (89) (1.0 g, 4.5 mmol) was dissolved in methanol (3 cm3). Lithium 
hydroxide monohydrate (0.1g, 22.5 mmol) was dissolved in a 3:1 methanol - 
water mixture (40 cm3) and was added in slowly over 1.5 h. The solution was 
stirred at ambient temperature for 24 h after which time it was a pale yellow 
colour. TLC (methanol:DCM, 4:1, acetic acid) of the reaction mixture indicated 
that all of (89) had been consumed and a spot appeared for a more polar 
product. The solution was stirred for a further 6 h after which time it was 
colourless.
The reaction mixture was washed with ether ( 3 x 1 0  cm3) and 3 M HCI 
was added until the solution reached pH 2. The acid solution was extracted 
with ethyl acetate (3x 10 cm3). The extracts were dried with anhydrous sodium 
sulfate, filtered and concentrated to give 0.50 g of a white solid. 1H NMR 
spectroscopy indicated the presence of aromatised and hydrolysed products.
Attem pted synthesis  of 4 ,5 -D im eth y lcyc lo hexa-1 ,4 -d ien e-1 ,2 - 
dicarboxylic acid (94)
To a round-bottom flask fitted with a condenser was added diester (1) 
and a 5% sodium hydroxide solution. The mixture was stirred and heated at 
reflux for 4 h. The reaction was worked up in the manner previously described 
to afford 0.3 g of a white solid which was insoluble in all deuterated solvents 
investigated.
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Further attempts to complete the reaction with sodium hydroxide 
solutions of different concentrations proved unsuccessful.
A ttem pted syn thes is  of 4 ,5 -D im eth y lcyc lo hexa-1 ,4 -d ien e-1 ,2- 
dicarboxylic acid (94)
The following procedure was adapted from Olah e ta ! ,130
To a dry 3-necked flask fitted with a nitrogen balloon, condenser and 
septum was added diester (89) (1.1 g, 6.4 mmol) followed by dry acetonitrile 
and the solution was stirred. Sodium iodide (2.9 g, 19.7 mmol) was added and 
stirring was continued. Trimethylsilyl chloride (1.4 g, 13.1 mmol) was added 
dropwise and the solution turned a yellow colour. The reaction was heated at 
reflux for 1 h after which a brown colour persisted in the flask. The reaction was 
stirred at ambient temperature for 14 h and then taken up in ether (30 cm3) and 
washed sequentially with water (10 cm3); 10% sodium thiosulfate (10 cm3) and 
brine (10 cm3). Acidification of the combined sodium bicarbonate extracts with 
6 M hydrochloric acid did not produce the expected precipitate.
Drying and evaporation of the ether extracts yielded 40 mg of the starting 
diester (89).
A ttem pted synthesis  of 4 ,5 -D im eth y lcyc lo h exa-1 ,4 -d ien e-1 ,2- 
dicarboxylic acid (94)
The following procedure was adapted from that of Laganis and 
Chenard128.
To a dry 3-necked flask fitted with a nitrogen balloon, condenser and 
septum was added diester (89) (0.56 g, 2.5 mmol) and dry THF (50 cm3) and 
the solution was stirred. Potassium trimethylsilanolate was added and the 
resultant mixture was stirred at ambient overnight, after which time TLC (1:1 
hexane - ethyl acetate) indicated the presence of starting material and two more 
polar products. Concentrated hydrochloric acid (5 cm3) was added followed by 
water (40 cm3). The reaction mixture was then washed with ethyl acetate (3 x 
40 cm3); dried, filtered and concentrated to give a thin oily film. Drying of the 
ethyl acetate extracts and subsequent filtering and concentration yield 400 mg 
of starting material.
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Synthesis of 4,5-Dimethylcyclohexa-1,4-diene-1,2-dicarboxylic acid
(94)118
The following procedure was adapted from that of Kucherov and 
Grigovera118. To a dry 3-necked flask fitted with a nitrogen balloon, condenser 
and septum was added acetylenedicarboxylic acid (2.0 g, 17.6 mmol) and dry 
dioxane (30 cm3). With stirring 2,3-dimethyl-1,3-butadiene (3.0 g, 36.6 mmol) 
and pyrogallol (0.2g, 1.56 mmol) were added and the reaction mixture was 
stirred and heated at 75 °C for 15 h. Dioxane and the excess diene were 
distilled off under vacuum and the resulting brown residue was washed with a 
1:1 mixture of diethyl ether and pet ether ( bp 60 - 80 °C) to give a white solid. 
1H NMR spectroscopy indicated this to be a mixture of the desired diacid (94) 
and the corresponding anhydride. The mixture was dissolved in 5% NaOH 
solution (25 cm3) and the flask shaken until almost all the solid had dissolved. 
The volume of the solvent was reduced in vacuo to 5 cm3 and then the flask 
was cooled to 0 °C. Concentrated hydrochloric acid was added to precipitate 
out a white solid (94) which could not be recrystallised from the solvents 
investigated (2.1 g, 10.7 mmol, 60%); mp 157-161°C (lit118 158.5-160.5°C); 
8h (200 MHz, D20); 1.66 (3 H, s, 1-H3) and 2.87 (2 H, s, 3-H2).
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4 ,5 -D im eth y lcyc lo h exan e -1 ,2 -d icarb o xy lic  acid, mono N -
benzylamide (113)
OH
To an ice cooled stirred suspension of crude (105) (1.68 g, 9.4 mmol) in 
dry ether (10 cm3) was added benzylamine (1.1 g, 10.5 mmol) in dry ether (10 
cm3) dropwise. Stirring was continued at 0 °C under a dry nitrogen atmosphere 
for 4 h. The white precipitate that formed was filtered, dried and crystallised to 
give a crude sample of (113) (Found (M+H)+286.1445. C17H20NO3 requires 
286.1443).
A/,/V-Dibenzyl-4,5-dimethylcyclohexa-1,4-diene-1,2-dicarboxamide 
(95)
5 NH
NH
To an ice cooled solution of crude (113) (0.5 g, 1.7 mmol) and dry 
triethylamine (0.3 g, 2.3 mmol) in dry THF (15 cm3) was added ethyl 
chloroformate (0.22 g, 2.1 mmol) and the resulting solution was stirred for 20 
min. A solution of benzylamine (0.22 g, 2.1 mmol) in THF (10 cm3) was added 
dropwise and stirring was continued for 15 h. Water (10 cm3) was added and 
the reaction mixture was extracted with chloroform ( 2x10 cm3). The combined 
organic layers were washed with water ( 2 x 1 5  cm3), dried with anhydrous
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magnesium sulfate, filtered and concentrated. The white solid was crystallised 
from ethyl acetate to give the title compound (95) (250 mg, 0.67 mmol, 39%); 
Rf (1:1 hexane - ethyl acetate); mp 197.5 -198.5 °C (ethyl acetate). 
Vmax(KBr)/cnr1, 3409, 3288, 1697, 1529, 1453, 1027, 690 and 650; 6H 
(200 MHz, CDCI3); 1.61 (6 H, s, 1-H3); 2.87 (4 H, s, 3-H2); 4.20 (4 H, d, 6- 
H2); 6.87 (2 H, broad, NH) and 7.26 (10 H, m, 8 , 9and10-H). 8C (50 MHz, 
CDCI3); 17.9 (CH3); 34.3 (CH2); 43.2 (CH2); 121.8 (C); 127.4 (CH); 127.8 
(CH); 128.6 (CH); 132.3 (C), 137.8 (C) and 169.6 (C). (m/z) 374 (+EI) (%) 
(M+)(1%); 269 (85), 240(30), 133(25), 119(30), 91 (100), 77 (15) and 65 
( 12).
Acetylenedicarboxamide (111)132
The title compound was synthesised in a yield of 78% in the manner 
reported by Saggiomo132 mp 214 -218 °C (decomp) from ethanol, (lit133 216- 
218 °C, ethanol).
H2NOC— — CONH2 
111
Norborn-5-ene-2-e/7c/o,3-e/7do-dicarboxylic acid anhydride (119)
The title compound was synthesised on a 30 mmol scale by the method 
of Sadukin et al. 140 (85%); mp 165-167 °C (Lit178 165-167 °C).
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Bicyclo[2.2.1]hept-5-ene-enc/o-c/s-1,2-dicarboxylic acid mono /V-
benzylamide (120) 179
9 OH
To an ice cooled stirred suspension of the endo-cis-anhydride (119) (2 g,
12.2 mmol), was added benzylamine (1.4 g, 13.4 mmol) in dry ether (10 cm3) 
dropwise. Stirring was continued at 0 °C for 4 h. The white precipitate that 
formed was filtered, dried and crystallised from chloroform-hexane and 
recrystallised from 95% aqueous ethanol to give (120) (2.71 g, 10.0 mmol, 
82%); mp 123-130° C; v max (KBr disc)/cnr1 3314, 3030, 1635, 1496, 1267 
and 749; 8H (200 MHz, D6 DMSO); 1.30 (2 H, m, 5-H2), 3.04 (2H, broad 1-H 
and 4-H), 3.17 ( 2 H, m, 2-H and 3-H), 4.32 (2-H, m, 10-H), 5.9 ( 1 H, m, 
7-H), 6.25(1 H, m, 6-H), 7.36 (5 H, m, 12, 13 and 14-H), 8.37(1 H, t, J6.0, 
NH) and 11.77(1 H, b.s., OH); 8C (50 MHz, D6 DMSO); 42.2 (CH2), 45.4(1- 
CH), 47.1 (4-CH), 48.4 (CH2 and CH,), 48.6 (CH) 126.7 (CH), 127.2 (CH),
128.3 (CH), 133.6 (CH), 135.3 (CH), 171.3 (C) and 140.0 (C); (m/z)  (+EI) 
271 ( M+, 2.7%), 266, 253, 187, 106,91 and 79 (Found M+. 271.1203 
C16H17NO3 requires 271.1208).
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/V,/V-Dibenzyl-bicyclo[2.2.1]hept-2-ene-2,3-endoc/s-dicarboxamide
(121)
To an ice cooled, stirred solution of (120) (2 g, 7.38 mmol) and dry 
triethylamine (1.33 cm3, 9.5 mmol ) in dry THF (15 cm3) was added ethyl 
chloroformate ( 0.97 g, 8.90 mmol ). The resulting solution was stirred for 20 
min. A solution of benzylamine (0.97 g, 8.90 m m ol) in dry THF (10 cm3) was 
added dropwise. Stirring was continued for 5 h at room temperature and the 
mixture was left overnight. Water (25 cm3) was added and the reaction mixture 
was extracted with chloroform (2 x 30 cm3). The combined organic layers were 
washed with water (2 x 20 cm3) dried with anhydrous magnesium sulphate, 
filtered and concentrated to give (2.42 g) of a white solid, crystallisation of the 
solid from ethyl acetate gave the title compound (1.9g, 5.23 mmol, 71%); mp 
140-141°C; Vmax ( KBr disc)/cm -1 3331, 3030, 1656, 1548,731 and 698; 6H 
(200MHz, CDCI3); 1.22 ( 2 H, m, 3-H2); 2.98 ( 2 H , broad singlet, 1-H), 
3.16 (2 H, broad singlet, 2-H), 4.17 (4 H, m, 6-H2); 6.23 (2 H, broad singlet,
4-H), 7.22 (10 H, m, 8 , 9, and 10-H); 6c (200 MHz, D6-DMSO); 43.4 ( 3- 
CH2); 47.3 (1-CH), 49.9 ( 6-CH2), 51.8 (2-CH), 127.3 (10-CH), 127.6 (8-CH),
128.6 (9-CH), 135.7 (4-CH), 138.2 (7-CH) and 173.2 (5-C); (m/z)(+EI) 360, ( 
M+, 26%), 342, 253, 226, 185, 106, 91, 66 and 65; (Found M+360.1831. 
C16H17NO3 requires 360.1838).
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N-Benzyl-A/', A/'-dimethy lbicyclo[2.2.1 ]hept-5-ene-enc/o-c/s-1,2-
dicarboxamide (122)
CH
To a suspension of (120) (1 g, 3.7 mmol) in benzene (10 cm3) was 
added hexamethylphosphorus triamide (0.31 g, 1.9 mmol) over 5 min. The 
solution was then heated to reflux for 20 min, cooled to room temperature then 
saturated sodium carbonate (10 cm3) was added. The aqueous layer was 
extracted with DCM (3 x 20 cm3). The organic extracts were filtered and the 
solvent evaporated in vacuo to give a yellow oil which crystallised on standing. 
The solid was recrystallised from a small amount of ethanol (0.68 g, 2.3 mmol, 
62%); mp 164 -166 °C; V max (solution)/ cm-1 3022, 2397, 1651, 1524, 1209 
and 915; 5H (200MHz, CDCI3); 1.34- 1.48, (2 H, m, 5-H2), 2.58 (3 H, s, 
IO 0M I-H 3), 2.93 ( 3 H, s, IO 0M I-H 3) ,  3.08 (1 H, broad signal, 1 or 4-H), 
3.27(1 H, broad signal, 1 or 4-H), 3.36-3.46 (2 H, m, 2 and 3-H); 4.18 (1 H, 
dd, J 14 and 6 , 12-H2), 4.36 (1 H, dd, J16, 6 , 12-H'2) 5.98 (2 H, dd, J 
10.8, 6.3, 6 and 7-H), 6.73 (1 H, dd, J10.8, 6.3, NH); and 7.17-7.36 (5 H, 
m, 14, 15 and 16-H); 6C (50 MHz, CDCI3); 35.1 (CH3), 36.7 (CH3), 43.3 
(CH2), 47.0 (CH), 47.6 (CH), 49.4 (CH3), 49.6 (CH), 51.9 (CH), 127.2 (CH),
127.8 (CH), 128.5 (CH), 131.8 (CH), 138.5 and 139.7; (m/z)(+EI) 297 (M+H) + 
(%) 298 (10), 253 (86), 187 (100), 106 (40), 91 (82), 66 (68) and 44 (20). 
(Found (M+H)+ 298.1678 C18H22N2O2 requires 298.1681).
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N-Benzyl-/\r,A/'-diethylbicyclo[2.2.1 ]hept-5-ene-encto-c/s-1,2-
dicarboxamide (123)
10'
The title compound was prepared in a manner similar to that (122) using 
(120) (1 g, 3.7 mmol) and hexaethylphosphorus triamide (0.47 g 1.9 mmol). 
The desired compound was recrystallised from ethanol (0.54 g, 1.67 mmol, 
45%); mp 128-130 °C; V max (nujol)/crrr1 , 3024, 2394, 1645, 1265, 1206 
and 930; SH (400 MHz, CDCI3); 0.96 (3 H, t, J 6 , 11 or 11'-H3), 1.17 (3 H, t, 
J7.1, 11 or H -H 3), 1.37(1 H, d, J  8 , 5-H ), 1.48-1.51 (1 H, m, 5-H ), 2.92 
-3.57 (8 H, m, 1, 2 , 3 and 4-H and 10 and 10'H2) 5.96 (1 H, dd, J 3.1 and
5.4, 6-H or 7-H); 4.43(1 H, dd, J 14.7, 6.7, 12-H), 4.05(1 H, dd, J 14.7,
6.7, 12'-H), 6.12(1 H, broad signal, NH), 6.70(1 H, dd, J  3 .2 , 5.4, 6-H or 
7-H) 7.19 - 7.32 (5 H, m, 14, 15 and 16-H); 8 C  (100 MHz, C D C I 3 ) ;  13.3 
(CH3), 14.5 (CH3), 40.5 (CH2), 41.9 (CH2), 43.9 (CH2), 47.9 (CH), 48.2 
(CH), 49.4 (CH), 50.3 (CH2), 53.0 (CH), 127.6 (CH), 128.1 (CH), 128.9 
(CH), 132.3 (CH), 138.7 (CH), 140.1 (CH), 172.5 (C=0) and 172.5 (C=0); 
(m/z)(+EI) 297 (M + H)+ (%) 298 (10), 253 (86), 187(100), 106 (40), 91 (82), 
66 (68) and 44 (20). (Found (M+H)+ 326.1995 C2oH26N20 2 requires 
326.1994).
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Norbornane-2-endo,3-enc/odicarboxylic acid anhydride (135)147
The title compound was made on a 30 mmol scale using the procedure 
of O hanti147 and was recrystallised from ethyl acetate (26 mmol, 98 %). The 
1H NMR spectrum is in good agreement with that published.147
Bicyclo[2.2.1]heptane-e/?c/o-c/s-1,2-dicarboxylic acid mono N- 
benzylamide (136)
^  NH 
OH
The title compound was made on a 5 mmol scale in a similar manner to 
that already described for (120). Recrystallisation from ethanol gave (136) (1.04 
g, 3.8 mmol, 76%); mp 170- 174 °C; (Found: C, 70.47; H, 6.96; N, 5.27 
C i6H i9N 03 requires C, 70.33; H, 6.96; N, 5.13); 8H (400 MHz, D6 DMSO);
I.17-1.31 (4 H, m, 6and7-H 2), 1.34 - 1.55 (2 H, m, 5-H2), 2.30(1 H, m, 1 
or 4-H), 2.51 (1 H, m, 1 or 4-H), 2.68(1 H, m, 2 or 3-H), 3.00(1 H, dd, J
I I.7 , 4.1, 2 or 3-H), 3.51 (1 H, broad signal, OH), 4.28(1 H, dd, J  6.0,
15.4, 10-H2), 4.23 (1 H, dd, J6.1, 15.4, 10'-H2) 7.24 (5 H, m, 12, 13 and 
14-H), 8.28(1 H, t, J  5.9, NH); 5C (100 MHz, D6 DMSO); 22.9 (CH2), 25.1 
(CH2), 40.3 (CH), 40.5 (CH2), 41.8 (CH), 42.3 (CH2), 46.8 (CH), 46.8 (CH),
126.9 (CH), 127.4 (CH), 128.5 (CH), 140.2 (C), 172.6 (C=0) and 174.1
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(C=0); vmax (KBr disc)/cm -1 3310, 3032, 1600, 1496, 1235 and 739; (m/z) 
(+EI) 273 (M+) (%) 273 (7), 255 (14), 227 (5), 189 (7), 106 (14), 91 (46), 79 
(35) and 66 (100); (Found (M+H)+ 273.1368 requires 273.1365).
A/,A/-Dibenzyl-bicyclo[2.2.1]heptane-2,3-ei7c/o-c/s-dicarboxamide
(137)
NH
The title compound was made on a 10 mmol scale in a similar manner to 
that already described for (121). Recrystallisation from ethyl acetate gave (137) 
(2.3 g, 6.5 mmol, 65%); mp 158-161 °C; vmax (KBr)/cnr1 3327, 3285, 2948, 
1650, 1549, 1229, 760 and 701; 5H (400 MHz, CDCI3); 1.44 (4 H, m, 4-H2), 
1.95 (2 H, m, 3-H2 ), 2.50 (2 H, broad signal, 1-H), 2.83 (2 H, broad signal,
2-H), 4.19(1 H, dd, J15.2, 5.8, 6-H2), 4.28(1 H, dd, J 15.2, 5.9, 6 '- 
H2),7.28 (10 H, m, 8 , 9 and 10-H), 7.95 (2 H, t, J 5.6, NH); 6C (100 MHz, 
CDCI3); 24.5 (CH2), 40.9 (CH2), 41.9 (CH), 44.0 (CH), 49.4 (CH2), 127.7 
(CH), 128.2 (CH), 129.0 (CH), 138.9(C), 172.8 (C=0) (m/z)(+EI) 362 (M+) 
(%) 362 (7), 344 (7), 296 (20), 255 (68), 228 (14), 188 (10), 162 (14), 106 
(40), 91 (100), 79 (7) and 65 (5); (Found (M+H)+ 362.1994 C20H26N2O2 
requires 362.1994).
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2,3-Endoc/s-bis(benzylaminomethyl)bicyclo[2.2.1]heptane 
Dihydrochloride (138)
To a stirred solution of (137) (0.5 g, 1.4 mmol) in dry THF (20 cm3) was 
added a 1 M THF-borane solution (5.6 cm3, 5.6 mmol). The solution was 
stirred for 1 h at room temperature, then heated to reflux and maintained at this 
temperature for 17 hours. The reaction was cooled to 0 °C and 6 M HCI was 
added cautiously until hydrogen evolution had ceased. The THF and water was 
evaporated to leave a glassy solid which was recrystallised from ethanol. The 
solid was added to a small amount of ethanol and ethereal HCI was added and 
the solution was scratched until a white precipitate of (138) formed (0.44 g, 1.1 
mmol, 75%); mp 266-268 °C decomp; Vmax (KBr)/crrr1, 3447, 2956, 2743, 
2673, 2589, 2049, 1587, 1458, 1211, 1016, 752, 697 and 488; §H (400 
MHz, D20); 1.11 -1.99 (2 H, m, 3-H2) 1.36 - 1.46 (4 H, m, 4-H2), 2.31 (2 H, 
Broad, 2-H), 2.24 (2 H broad signal, 1-H), 2.88 (4 H, broad, 5-H2); 4.16(4 
H, s, 6-H2), 7.42 (10-H, m, 8 , 9and10-H); 6C (100 MHz, D20); 21.6 (CH2),
37.7 (CH), 38.5 (CH), 39.1 (CH2), 44.4 (CH2), 51.7 (CH2), 129.7 (CH), 130.2 
(CH), 130.4 (CH) and 130.6 (C); (m/z)(+CI/lsobutane) 334 (M+H)+(%) 335 
(100), 270 (5), 243 (18), 228 (28), 120 (14), 108 (10) and 91 (18); (Found 
(M+H)+ 335.2487 C23H30N2 requires 335. 2487).
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Section 7.4 Experimental to Chapter 5 
General Procedure B - Synthesis of N, Af-Dibenzyldiaminoalkanes
To a stirred solution of the aldehyde (2 eq) in absolute ethanol was 
added the appropriate diamine dropwise. The solution was stirred at room 
temperature for 20 min, at reflux for 25 min, allowed to cool and the solvent 
evaporated in vacuo to give a syrup which solidified on cooling. The residue 
was dissolved in methanol and the solution was stirred at 0°C. Excess sodium 
borohydride was dissolved in methanol and added cautiously. The solution 
was stirred for 40 min more, heated at reflux for 15 min, then stirred at room 
temperature overnight.
The solution was taken up in water and extracted with dichloromethane 
(2 x 30 cm3). The organic extracts were dried with anhydrous sodium sulfate, 
filtered and concentrated to give the appropriate dibenzyldiamine as the free 
base. For the purposes of microanalysis, melting point analysis and biological 
testing a sample or all of the free base was converted into the corresponding 
dihydrochloride salt in almost quantitative yield by dissolving it in a small 
amount of chloroform, adding concentrated hydrochloric acid and crystallising 
the precipitated solid from water.
/V,Af-Dibenzyl-1,2-diaminoethane (143)170
General procedure B was used with benzaldehyde (3.5 g, 33.2 mmol), 
1,2-diaminoethane (1 g, 16.6 mmol) and sodium borohydride (2.1 g, 54.8 
mmol) to give (143) as the free base (3.8 g, 15.9 mmol, 96%); hydrochloride 
salt 5h (400 MHz, D20 ),170 3.35 (4H, s , 1 and 2-H2), 4.18 (4 H, s , 3-H2) 
and 7.26 (10 H, m, 5-H, 6-H and 7-H).
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N ,AT-Dibenzyl-1,3-diaminopropane (144)180
The title compound was made by general procedure B using 
benzaldehyde (5.73 g, 54.0 mmol), 1,3-diaminopropane (2 g, 27 mmol) and 
excess sodium borohydride (3.8g, 0.1 mol) to give (144) as a clear oil (6.5 g,
25.7 mmol, 95%). 6H (200 MHz, CDCI3);(18°) 1.75 (2H, quin, J 6.0, 2-H2), 
2.41 (2H, bs, NH), 2.65 (4H, t, J 6.0, 1 and 3-H2), 3.76 (4 H, s, 4-H2) and 
7.31 (10 H, m, 6-H, 7-H and 8-H). Hydrochloride salt (Found: C, 62.15, H, 
7.49, N, 8.59, Cl, 21.63 % C i7H24N2CI2 0.2 H20  requires:C, 61.89, H, 7.40, 
N, 8.49, Cl, 21.34%).
/V,A/'-Dibenzyl-1,4-diaminobutane (145)151
Compound (145) was prepared using benzaldehyde (4.81 g, 45.4 
mmol), 1,4-diaminobutane (2 g, 22.7 mmol) and excess sodium borohydride 
(3.8 g, 0.1 mol) according to general procedure B. The title product was 
isolated as a clear oil. (5.60 g, 20.1 mmol, 92% ). 8h (200 MHz, CDCI3); free 
base 1.55 (4 H, broad, 2 and 3-H2), 2.89 (4 H, broad, 1 and 4-H2), 4.02(4 
H, s, 5-H2) and 7.31 (10 H, broad. 6-H, 7-H and 8-H). Hydrochloride salt 
(Found: C, 62.87, H, 7.98, N, 8.31, Cl, 20.84%, C i8H26N2CI2,0.2 H20 
requires:C, 62.86, H, 7.68, N, 8.15, Cl, 20.37%).
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/V,/V-Dibenzyl-1,5-diaminopentane (146)151
Compound (146) was synthesised by general procedure B using 
benzaldehyde (4.24 g, 40.0 mmol), 1,5-diaminopentane (2.0 g, 20.0 mmol) 
and excess sodium borohydride (3.8 g, 0.1 mol). (146) was isolated as a 
yellow oil. (5.4 g, 19.0 mmol, 95%). 8h (200 MHz, CDCI3); 1.21 (2 H, quin, 
J 8.0, 3-H2), 1.52 ( 4 H, quin, J 8.0, 2 and 4-H2), 2.86 (4 H, t, J8.0, la n d
5-H2), 4.01 (4 H, s, 6-H2) and 7.28 (10 H, broad, 8-H, 9-H and10-H).
A/,A/’-Dibenzyl-1,6-diaminohexane (147)181
General procedure B using benzaldehyde (1.1 g, 10 mmol), 1,6- 
diaminohexane (0.58 g, 5 mmol) and sodium borohydride (0.62 g, 16.5 
mmol) gave compound (147) as the free base (1.3 g, 4.4 mmol, 88%). The 
compound was converted into the dihydrochloride salt. 8h (400 MHz, D20);
1.22 (4 H, m, 3-H2 and 4-H2), 1.53 ( 4 H, m, 2-H2 and 5-H2), 2.89 (4 H, m, 
1-H2 and 6-H2), 4.06 (4 H, s, 7-H2) and 7.32 (10 H, 9, 10 and 11-H), 6C 
(100 MHz, D20); 25.5 (2 x  CH2), 47.1 (CH2), 51.2 (CH2), 129.5 (CH), 129.9 
(CH) and 130.1 (CH) and 131.0 (C).
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A/,/V-Dibenzyl-1,7-diaminoheptane (148)182
General procedure B was employed using benzaldehyde (3.0 g, 27.6 
mmol), 1,7-diaminoheptane (1.8 g, 13.8 mmol) and sodium borohydride (1.7 
g, 45.5 mmol) to give (148) as the free base. (3.82 g, 12.3 mmol, 89%). The 
compound was converted into the dihydrochloride salt. (Found: C, 65.81, H, 
8.40, N, 7.23, Cl, 18.57 % C21H32N2CI2 requires: C, 65.97, H, 8.38, N,
7.33, Cl 18.32%; 8h (400 MHz, D20); 1.20 (6 H, broad, 3-H, 4-H and 5-H2), 
1.52 (4 H, m, 2 and 6-H2), 2.90 (4 H, t, J 8.0, 1 and 7-H2), 4.08 (4 H, s, 8- 
H2), and 7.34 (10 H, broad, 10-H, 11-H and 12-H), 8C (100 MHz, D20); 25.6 
(CH2), 25.8 (CH2), 47.2 (N-CH2), 51.2 (N-CH2), 129.5 (CH), 129.9 (CH), 
130.1 (CH), 131.1 (C); (m/z) (+CI/lsobutane)(%) 310, (M+H)+ (%) 311(100) 
and 219 (10); (Found: (M+H)+ 311.2486 C21H30N2 requires 311.2487).
N,W-Dibenzyl-1,8-diaminooctane (149)183
General procedure B was employed using benzaldehyde ( 3.0 g, 27.6 
mmol), 1,8-diaminooctane (2.0 g, 13.9 mmol) and sodium borohydride (1.7 g,
44.9 mmol) to give (149) as the free base (3.96 g 12.3 mmol, 89%). The 
compound was converted into the dihydrochloride salt, mp (water) 278-280°C 
( lit183 276 -280°C, EtOH); 8H (400 MHz, D20); 1.17 (8 H, broad, 3, 4,5 and
6-H2), 1.53 (4 H, m, 2 and 7-H2), 2.90 (4 H, t, J 8.0, 1 and 8 -H2), 4.08(4 
H, s, 9-H2) and 7.35 (10 H, m, 11-H, 12-H and 13-H), 8c (100 MHz, D20);
25.6 (1 and 8-CH2), 25.9 (CH2), 28. 2 (CH2), 47.3 (CH2), 51.2 (CH2), 129.5
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(CH), 129.9 (CH) 130.1 (CH) and 131.1 (C); (m/z) (+CI/lsobutane) (%)325 
(100) and 235 (5); (Found: 325.2645. C22H32N2 requires 325.2644).
N,/V-Dibenzy 1-1,9-diaminononane (150)184
General procedure B was employed using benzaldehyde (2.70g, 25.2 
mmol), 1,9-diaminononane (2.0 g, 12.6 mmol) and sodium borohydride (1.6 g,
41.2 mmol) to give (150) as the free base. (3.9 g, 11.6 mmol, 92%). The 
compound was converted into the dihydrochloride salt, mp (water) 268-269°C 
(lit184 269-270°C); 8H (400 MHz, D20); (Found: C, 67.32, H, 8.78, N, 6.83, 
Cl, 17.07 % C23H36N2CI2 requires: C, 67.32, H, 8.71, N, 6.78, Cl 17.27%; 
8h (400 MHz, D20); 1.15 (10 H, b.s. 3, 4, 5, 6 and 7-H2), 1.52 (4 H, m, 2 
and 8-H2), 2.90 (4 H, t, J 8 , 1 and 9-H2), 4.08 (4 H, s, 10-H2) and 7.36 (10 
H, m, 12, 13 and 14-H), 5c (100 MHz, D20); 25.7 (CH2), 25.9 (CH2), 28.3 
(CH2), 28.5 (CH2), 47.3 (N-CH2), 51.2 (N-CH2), 129.5 (Ar-CH), 129.9 (Ar- 
CH), 130.1 (Ar-CH) and 131.1 (Ar-C), (m/z) (+CI/lsobutane)(%) 339 (100), 
337 (15) and 247 (10); (Found: 339.2799 C23H34N2 requires 339.2800).
A/,A/,-Dibenzyl-1,10-diaminodecane (151)185
General procedure A was employed using benzaldehyde (2.46 g, 23.2 
mmol), 1,10-diaminodecane (2.0 g, 11.6 mmol) and sodium borohydride (1.6 
g, 41.2 mmol) to give (151) as the free base. (2.9 g, 8.2 mmol, 71%). The 
compound was converted into the dihydrochloride salt; mp (water) 270- 
272°C; (Found: C, 67.72, H, 8.96, N, 6.58, Cl, 16.72 % C24H38N2CI2
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requires: C, 67.92, H, 8.96, N, 6.60, Cl 16.51%); 5H (400 MHz, D20); 1.02 
(12-H, m, 3, 4, 5, 6, 7 and 8-H2), 1.42 (4-H, m, 2 and 9-H2), 2.52 (4-H, m, 1 
and 10-H2), 3.70 (4-H, s, 11-H2) and 7.20 (10-H, m, 13, 14and15-H); 8C 
(100 MHz, D20); 25.7 (CH2), 26.0 (CH2), 28.4 (CH2), 28.6 (CH2), 47.3 (N- 
CH2), 51.2 (N-CH2), 129.5 (Ar-CH), 129.5 (Ar-CH) and 130.0 (Ar-CH); 130.1 
(Ar-CH) and 131.1 (Ar-C); m/z (+CI/lsobutane)(%) 353 (100), 351 (15) and 
261 (7); (Found 353.2958 C24H36N2 requires 353.2957).
/V,A/-Bis(2-hydroxyethyl)-/V,/V-dibenzyl-1,3-diaminopropane (152)151
To a stirred solution of (144) (1 g, 3.94 mmol) in methanol (15 cm3) at 
-78 °C was added freshly distilled ethylene oxide ( 4 cm3, 0.08 mol). The flask 
was stoppered and the solution allowed to return to room temperature and 
was stirred overnight. The solvent was evaporated in vacuo to leave 1.6 g of 
a clear oil which was dissolved in dichloromethane (10 cm3) and washed with 
water ( 3 x 1 0  cm3). The organic layer was dried with anhydrous sodium 
sulfate, filtered and concentrated to give (152) with sufficient purity for the 
next step (1.01 g, 2.95 mmol, 75 %). New data; 5h (200 MHz, CDCI3); 1.67 
(2 H, quin, J  8.0, 2-H2), 2.48 (4 H, t, J 8.0, 1,3-H2), 2.53 (4 H, t, J 6.0, 9- 
H2), 3.55 (8 H, m, overlapping signals, 4-H2 and 10-H2), 7.26 (10 H, m, 6- 
H, 7-H and 8-H); 8C (50 MHz, CDCI3); 24.3 (CH2), 51.4 (CH2), 55.2 (CH2),
55.7 (CH2), 58.6 (CH2), 127.2 (CH), 128.3 (CH), 128.9 (CH), 138.4(C).
161
/V,/\f-Bis(2-hydroxyethyl)-/V,A/,-dibenzyl-1,4-diaminobutane (153)151
11 OH
(153) was prepared as that described for (152) using (145) (1.0 
g, 3.73 mmol) in methanol (15 cm3) with ethylene oxide (4 cm3, 0.08 mol) to 
give (153) with sufficient purity for the next step (0.92 g, 2.57 mmol, 69 %), 
v max (thin film)/cm -1 3093, 3084, 1601, 1549, 1493, 1049 and 737, 6H 
(200MHz, CDCI3); 1.44 (4 H, m, 2 and 3-H2), 2.43 (4 H, m, I-H2 and 4-H2), 
2.60 (4 H, t, J 6 .0 , IO-H2), 2.80 (2 H, b.s., OH), 3.57 (8 H, m, overlapping 
signals, 4-H2 and H-H2), 7.30 (10H, m, 7, 8 , 9-H); 6c (50 MHz, CDCI3);
24.6 (CH2), 53.3 (CH2), 55.1 (CH2), 58.3 (CH2), 58.4 (CH2), 127.1 (CH),
128.3 (CH), 128.7 (CH) and 138.9 (CH); {m/z )(+EI) (%) 356, 357 (< 0.1), 338 
(3), 325 (5), 308 (8), 296 (5), 265 (7), 204 (55), 190 (25), 174 (60), 148 
(100), 114 (65), 91(100) and 85 (25).
A/,A/-Bis (2-hydroxyethyl)-/V,A/,-dibenzyl-1,5-diaminopentane (154)151
HO
Using (146) (1 g, 3.55 mmol) in methanol (15 cm3) and ethylene 
oxide (4 cm3, 0.08 mol) yielded (154) with sufficient purity for the next step
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(0.97 g, 2.63 mmol, 74%). New data; 8h ( 200 MHz, C D C I 3 ) ;  1.11 (2H, m,
3-H2), 1.25 (4 H, distorted quintet, J4.0, 2 and 4-H2), 2.38 (4 H, t, J 6.0, 1- 
H2 and 5-H2), 2.54 (4 H, t, J 6.0, 11-H2), 2.79 (2 H, b.s., OH), 3.46 (8 H, 
overlapping signals, 6-H2 and I 2-H2) and 7.20 (10 H, m, 8-H , 9-H and 10- 
H); 5C (50 MHz, C D C I 3 ) ;  24.8 (CH2), 26.8 (CH2), 53.4 (CH2), 55.1 (CH2),
58.3 (CH2), 58.4 (CH2), 127.1 (CH), 128.3 (CH), 128.9 (CH) and 139.0 (C).
/V,Ar-B/s(2-chloroethyl)-/V,AT-dibenzyl-1,3-diaminopropane 
Dihydrochloride (155)151
2CI
To a stirred solution of the bishydroxyamine (152) (0.9 g, 2.63 
mmol) in chloroform (3 cm3) was added freshly distilled thionyl chloride (6.0 g, 
0.05 mol). The mixture was heated at reflux for 3 h and then poured into 
petroleum ether (bp. 40-60 °C) (40 cm3). The precipitate that formed was 
extremely sticky and was stirred in hexane for 2 d which had no affect on the 
nature of the product. Water (30 cm3), followed by 1 M KOH (20 cm3) was 
added and a white precipitate formed which dissolved in the water layer. The 
water layer was separated, acidified then extracted with chloroform - ethyl 
acetate (1:1), (3 x 30 cm3). The combined organic extracts were dried with 
anhydrous sodium sulfate, filtered and concentrated to give (155) as a brown 
oil (0.40 g, 0.88 mmol, 31%). vmax (thin film)/ cm-1 3384, 3060, 1956, 1600, 
1252, 830 and 720. 6H (200 MHz, CDCI3); 1.67(2 H, quin, J 8.0, 2-H2), 
2.57 (4 H, t, J 8.0, 1,3-H2), 2.81 ( 4 H, J 6.0, 9-H2), 3.54 (4 H, t, J 6.0, 10- 
H2), 3.64 (4 H, s, 4-H2) and 7.35 (10 H, m, 6-H, 7-H and 8-H); 6C (50 MHz, 
C D C I 3 ) ;  25.2 (CH2), 42.0 (CH2), 52.2 (CH2), 55.8 (CH2), 59.1 (CH2), 127.2 
(CH), 128.3 (CH), 128.7 (CH) and 139.3(C).
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A/,A/-S/s(2-chloroethyl)-A/,Ar-dibenzyl-1,4-diaminobutane
Dihydrochloride (156)151
2CI
To a stirred solution of the bishydroxyethylamine (153) (0.9 g, 2.53 
mmol) in chloroform (3 cm3) was added freshly distilled thionyl chloride (6.0 g, 
0.05 cm3) The mixture was heated at reflux for 1 h, allowed to cool to room 
temperature and then poured on to petroleum ether (bp 40-60 °C) (40 cm3). 
The precipitate was collected, washed with pet. ether then benzene to give 
crude product (1.1 g). Crystallisation from 95% aqueous ethanol gave the title 
product ( 0.79 g, 1.7 mmol, 67%), mp 231- 233 °C (lit. 151 230-232°C); v max 
(KBr d isc)/cm -1 3424, 3007, 2475, 1624, 1497, 1066 and 735; §H (200 
MHz, D2O); 1.64 (4 H, broad, 2-H2 and 3-H2), 3.05 (4 H, broad, 1-H2and
4-H2) 3.41 ( 4 H, t, J 6.0, 10-H), 3.72 (4 H, t ,  J 6.0, 11-H2), 4.26 (4 H, s,
5-H2) and 7.33 (10 H, broad, 7, 8 and 9-H); 5C (50 MHz, D20); 21.0 (CH2),
38.3 (CH2), 52.8 (CH2), 54.5 (CH2), 58.3 (CH2), 129.0 (CH2), 130.3 (CH),
131.3 (CH) and 132.0 (CH ); (m/z) (+EI) (%) 392, (M+ +2) 394 (< 0.1%), 357 
(2), 222 (20), 187 (35), 182 (30), 160(25), 148 (95), 132 (50), 120 (15), 91 
(100) and 85 (10).
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/V,A/-Bis(2-chloroethyl)-/V,Af-dibenzyl-1,5-diaminopentane
Dihydrochloride (155)151
2CI
To a stirred solution of the bishydroxyethylamine (154) (0.5 g, 1.35 
mmol) in chloroform (3 cm3) was added freshly distilled thionyl chloride (3.0 g, 
25 mmol). The mixture was heated at reflux for 3 h then allowed to cool to 
room temperature and was then poured onto petroleum-ether ( bp 40-60 °C), 
(20 cm3). The precipitate that formed was washed with pet-ether. The 
resulting sticky brown solid was stirred in hexane for 1 week after which time a 
white solid (157) was obtained, which was crystallised from ethanol-hexane, 
(0.3 g, 0.61 mmol, 45 %), mp 180-181°C (lit.151 180-181.5 °C), vmax. 3424, 
3056, 3004, 2483, 1499, 1002, 923 and 736; 6H (200 MHz, D20); 1.15(2 
H, m, 3-H2), 1.62 (4 H, broad, 2-H2 and 4-H2), 2.99 ( 4 H, t, J 8.0, 1-H2and
5-H2), 3.40 (4 H, t, J 6.0, 11-H2), 3.71 (4 H, t, J 6.0, 12-H2), 4.25 (4 H, s,
6-H2) and 7.32 (10 H, broad signal, 8, 9 and 10-H); 6c (50 MHz, D20), 23.2 
(CH2), 23.6 (CH2), 38.3 (CH2), 53.4 ( CH2), 54.3 (CH2), 58.3 (CH2), 129.1 
(C), 130.2 (CH), 131.2 (CH) and 132.0 (CH).
General Procedure C- Synthesis of N, A/'-dipyridylmethyldiamino 
alkanes
General procedure B was followed to synthesise solutions of the 
appropriate free base.
The solution was taken up in chloroform and washed with 1M NaOH. 
The organic extracts were dried with anhydrous sodium sulfate, filtered and 
concentrated to give the appropriate dipyridyldiamine as the crude free base. 
The free base was dissolved in a small amount of methanol. Oxalic acid (2 eq) 
was dissolved in methanol and added to give a white precipitate of the 
dioxalate which was recrystallised from 95% aqueous ethanol or water.
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M,Af-Bis(2-pyridylmethyl)-1,2-diaminoethane Dioxalate (158)186
General procedure C was applied using pyridine-2-carbaldehyde (3.5 
g, 33.3 mmol), 1,2-diaminoethane (1.0 g, 16.7 mmol) and sodium 
borohydride (2.2 g, 58 mmol) to give the free base (2.6 g, 10.8 mmol, 65%) 
which was treated with oxalic acid and recrystallised from water to give (158); 
mp 236-240 °C decomp; 5h (400 MHz, D20); 3.36 (4 H, s, 1 and 2-H2), 4.18 
(4 H, s, 3-H2) and 7.38 (8 H, m, 5-H, 6-H, 7-H and 8-H2).
/\/,A/,-Bis(2-pyridylmethyl)-1,3-diaminopropane Dioxalate (159)186
General procedure B was applied using pyridine-2-carbaldehyde (0.41 
g, 3.8 mmol), 1,3-diaminopropane (0.14 g, 1.9 mmol) and sodium 
borohydride (0.24 g, 6.7 mmol) to give (159) as white crystals (0.98 g, 1.12 
mmol, 59%), mp 214-215 °C, v max(KBr)/cnr1 3567, 3052, 2858, 1718, 
1646, 1476 and 708; 5 h  (400 MHz, D20); 2.05 (2H, b.s., 9-H2), 3.09 (2 H, t, 
J 8.0, 8 and 10-H2), 4.24 (4 H, s, 7-H2), 7.35 (4 H, m, 3 and 5-H), 7.78 (4 H, 
m, 4-H), 8.41 (2 H, d, J4.0, 6-H); 5C (100 MHz, D20); 22.9 (CH2), 44.6 
(CH2), 51.2 (CH2), 124.7 (CH), 152.1 (CH), 139.4 (CH), 149.2 (CH), 149.7 
(C) and 166.6 (C=0); (m /z) (+CI/NH3) 256 (M+H)+ (%) 257 (50), 166 (45), 147 
(50), 109 (100), 107 (85), 94 (57) and 80 (30).
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/V,/\f-Bis(2-pyridylmethyl)-1,4-diaminobutane Dioxalate (160)186
The reported procedure was applied using pyridine-2-carbaldehyde 
(0.32 g, 3.0 mmol), (0.13 g, 1.5 mmol) and sodium borohydride (0.20 g, 5 
mmol) to give (160) as tan crystals (0.82 g, 61%), mp 226-228 °C, vmax 
(KBr)/cnrr1 3437, 3061, 2781, 1720, 1637, 1217, 720; 8H (400 MHz, D20);
1.66 (4 H, quintet, J 4.0, 9-H2and 10-H2), 3.08 (4 H, b.s., 8-H2 and 11-H2),
4.23 (4 H, s, 7-H2), 7.36 (4 H, m, 3-H and 5-H), 7.74 ( 2 H, m, 4-H) and 
8.43 ( 2 H, d, J 4.0, 6-H); 8C (100 MHz, D20); 23.0 (CH2), 47.0 (CH2), 51.0 
(CH2), 124.8 (CH), 125.1 (CH), 139.7 (CH), 149.0 (CH), 149.8 (C) and
166.5 (C=0); (m /z) (+CI /NH3) (%) 270 (100), 269 (10) 180 (50), 161 (70), 
109 (87), 107 (65), 94 (55) and 80 (17).
/V,Af-Bis(2-pyridylmethyl)-1,5-diaminopentane Dioxalate (161)
H 7
6Ti^© ^T2 N'
^ H;
The procedure was repeated using pyridine-2-carbaldehyde (0.32 g, 
3.0 mmol), 1,5-diaminopentane (0.15 g, 1.5 mmol) and sodium borohydride 
(0.20 g, 5 mmol) to give (161) as a white powder (1.03 g, 74%), mp 223- 
224 °C; (Found:C, 55.14, H, 5.76, N, 12.29 %, C2iH 28N40 8 requires: C,
55.33, H, 5.78 N, 12.44%); 8H (400 MHz, D20); 1.28 (2 H, quintet, J 8.0, 
10-H2), 1.57 (4 H, quintet, J 8.0, 9-H2 and 11-H2), 2.96 (4 H, t, J8.0, 8-H2 
and 12-H2), 4.20 (4 H, s, 7-H2), 7.33 (4 H, m, 3-H and 5-H), 7.78 (2 H, m,
4-H) and 8.39 (2 H, d, J4.0, 6-H); 8C (100 MHz, D20); 23.1 (CH2), 25.2
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(CH2), 47.4 (CH2), 50.9 (CH2), 124.8 (CH), 125.1 (CH), 139.7 (CH), 148.9 
(CH), 166.5 (C) and 167.0 (C=0 oxalate); (m/z )(+CI/NH3) 284 (M+H)+ (%) 
285 (100), 283 (15), 194 (30), 175 (55), 122 (18), 108 (50) and 80 (8); 
(Found (M+H)+ 285.2077. C i7H24N4 requires 285.2079).
A^AT-Bis(2-pyridylmethyl)-1,6-diaminohexane Dioxalate (162)
2(COO)2
The procedure was applied using pyridine-2-carbaldehyde (0.32 g, 3.0 
mmol), 1,6-diaminopentane (0.17 g, 1.5 mmol) and sodium borohydride (0.20 
g, 5 mmol) to give (162) as a white powder (1.28 g, 91%), mp 248-249 °C; 
(F ound : C, 55.13, H, 6.24, N, 11.60 %, C22H30N4O8 requires: C, 55.23, 
H, 5.28 N, 11.59%); V max (KBr disc)/crrr1, 3434, 3050, 1720, 1593, 1475, 
710 and 499, 5H (400 MHz, D20); 1.23 (4-H, b.s., 10-H2 and 11-H2), 1.56(4 
H, m, 9-H2and 12-H2), 2.95 (4  H, t, c/8.0, 8-H2 and 13-H2), 4.20 (4 H, s,
7-H2), 7.36 (4 H, m, 3-H and 5-H), 7.81 (2 H, m, 4-H) and 8.42 (2 H, d, J
4.0, 6-H), 6C (100 MHz, D20); 25.4 (CH2), 25.5 (CH2), 47.6 (CH2), 50.9 
(CH2) 124.7 (CH), 125.0 (CH), 139.5 (CH), 149.1 (CH), 150.0 (C) and 166.4 
(C=0 oxalate); (m/z ) (+CI/NH3) 298 (M+H)+ (%) 299 (100), 297 (12), 208 
(10), 189 (30), 155 (17), 109 (37) and 79 (40); (Found: (M+H)+299.2236 
C i8H24N4 requires 299.2236).
M,y\f-Bis(cyclohexylmethyl)-1,3-diaminopropane (163)
Compound (163) was prepared by general procedure B, using 
cyclohexanecarbaldehyde (1.0 g, 8.9 mmol), 1,3-diaminopropane (0.33 g,
4.5 mmol) and sodium borohydride (0.56g, 14.9 mmol) as the free base (1.1 
g, 4.1 mmol, 91%) which was converted into the dihydrochloride salt and
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recrystallised from 95% aqueous ethanol; mp 294 -297°C decomp; v max (KBr 
disc)/cm -1 2852, 2776, 2360, 2341, 1455 and 668; SH (400 MHz, D20); 
0.89 -1.04 (4 H, m), 1.07 - 1.23 (7 H, m), 1.56-1.66 (12 H. m), 2.03 (2 H, m,
5-H), 2.84 (4 H, m, 3-H2), 3.04 (4 H, t, J 8, 4-H2); 6C (100 MHz, D20); 22.7 
(CH2), 25.3 (CH2), 25.8 (CH2), 30.1 (CH2), 35.0 (CH), 45.2 (CH2) and 54.1 
(CH2); (m/z) (+CI/isobutane) 336 (M+H)+ (%) 337 (100).
N, W-Bis(cyclohexy lmethyl)-1,7-diaminoheptane (164)
Compound (164) was prepared by general procedure B, except that 
the crude p roduct was washed w ith 1M NaOH, using 
cyclohexanecarbaldehyde (3.3 g, 30.8 mmol), 1,7-diaminoheptane (2.0 g,
15.4 mmol) and sodium borohydride (1.9 g, 50.8 mmol), as the free base (4 g,
13.7 mmol, 89%) which was converted into the dihydrochloride salt and 
recrystallised from 95% aqueous ethanol; mp 288-292 °C decomp; (Found: C, 
63.86, H, 10.98, N, 6.92 %, C22H44N2CI2 requires: C, 63.96, H, 11.17, N, 
7.11%); vmax (KBr disc)/cm-1 3423, 2853, 2473, 2417, 1593, 1447, 1000 
and 888; 8H (400 MHz, D20 ) 0.83 - 0.92 (4 H, m), 1.06 - 1.16 (8 H, m), 1.22 
(8 H, broad signal), 2.76 (4 H, m, 7-H2) and 2.89 (4 H, m, 8-H2); 8c (100 
MHz, D20), 25.3 (CH2), 25.6 (CH2), 25.8 (CH2), 25.9 (CH2), 28.3 (CH2),
30.2 (CH2), 34.9 (CH), 48.3 (CH2) and 53.7 (CH2); (m/z) (+CI/lsobutane) (%) 
323 (100) and 239 (20); (Found: (M+H)+ 323.3426. C22H42N2 requires 
323.3426).
169
N ,Af-Bisfcyclohexylmethyl)-1,8-diaminooctane (165)
Compound (165) was prepared by general procedure B, except that 
the crude product was washed w ith 1M NaOH, using 
cyclohexanecarbaldehyde (3.1 g, 27.8 mmol), 1,8-diaminooctane (2.0 g, 13.9 
mmol) and sodium borohydride (51 mmol) as the free base (4.1 g, 12.2 mmol, 
88%) which was converted into the dihydrochloride salt and recrystallised 
from 95% aqueous ethanol; mp. 278 -280°C decomp; vmax (KBr disc)/ cm’1 
3431, 2938, 2473, 2419, 1595, 1149 and 1033. 8H (400 MHz, D20) 0.83 -
0.99 (4 H, m), 1.08 - 1.15 (7 H, m), 1.24 (7 H, broad signal), 1.51-1.61 (16 
H, m), 2.75 (4 H, d, J 6.8, 1 and 8-H2) and 2.90 (4 H, m); 5C (100 MHz, 
D20), 25. 3 (CH2), 25.5 (CH2), 25.8 (CH2), 25.8 (CH2), 28.0 (CH2), 30.2 
(CH2), 34.9 (CH), 48.3 (CH2) and 53.7 (CH2); (m/z )(+CI/NH3) (%) 337 (100) 
and 253 (20); (Found: (M+H)+ 337.3582. C23H44N2 requires 337.3583).
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